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General introduction 
Pathophysiology of chronic obstructive pulmonary disease  
Worldwide, more than 64 million people suffer from chronic obstructive pulmonary 
disease (COPD) (1). COPD is a chronic inflammatory disease characterized by 
persistent, not fully reversible, and usually progressive airflow limitation. COPD is 
characterised by chronic pulmonary inflammation that may cause irreversible breakdown 
of alveolar tissue (emphysema), small airway wall remodelling and mucus 
hypersecretion (2) (Figure 1). In the western world, COPD is caused primarily by 
cigarette smoke exposure, but in low-income countries also by job-related exposures to 
dust and fumes and wood or charcoal smoke (3-5). Presently, COPD contributes to ~3 
million deaths per year, and is still increasing in incidence (1, 6). By 2030, COPD is 
predicted to be the fourth leading cause of death worldwide (7).  
COPD is divided in different stages, stages I – IV using the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) definition of chronic airflow obstruction (6). 
COPD is characterised by a post-bronchodilator ratio of forced expiratory volume in 1 s 
(FEV₁) to forced vital capacity (FVC) of 0.7, the various GOLD stages being defined by a 
progressive decline in FEV1 (% predicted) (Table 1) (6). The GOLD classification was 
recently updated in 2013, using categories A – D, also including severity of symptoms 
and number of exacerbations (8). In this classification categories A-B represent the early 
stages of the disease (FEV1 >50% of predicted comparable to stages I-II), whereas 
categories C-D are associated with the highest mortality risk and high morbidity rates 
(FEV1 <50% of predicted comparable to stages III-IV) (8). In this thesis we adhere to the 
GOLD stages I-IV, due to the use of samples obtained prior to the new classification 
(Table 1). 
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Figure 1: Cigarette smoke-induced changes found in COPD, with a focus on inflammation. After exposure 
to cigarette smoke, the neutrophil attractant IL-8 is released by the epithelium, airway smooth muscle and/or 
macrophages. The cigarette smoke-induced inflammatory effects lead to damage of the alveolar tissue 
(emphysema). In addition, structural cells change their primary functional outcomes leading to hypercontractility 
and to responses such as increased contraction, small airway remodeling, including increased airway smooth 
muscle mass, peribronchial fibrosis and mucus cell hyperplasia. 
 
Table 1: Classification of COPD stages according to the Global Initiative for Chronic Obstructive Lung 
Disease until 2013. COPD stages based on lung function, with all having an FEV1/FVC ratio below 0.7, with 
decreasing FEV1 as the severity progresses. FEV1: Forced expiratory volume in 1 s (post-bronchodilator); FVC: 
forced vital capacity. *respiratory failure: arterial pressure of oxygen <8.0 kPa (60 mm Hg) with or without arterial 
pressure of carbon dioxide >6.7 kPa (50 mm Hg) while breathing air at sea level (6).  
Stage: Description FEV1/FVC FEV1 
I Mild COPD <0.70 ≥ 80% predicted 
II Moderate COPD <0.70 50-80% predicted 
III Severe COPD <0.70 30-50% predicted 
IV Very severe COPD <0.70 
<30% predicted , or <50% 
predicted with chronic 
respiratory failure present* 
	
	
Inflammation 
Inhalation of cigarette smoke generates a local and systemic inflammatory response, 
involving both the innate and the adaptive immune system (9, 10) (Figure 1). Although 
all smokers have an inflammatory response in the lung (9) those susceptible to develop 
COPD show an amplification of this inflammation (11, 12). In COPD, lung inflammation 
is characterized by increased numbers of neutrophils, macrophages, dendritic cells and 
lymphocytes, varying with disease severity, and increasing during exacerbations (10, 13-
15). This is accompanied by an increased release of proteases and a variety of 
inflammatory mediators. Importantly, interleukin-8 (IL-8 (CXCL8); KC (CXCL1) in mice), 
a neutrophil chemoattractant, is markedly increased in sputum from COPD patients, 
which is associated with considerable infiltration of neutrophils in the lung, which 
importantly drives the pathology of this disease (16, 17). The pulmonary inflammation 
persists long after smoking cessation and the inflammatory pathways lead to tissue 
remodelling such as fibrosis of the small airways and/or goblet cell hyperplasia leading 
to mucus hypersecretion (9, 18) and destruction of the lung parenchyma (emphysema) 
(19) (Figure 1). 
 
Airway smooth muscle  
COPD patients suffer from chronic airflow obstruction. One contributing factor to airflow 
obstruction is an increase in airway smooth muscle (ASM) mass found in the small 
airways of patients suffering from moderate to severe COPD (20). Indeed, an increased 
smooth muscle area in the peripheral airways is found in smokers with a decreased lung 
function (21). In addition, peripheral ASM preparations obtained from obstructed 
patients, from a mixed population of COPD an asthma patients, exhibited an increased 
isometric force ex vivo compared to preparations obtained from control subjects, which 
inversely correlated with lung function (22). This is in agreement with the model of 
Lambert and colleagues (23) which found that increased smooth muscle mass was the 
only structural change likely to affect maximal airway contraction by allowing greater 
smooth muscle shortening in response to bronchoconstricting stimuli. Besides 
determining airflow by contraction, ASM cells are also known to release inflammatory 
mediators (e.g. IL-8), growth factors and extracellular matrix proteins in response to 
cigarette smoke or inflammatory mediators (24). Together, this suggests that alterations 
in the ASM functioning may be involved in the development of COPD.  
Since ASM plays an important role in the regulation of airflow obstruction in 
COPD, it represents a key target for pharmacological intervention with bronchodilators 
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as a cornerstone treatment. Better understanding of the processes that regulate ASM 
function in COPD will help to improve current - and develop novel - strategies of 
targeting the disease.  
 
Pharmacological interventions 
In COPD, targeting the ASM for bronchodilation is a crucial part of the available 
therapies, preferentially using short- or long acting β2-agonists (e.g. salbutamol, 
olodaterol) or anticholinergics (e.g. ipratropium, tiotropium), individually or in combination 
(25-28). In addition, the non-selective phosphodiesterase (PDE) inhibitor theophylline 
can be used as a bronchodilator (Figure 2). Additional treatment options are inhaled 
glucocorticoids (with or without long-acting β2-agonists) and PDE4 inhibitors 
(roflumilast), depending on exacerbations and the severity of the disease (29).  
Although both PDE4 inhibitors and β2-agonists increase the cellular cAMP 
content, PDE4 inhibitors are mainly used for their anti-inflammatory – and not their 
bronchodilatory - properties, as the required dosage to induce bronchodilation causes 
adverse events, such as gastrointestinal symptoms and headache (30). β2-Agonists are 
not used for anti-inflammatory purpose, likely due to rapid β2-adrenoceptor 
desensitization in inflammatory cells, and because of a relatively low expression β2-
adrenoceptors on these cells (31) (Chapter 2).  
Resting airway tone is maintained by acetylcholine (ACh) released from 
cholinergic nerves (32), primarily by activation of muscarinic M3 receptors (33-35). 
Activation of M3 receptors induces a Gq-dependent stimulation of phospholipase C, 
which hydrolyzes phosphatidylinositol-4,5-biphosphate into inositol triphosphate (IP3) 
and diacylglycerol (DAG). IP3 elevates intracellular calcium levels, in the ASM causing 
activation of the calcium/calmodulin-dependent myosin light chain kinase leading to 
phosphorylation of myosin light chain, actin-myosin interaction and contraction DAG 
activates protein kinase C (PKC), which is involved in ASM contraction via Ca2+-
dependent and –independent mechanisms (36-39) (Figure 2).  
β2-Adrenoceptors on ASM cells are activated by the endogenous agonist 
adrenaline. The signal is transduced to adenylyl cyclases via Gs, which leads to an 
increase in the production of the second messenger cyclic AMP (cAMP) (40). cAMP in 
turn can activate several proteins, including protein kinase A (PKA) and exchange-
protein directly activated by cAMP (Epac), eventually leading to smooth muscle 
relaxation by controlling the phosphorylation status of the myosin light chain (41, 42) 
(Figure 2). Degradation of cAMP occurs upon hydrolysis by PDEs, in the ASM PDE3 
	
	
and PDE4, in neutrophils, macrophages and T-cells particularly through PDE4, which 
has been shown to have an increased activity in COPD patients (43, 44). 
 
		
Figure 2: β-Adrenergic and cholinergic signaling in the ASM. The β2-adrenoceptor (β2-AR) signaling pathway 
causing bronchorelaxation and inhibition of inflammatory signaling through its effectors Epac and PKA. β2-
Agonists used in this author’s studies presented in this thesis are fenoterol and isoprenaline. cAMP is also 
enhanced by inhibition of phosphodiesterases (PDEs). The muscarinic M3 receptor (M3)mediates intracellular 
calcium (Ca2+) signaling leading to an increased MLC phosphorylation causing bronchoconstriction (e.g. via 
myosin light chain (MLC) phosphorylation) and pro-inflammatory signaling. Therefore, the M3 receptor is the key 
target for anticholinergics. A-kinase anchoring proteins (AKAPs) organize cAMP-dependent multiprotein 
complexes. Airway smooth muscle (ASM) expresses several AKAPs with yet to be defined functions. . For 
references see text. 
 
Despite the fact that β2-agonists are generally well tolerated (45, 46), long term 
use of β2-agonists may cause variations in the treatment outcome in COPD patients, 
eventually providing no improvement mortality (47, 48). None of the current therapies, 
including bronchodilators and glucocorticosteroids, significantly affect disease 
progression, indicating a necessity to find alternatives (23, 28). 
Already around 40 years ago, it has been shown that different Gs-coupled 
receptor agonists, despite their ability to elevate intracellular cAMP to a comparable 
level, induce distinct functional outcomes (49-52). Such findings represented the 
rationale for the concept of cAMP compartmentalization, where different cellular 
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compartments of cAMP control distinct cellular functions. In search for novel drug 
targets, it is highly attractive to start looking beyond activating or blocking receptors and 
enzymes, and to investigate the intracellular organization of signaling events by 
intracellular macro-complexes and how disruption of these complexes potentially affect 
the efficacy of current drugs.  
A-kinase anchoring proteins (AKAPs), a superfamily of scaffolding proteins that 
function to be bring proteins to the right place at the right time and the one feature they 
all all share is a PKA-anchoring domain (Figure 3), provide such a new avenue worthy 
of exploration. The defining feature of an AKAP is its ability to bind PKA; however, 
AKAPs also form complexes with other signaling molecules, e.g. kinases, phosphatases 
and are part of macromolecular complexes with receptors or other networking proteins 
(i.e. adaptor, docking or scaffolding proteins), including in some cases other AKAPs. 
Each AKAP has a unique localization that guarantees targeting signals to different 
intracellular sites, such as the membrane, the cytoskeleton or nucleus and (53, 54). 
 
	
Figure 3: AKAP-PKA interaction. PKA RII subunits (purple and green) form a groove with their docking and 
dimerization domain on which the AKAP amphipathic helix of the A-kinase binding domain (blue) can bind. (A) 
Side view, (B) top view. Molecular Modeling database ID:41011 (65). Figures made using Cn3D v4.3.1. 
 
AKAPs 
The first member of the AKAP superfamily was MAP2, discovered in 1982 (55). 
Subsequently in 1984, a protein of 75 kDa (p75) was co-purified from bovine cerebral 
cortex cytosol together with the 55 kDa PKA type II regulatory subunit (56). A 150 kDa 
protein orthologue to the bovine p75 was found in rat brain and dubbed p150 (57). The 
p150 and p75 proteins were shown to have structural and functional similarities such as 
binding PKA in the brain (58). After introducing the term A-kinase anchoring protein 
(AKAP) for this group of PKA-binding proteins, human AKAP79 (previously known as 
Ht21) was found to be highly similar to bovine p75 (aka AKAP75, 79% homology) and 
	
	
murine p150 (aka AKAP150, 93% homology). The latter difference in molecular weight is 
a consequence of repeated sequences being present in AKAP150 (59, 60). The overall 
gene name for all species – human AKAP79, bovine AKAP75 and murine AKAP150 - 
became AKAP5.  
A few years after the discovery of AKAP5, AKAP12 was isolated from a patient 
with myasthenia gravis resulting in it originally being termed Gravin (61) and the murine 
orthologue SSeCKS (pronounced essex) was later discovered by the group of Gelman 
as a v-Src repressed gene in NIH/3T3 fibroblasts (62, 63). Gravin and SSeCKS share 
83% sequence similarity over the first ∼1000 amino acids, <20% similarity over the next 
∼500, and identity in two 15 amino acids stretches at the C-terminus, one of which 
encodes a PKA anchoring site (Figure 3). The finding that Gravin/SSeCKS binds PKA 
caused a change of its name to AKAP250 and later AKAP12. However, the names 
AKAP12, AKAP250, Gravin and SSeCKs are all still used throughout literature.  
In 2012, the group of Penn showed that ASM expresses several AKAPs, 
AKAP1 – AKAP13, Ezrin and MAP2B (64). By disrupting the interactions between 
AKAPs and PKA with the dominant interfering peptide st-Ht31 (described in more detail 
in chapter 2) the authors showed a prolonged cAMP signaling at the membrane after 
stimulation ASM cells with a β-agonist (64). Much remains to be explored about the 
functional roles of AKAPs in their respective compartments. AKAP12 was found by Penn 
and colleagues to be highly expressed in ASM cells, whereas AKAP5 was found to a 
much lower extent (64). In the context of COPD, it is interesting that AKAP5 is reported 
to increase the affinity of GPCR kinase 2 (GRK2) for βγ subunits of the G-protein leading 
to β2-adrenoceptor internalization. In addition, it has been reported in human epidermoid 
carcinoma cells that AKAP12 causes dephosphorylation and recycling of the β2-
adrenoceptor back to the membrane (Chapter 2). 
 
Scope of the thesis 
The scope of this thesis is to unravel the role of AKAPs in ASM functioning with a focus 
on AKAP5 and AKAP12 as known interaction partners of the β2- adrenoceptors. In 
chapter 2, the role of AKAP5 and AKAP12 in the internalization and recycling of the β2-
adrenoceptors will be discussed. As a novel target in the lung, there is little known about 
AKAPs in the pulmonary system, therefore chapter 2 will first discuss the numerous 
studies dealing with AKAPs, in particular AKAP5 and AKAP12 in intensively studied 
model systems for neuronal diseases in order to translate these findings to the role of 
AKAPs in pulmonary diseases.  
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Figure 3: AKAP-PKA interaction. PKA RII subunits (purple and green) form a groove with their docking and 
dimerization domain on which the AKAP amphipathic helix of the A-kinase binding domain (blue) can bind. (A) 
Side view, (B) top view. Molecular Modeling database ID:41011 (65). Figures made using Cn3D v4.3.1. 
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and colleagues to be highly expressed in ASM cells, whereas AKAP5 was found to a 
much lower extent (64). In the context of COPD, it is interesting that AKAP5 is reported 
to increase the affinity of GPCR kinase 2 (GRK2) for βγ subunits of the G-protein leading 
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In chapter 3 we investigate the expression of AKAPs in ASM and the effect of 
cigarette smoke extract on this expression profile. We focus on the expression of AKAP5 
and AKAP12 in COPD patients. We study functional consequences of disrupting AKAP-
PKA interactions using st-Ht31 on IL-8 secretion in cigarette smoke extract treated ASM 
cells and how st-Ht31 affects β2-agonist-induced reduction of cigarette smoke extract-
induced IL-8 release. The in vivo relevance of AKAP-mediated regulation of IL-8 release 
is studied in chapter 4, where we use AKAP5-/- and AKAP12-/- mice exposed to cigarette 
smoke for four days to measure the release of the murine IL-8 homologue, KC. In 
addition, we look into infiltration of inflammatory cells into the airways of these mice.  
Chapter 5 uses the AKAP5-/- and AKAP12-/- mice to study the effect these 
AKAPs have on β2-agonist induced relaxation of tracheal smooth muscle. Chapter 6 
tries to place our findings in the context of COPD patients by investigating the role of 
genetic variants of AKAP5 and AKAP12 in β2-agonist-induced improvement of lung 
function in these patients. Finally, Chapter 7 offers a general discussion of all data 
presented in this thesis and provides some insights into future perspectives for the field 
of compartmentalized signaling in COPD.   
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Abstract  
The universal second messenger cyclic AMP (cAMP) is generated upon stimulation of 
Gs protein-coupled receptors, such as the β2-adrenergic receptor (β2-AR), and leads to 
the activation of protein kinase A (PKA), the major cAMP effector protein. PKA oscillates 
between an on and off state and thereby regulates a plethora of distinct biological 
responses. The broad activation pattern of PKA and its contribution to several distinct 
cellular functions lead to the introduction of the concept of compartmentalization of 
cAMP. A-kinase anchoring proteins (AKAPs) are of central importance due to their 
unique ability to directly and/or indirectly interact with proteins that either determine the 
cellular content of cAMP, such as β2-AR, adenylyl cyclases and phosphodiesterases, or 
are regulated by cAMP such as the exchange protein directly activated by cAMP (Epac). 
We report on lessons learned from neurons indicating that maintenance of cAMP 
compartmentalization by AKAP5 is linked to neurotransmission, learning and memory. 
Disturbance of cAMP compartments seem to be linked to neurodegenerative disease 
including Alzheimer’s disease. We translate this knowledge to compartmentalized cAMP 
signalling in the lung. Next to AKAP5, we focus here on AKAP12 and Ezrin (AKAP78). 
These topics will be highlighted in the context of the development of novel 
pharmacological interventions to tackle AKAP-dependent compartmentalization.  
 
Introduction 
G protein-coupled receptors, such as the Gs-coupled β2-adrenergic receptor (β2-AR), 
currently represent one of the largest groups of drug targets (1). After receptor binding of 
β2-agonists such as isoprenaline and fenoterol, elevation in the cellular content of cyclic 
adenosine monophosphate (cAMP) is catalysed by membrane-bound adenylyl cyclases 
(ACs) (2-4), a process known to be shaped by cAMP-degrading phosphodiesterases 
(PDEs) (5-9). Among the PDE superfamily members, PDE4, PDE7 and PDE8 exhibit 
substrate specificity towards cAMP (7, 8).  
The best known effector of cAMP is protein kinase A (PKA). The PKA 
holoenzyme consists of two catalytic (C) subunits, which exist in three isoforms (Cα, Cβ 
and Cγ), and two regulatory (R) subunits. There are two major isoforms of PKA, 
designated as PKA(I) and PKA(II), which differ exclusively due to the RI and RII 
subunits, each again subdivided in an α and β isoform (RIα, RIβ, RIIα, RIIβ). Upon 
binding of two cAMP molecules to each R subunit, the dimer releases the C subunits 
and thereby initiates target protein phosphorylation. PKA is known to oscillate between 
an on and off state and thereby regulates a plethora of cellular responses (10). With the 
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discovery of the exchange factor directly activated by cAMP (Epac) (11, 12), the subset 
of biological functions driven by cAMP started to become even more diverse (13-16), 
and thereby further supported the concept of compartmentalization of cAMP. Tough 
cyclic nucleotide gated ion channels represent another cAMP targeted group, a detailed 
description of this is beyond the scope of our current review and we would like to refer 
the reader to recent review (17).  
 
Concept of compartmentalization of cAMP 
The localisation of the different PKA isoforms and of the Epac proteins as well as of 
cAMP generating and degrading enzymes is strictly regulated. Indeed, PKA was already 
some time ago found activated in either particulate or soluble cellular fractions (18, 19). 
Clustering of PKA to lipid rafts and caveolae further support the existence of subcellular 
regions specialised in cAMP signalling that are characterized by a rather dynamic 
composition of a specific subset of signalling molecules which include Gs-coupled 
receptors, ACs, PDEs and Epac (20-24). 
About 40 years ago, studies primarily performed in heart tissue reported that 
the two prototypical Gs-coupled receptor agonists isoprenaline and prostaglandin E1 
elevated both the cellular content of cAMP, while only isoprenaline increased cardiac 
contractility (18, 19, 25, 26). Based on these early studies, the concept of 
compartmentalization of cAMP signalling was introduced, which ignited a new surge of 
cAMP-related research. Since then, several studies have provided further insights into 
the diversity of cellular strategies to compartmentalize intracellular signalling, a concept 
currently believed to enable a tightly and fine-tuned control of biological functions. Of 
particular interest is a recent study from Feinstein et al. (27). Combining mathematical 
modelling and experimental measurements, the authors demonstrated that the 
microvascular endothelial barrier strictly relies on subtle local changes in cellular cAMP. 
Cytosolic produced cAMP disrupted the microvascular endothelial barrier integrity 
whereas cAMP produced at the plasma membrane increased pulmonary microvascular 
endothelial barrier integrity (27). Thus, studies on compartmentalization of cellular cAMP 
emerged as a theme of central importance to unravel the multiple facets of cAMP 
signalling and its effect in physiological and pathophysiological situations. Such cAMP 
gradients may display high spatial resolution, as cAMP signalling often occurs within one 
protein complex orchestrated by a scaffold protein; the most studied family of scaffold 
proteins coordinating cAMP signalling is the A-kinase anchoring protein (AKAP) family, 
outlined in the next paragraph. 
	
	
A-kinase anchoring proteins 
Microtubule-associated protein 2 (MAP2) was the AKAP that tether PKA together with 
microtubules (28). Members of the AKAP family represent important scaffolding proteins 
and thereby determine the specificity of cellular cAMP signalling. AKAPs control the 
spatio-temporal activity of the main cAMP effector PKA and some AKAPs have been 
shown to bind Epac (29-31).  
Through their association with cAMP-elevating receptors, ACs and/or cAMP-
degrading PDEs, AKAPs are able to create and maintain local cAMP pools (4, 32-34). 
To date, over 50 members and splice variants of the AKAP family have been identified 
(35-40).  
 
A-kinase anchoring proteins: PKA-RI and PKA-C 
Differentiation between AKAPs is based on their ability to bind exclusively PKA-RI, PKA-
RII subunits or in the case of dual specific AKAP members both PKA-R subtypes. Most 
of the AKAP superfamily members bind the PKA-RII subunit (35). In 2010, however, 
sphingosine kinase interacting protein (SKIP) was identified as the first mammalian 
AKAP specific for the binding of PKA-RI (41-43). In RIα−⁄− mouse embryonic fibroblasts, 
SKIP was unable to bind any PKA thereby strongly supporting the notion that SKIP 
specifically binds PKA-RI (42). SKIP is also one of the few AKAPs shown to sequester 
two PKA holoenzymes thereby leading to their sequestration at the inner mitochondrial 
membrane (42). Most AKAPs bind with the R subunits and thereby interact also 
indirectly with the catalytic (C) subunit of PKA. This is distinctly different from the 
scaffolding proteins A-kinase interacting protein (AKIP1) (44) and caveolin-1 (45) which 
directly interact with the C subunit. Upon binding to both the C subunit of PKA and the 
p65 subunit of NFkB, AKIP1 seems to act as a molecular switch in PKA driven NFkB 
signalling (46, 47). In cardiomyocytes AKIP1 protected against ischemia/reperfusion 
damage by decreasing reactive oxygen species generation, a process requiring the 
mitochondrial localization of AKIP1 (48). As both SKIP and AKIP1 seem to exert their 
primary biological functions in close proximity to mitochondria, it is tempting to speculate 
that AKAP scaffolding mechanisms via the PKA-RI subunit and/or PKA C subunit most 
likely represent novel molecular mechanisms to unravel yet undefined cellular roles of 
AKAP-dependent compartmentalization of cAMP. 
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A-kinase anchoring proteins: Functional diversity and oligomerization 
Utilization of distinct combinations of broad-spectrum signalling proteins, such as PKA, 
protein kinase C (PKC) and protein phosphatase 2B/calcineurin (PP2B/CaN), on the 
same AKAP, namely AKAP5, modulated the activity of the two distinct neuronal ion 
channels: 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid (AMPA)-type 
glutamate receptor and M-type potassium channels, thereby triggering precise localized 
cellular responses (49). With this notion, it is meanwhile generally accepted that AKAPs 
act as a Swiss army knife that seem to execute differential cellular tasks upon subtle 
changes in their interacting proteins. Together with the huge number of different 
members of the AKAP family, the multitude of cellular tasks being performed in different 
cellular compartments is largely increased.  
Even further complexity is added with the finding that AKAPs form homo- (50-
52) and hetero-dimers (53), a process initially described for AKAP-Lbc (50). For 
example, overexpression of AKAP12 in cells that endogenously express AKAP5, such 
as HEK293 or A431 cells, potentiates AKAP5-mediated phosphorylation of extracellular 
signal-regulated kinase 1/2 (ERK1/2) in response to the β2-agonist isoprenaline (53). 
Interestingly, however, AKAP12 mediated recycling of the β2-AR was unaffected upon 
AKAP5 overexpression (53) (Figure 1). Thus, oligomerization of AKAP family members 
may regulate a distinct subset of signalling properties. However, mechanisms involved in 
AKAP oligomerization, and how such dimer formation is triggered by molecular cues still 
remain obscure.  
For the purpose of this review, we will summarize the most important features 
of AKAP5, AKAP12, and Ezrin (AKAP78) (Table 1). Neuronal key discoveries will be 
recapitulated to introduce paradigm shifts that illustrate the general spatio-temporal 
nature of the compartmentalized cAMP signalling. Our goal is to translate the lessons 
learned from neurons to the lung as our current knowledge about cAMP 
compartmentalization in the airways is rather limited. Before that, we will focus in the 
next section on cAMP compartmentalization via AKAPs acting alone with PKA or in 
concert with Epac, starting in the following section with the different tools currently 
available or under development. 
Tools to study compartmentalization of cAMP 
In the following section, we will highlight novel tools used to study the effect of AKAP-
bearing multiprotein complexes on a diverse subset of biological functions. As some 
AKAPs bind to Epac in additionto PKA, we will briefly discuss some tools that are used 
to interfere at the level of PKA or Epac. For further details about Epac, we would like to 
	
	
refer the reader to recent reviews on this topic (13-16). Our main focus is the tools that 
interfere with AKAP-bearing multiprotein complexes. 
 
 
Figure 1. Member of the AKAP family and β
2
-AR functioning. Left: AKAP5 has been shown to constitutively 
associate with the β
2
-AR receptor (164, 200, 204). Upon β
2
-AR activation, AKAP5 bound PKA phosphorylates the 
receptor, facilitates the switch of G
s
 to G
i
 and thereby permits signaling to ERK (164, 200, 204). In addition, 
AKAP5 bound PKA phosphorylates G-protein coupled receptor kinase 2 (GRK2), enhances the affinity of GRK2 
for Gβγ subunits and subsequent interaction with the β2-AR (207). Middle: Receptor bound GRK2 bears the ability 
to interact with Ezrin (AKAP78), the latter known to be required for the internalization of the β
2
-AR (208). Right: β
2
-
AR activation leads also to phosphorylation of AKAP12 via bound PKA and increases the association of AKAP12 
with the β
2
-AR receptor, a process known to be essential for the recycling of the β
2
-AR (201, 241).  
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A-kinase anchoring proteins: Functional diversity and oligomerization 
Utilization of distinct combinations of broad-spectrum signalling proteins, such as PKA, 
protein kinase C (PKC) and protein phosphatase 2B/calcineurin (PP2B/CaN), on the 
same AKAP, namely AKAP5, modulated the activity of the two distinct neuronal ion 
channels: 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid (AMPA)-type 
glutamate receptor and M-type potassium channels, thereby triggering precise localized 
cellular responses (49). With this notion, it is meanwhile generally accepted that AKAPs 
act as a Swiss army knife that seem to execute differential cellular tasks upon subtle 
changes in their interacting proteins. Together with the huge number of different 
members of the AKAP family, the multitude of cellular tasks being performed in different 
cellular compartments is largely increased.  
Even further complexity is added with the finding that AKAPs form homo- (50-
52) and hetero-dimers (53), a process initially described for AKAP-Lbc (50). For 
example, overexpression of AKAP12 in cells that endogenously express AKAP5, such 
as HEK293 or A431 cells, potentiates AKAP5-mediated phosphorylation of extracellular 
signal-regulated kinase 1/2 (ERK1/2) in response to the β2-agonist isoprenaline (53). 
Interestingly, however, AKAP12 mediated recycling of the β2-AR was unaffected upon 
AKAP5 overexpression (53) (Figure 1). Thus, oligomerization of AKAP family members 
may regulate a distinct subset of signalling properties. However, mechanisms involved in 
AKAP oligomerization, and how such dimer formation is triggered by molecular cues still 
remain obscure.  
For the purpose of this review, we will summarize the most important features 
of AKAP5, AKAP12, and Ezrin (AKAP78) (Table 1). Neuronal key discoveries will be 
recapitulated to introduce paradigm shifts that illustrate the general spatio-temporal 
nature of the compartmentalized cAMP signalling. Our goal is to translate the lessons 
learned from neurons to the lung as our current knowledge about cAMP 
compartmentalization in the airways is rather limited. Before that, we will focus in the 
next section on cAMP compartmentalization via AKAPs acting alone with PKA or in 
concert with Epac, starting in the following section with the different tools currently 
available or under development. 
Tools to study compartmentalization of cAMP 
In the following section, we will highlight novel tools used to study the effect of AKAP-
bearing multiprotein complexes on a diverse subset of biological functions. As some 
AKAPs bind to Epac in additionto PKA, we will briefly discuss some tools that are used 
to interfere at the level of PKA or Epac. For further details about Epac, we would like to 
	
	
refer the reader to recent reviews on this topic (13-16). Our main focus is the tools that 
interfere with AKAP-bearing multiprotein complexes. 
 
 
Figure 1. Member of the AKAP family and β
2
-AR functioning. Left: AKAP5 has been shown to constitutively 
associate with the β
2
-AR receptor (164, 200, 204). Upon β
2
-AR activation, AKAP5 bound PKA phosphorylates the 
receptor, facilitates the switch of G
s
 to G
i
 and thereby permits signaling to ERK (164, 200, 204). In addition, 
AKAP5 bound PKA phosphorylates G-protein coupled receptor kinase 2 (GRK2), enhances the affinity of GRK2 
for Gβγ subunits and subsequent interaction with the β2-AR (207). Middle: Receptor bound GRK2 bears the ability 
to interact with Ezrin (AKAP78), the latter known to be required for the internalization of the β
2
-AR (208). Right: β
2
-
AR activation leads also to phosphorylation of AKAP12 via bound PKA and increases the association of AKAP12 
with the β
2
-AR receptor, a process known to be essential for the recycling of the β
2
-AR (201, 241).  
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Table 1: Subset of AKAP family members known to regulate biological functions in the lung and 
brain. The most important AKAP interactions are highlighted, except of their primary binding partner PKA. 
Text between parentheses, AKAP synonym using the HUGO gene nomenclature or name of a certain 
orthologue. For further details and references, see text.  
AKAP Interactions Processes involved 
AKAP5 (HUGO) 
AKAP79 (Human) 
AKAP150 (Murine) 
AKAP75 (Bovine) 
H21 
 
AKAP12, AKAP5 
β1-AR, β2-AR 
AC5, Epac2 
PKB/Akt, PKC 
PP2A/B, Calcineurin, Calmodulin 
PSD-95, MAGUK, SAP97 
PIP2, F-actin 
E-/N-Cadherin 
AMPA/NMDA receptor 
Cav1.2 
 
β2-AR switching to ERK 
β2-AR desensitization 
Cell cycle progression 
Synaptic plasticity 
 
AKAP12 (HUGO) 
AKAP250  
Gravin (Human) 
SSeCKS (Murine) 
Tsga12 
Srcs5  
AI317366 
 
AKAP5, AKAP12 
β2-AR 
PKC 
 
β2-AR resensitization 
Cell cycle progression 
Synaptic plasticity 
Ezrin 
AKAP78 
Cytovillin 
p81 
Villin-2 
EBP50 (NHERF1) 
GRK2 
RhoGDI 
Rho 
Rac  
Epac 
β2-AR internalisation 
Actin-binding linker protein 
 
  
	
	
Epac and PKA 
To distinguish between PKA and Epac, cell membrane-permeable cyclic nucleotide 
analogues have been developed, such as N6-benzyladenosine-3',5'-cyclic 
monophosphate (6-Bnz-cAMP) for PKA or 8-(4-chlorophenylthio)-2'-O-methyl-cAMP (8-
pCPT-2'-O-Me-cAMP) for Epac (15, 54, 55). In addition, inhibitors of PKA have also 
been synthesized, such as Rp-8-CPT-cAMPS, and have been shown to abolish the 
dissociation of PKA-C subunits from the PKA-R subunits (54). These compounds seem 
to provide more specificity compared to PKA inhibitors known to act on the ATP binding 
site, such as H-89 (56). Inhibition of PKA can also be achieved with the PKA inhibitor 
(PKI) (57). Very recently, pharmacological inhibitors of Epac have been identified, which 
seem to act primarily on Epac1 (CE3F4) or Epac2 (ESI-05) (58-60). Even though 
researchers worldwide use the novel compounds to gain insight into the contribution of 
Epac1 and/or Epac2 to biological functions (61), their mode of action and specificity 
warrants further studies (62). Specific activators for Epac1 and Epac2 are still lacking.  
 
A-kinase anchoring proteins: Genetically modified mice 
To address the physiological importance of specific AKAPs in vivo, mice deficient for a 
specific AKAP gene e.g. AKAP5-/--, or for a specific AKAP-protein interaction, for 
example by introducing a truncation e.g. AKAP5Δ36 for AKAP5-PKA interactions, have 
been developed. Ablation of AKAP members has led to several phenotypes such as 
decreased fertility (e.g. AKAP1, AKAP4), cardiac arrhythmias (e.g. AKAP10 (D-AKAP2)), 
developmental (e.g. mAKAP (AKAP6), WAVE-1) and neuronal defects (e.g. AKAP5, 
MAP2) (35, 63). Based on these findings, it has been suggested that drug targets 
interfering at the level of AKAPs might have the ability to disturb signalling driven by 
cAMP and might, therefore, represent a novel layer of pharmacological interventions (39, 
63, 64).  
 
A-kinase anchoring proteins: Dynamics of PKA and AKAP 
To assess the dynamics of the primary AKAP interaction partner PKA in vivo, several 
fluorescence resonance energy transfer (FRET) tools have been developed taking 
advantage of genetically encoded A-kinase activity reporters (65-70). The addition of 
cellular localization signals permits the recruitment of these tools to subcellular 
compartments, including the cytosol, the nucleus, the sarcoplasmic reticulum, the 
mitochondria (using an AKAP based localization), the plasma membrane (68, 71) and 
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monophosphate (6-Bnz-cAMP) for PKA or 8-(4-chlorophenylthio)-2'-O-methyl-cAMP (8-
pCPT-2'-O-Me-cAMP) for Epac (15, 54, 55). In addition, inhibitors of PKA have also 
been synthesized, such as Rp-8-CPT-cAMPS, and have been shown to abolish the 
dissociation of PKA-C subunits from the PKA-R subunits (54). These compounds seem 
to provide more specificity compared to PKA inhibitors known to act on the ATP binding 
site, such as H-89 (56). Inhibition of PKA can also be achieved with the PKA inhibitor 
(PKI) (57). Very recently, pharmacological inhibitors of Epac have been identified, which 
seem to act primarily on Epac1 (CE3F4) or Epac2 (ESI-05) (58-60). Even though 
researchers worldwide use the novel compounds to gain insight into the contribution of 
Epac1 and/or Epac2 to biological functions (61), their mode of action and specificity 
warrants further studies (62). Specific activators for Epac1 and Epac2 are still lacking.  
 
A-kinase anchoring proteins: Genetically modified mice 
To address the physiological importance of specific AKAPs in vivo, mice deficient for a 
specific AKAP gene e.g. AKAP5-/--, or for a specific AKAP-protein interaction, for 
example by introducing a truncation e.g. AKAP5Δ36 for AKAP5-PKA interactions, have 
been developed. Ablation of AKAP members has led to several phenotypes such as 
decreased fertility (e.g. AKAP1, AKAP4), cardiac arrhythmias (e.g. AKAP10 (D-AKAP2)), 
developmental (e.g. mAKAP (AKAP6), WAVE-1) and neuronal defects (e.g. AKAP5, 
MAP2) (35, 63). Based on these findings, it has been suggested that drug targets 
interfering at the level of AKAPs might have the ability to disturb signalling driven by 
cAMP and might, therefore, represent a novel layer of pharmacological interventions (39, 
63, 64).  
 
A-kinase anchoring proteins: Dynamics of PKA and AKAP 
To assess the dynamics of the primary AKAP interaction partner PKA in vivo, several 
fluorescence resonance energy transfer (FRET) tools have been developed taking 
advantage of genetically encoded A-kinase activity reporters (65-70). The addition of 
cellular localization signals permits the recruitment of these tools to subcellular 
compartments, including the cytosol, the nucleus, the sarcoplasmic reticulum, the 
mitochondria (using an AKAP based localization), the plasma membrane (68, 71) and 
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even the raft or non-raft domains of the cell membrane (69). Interestingly, the PKA 
based biosensors have been transferred to AKAP research by combining them with 
AKAP12 (72) and AKAP5 (73). Using this novel approach, distinct dynamics of PKA 
bound to either AKAP12 or AKAP5 at the membrane compared with 
cytosolic/perinuclear regions were identified (72, 73). Currently, several novel insights 
into the subcellular dynamics of AKAP bound PKA are based on cell transduction with 
PKA defined AKAP reporters and studies in genetically modified mice.  
 
A-kinase anchoring proteins: Pharmacological Tools 
Novel pharmacological tools have been developed to overcome the technical limitations 
and to study the biological effect of AKAP-based multiprotein complexes in vivo. A 
conserved amphipathic helix represents a well-defined domain structure present in all 
AKAP superfamily members which is required for the interaction with the primary AKAP 
binding partner PKA (74, 75). The amphipathic helix is inserted into the hydrophobic 
pockets formed by the dimer of the PKA-R subunits (76, 77). It is this amphipathic helix 
that provided the first basis for the design of dominant interfering peptides able to disrupt 
the interaction between PKA and AKAP, such as Ht31 (Figure 2A). The stearated form 
of Ht31, st-Ht31, exhibits an improved membrane permeability (35). It is important to 
note that the generation of such PKA-AKAP interfering peptides has enabled the 
research community to gain insights into the contribution of AKAP–PKA interactions to a 
diverse subset of cellular functions in physiology and pathophysiology (35, 38, 39, 63). 
The original peptides, however, provided little, if any, distinction between PKA-RI and 
PKA-RII subtypes and members of the AKAP family. Through bioinformatics RI (AKB-RI, 
RIAD) (78, 79) and RII-specific (AKB-RII, (Super)-AKAP-IS) (77, 78, 80) were designed 
to discriminate between different type of PKA-AKAP interactions, PKA-RI or PKA-RII 
subunits. In attempts to overcome the central limitation in the current AKAP research 
field, a recent study from Scott and colleagues reported on the design of Rselect peptides, 
based on the RII subunits of PKA, that seem to exhibit selective affinity for certain 
members of the AKAP family (81). Intriguingly, using phage selection procedure 
combined with high-resolution structural bioinformatics AKAP2 (AKAP-KL) and AKAP7 
(AKAP18) selective Rselect peptides were validated by biochemical and cell-based 
experiments (81). The AKAP5 (AKAP79, AKAP150) Rselect peptide, however, not only 
interfered with the binding of PKA to AKAP5, but also its binding to AKAP7 and AKAP11 
(81). Functional data for these new tools have yet to come, however, the importance of 
	
	
this development is evident as for the first time it is possible to distinguish between the 
individual PKA compartmentalizers without genetic modifications.  
 
	
Figure 2. Strategies to disrupt AKAP 
complexes. Schematic illustration of the different 
ways to disrupt AKAP complexes. A, using PKA-
AKAP dominant interfering peptides, such as 
Ht31, to displace PKA as the archetypical AKAP 
interaction partner. B, using dominant interfering 
peptides to disrupt interactions between proteins 
and AKAPs, such as GSKIPtide to remove GSK3 
from AKAP complexes. C, Similar strategies are 
now applied by using small molecules such as 
FMP-API-1. Further details, see text. 
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In addition, recent studies intend to facilitate a distinction between different 
AKAPs based on their ability to interact with a discrete interaction partner and/or on 
mechanisms distinct from the AKAP–PKA interaction outlined earlier. The dominant 
interfering peptide GSKIPtide, structurally based on the glycogen synthase kinase 3β 
(GSK3β) binding site of GSK3β interaction protein (GSKIP), competes with AKAP 
members known to bind to GSK3β, including GSKIP, AKAP11 and MAP2D (in rat) and 
thereby to disrupt the compartmentalization of GSK3β (82) (Figure 2B). Meanwhile, 
similar peptides were designed, such as a phospholamban peptide, which is able to 
prevent the interaction with AKAP7δ (83) and EBP50 (also known as NHERF1, 
SLC9A3R1) peptide which prevents the interaction with Ezrin (AKAP78) (84) (Table 1). 
Also of particular interest are peptides that specifically inhibit the interaction between 
mAKAP and the AC isoform 5 (AC5), leaving the interaction between AKAP5-AC5 
unaltered (85). Recently, a disruptor for the Hsp20-PDE4 interaction has been described 
that liberates PDE4 from the AKAP-Lbc based complex (86).  
Most tools being developed thus far, however, are still peptide based and might 
therefore exert some unknown interactions. For example, it has been reported that st-
Ht31P, generated from st-Ht31 by two proline substitutions believed to render the 
molecule incapable of disrupting the AKAP–PKA interaction (35), seems to inhibit PKA 
(87). The aim of current research is to design small molecule inhibitors for AKAP–PKA 
interactions (88, 89). Intriguingly, it has been reported that the small molecule 3,3’-
diamino-4,4’-dihydroxydiphenylmethane (FMP-API-1) and its derivatives inhibit AKAP–
PKA interactions in vitro and in cultured cardiomyocytes (88) (Figure 2C). As FMP-API-
1, however, also activates PKA (88), synthesis of additional small molecules is still 
warranted. Indeed, new terpyridine scaffolds has been recently synthesized (89), 
representing the non-peptidic compounds which might exert less unwanted biological 
side effects. 
 
Relation to disease 
Disturbance of AKAPs either at the level of their expression profile or biological functions 
has been associated with a variety of diseases (35, 38, 39, 63). For example, AKAP12, 
also known as AKAP250 or Gravin, was first identified as an auto-antigen in myasthenia 
gravis (90). Down regulation of AKAP12 is associated with prostate hyperplasia (91) and 
several types of cancer (92), including gastric cancer (93). It is tempting to speculate that 
down regulation of AKAP12 might be mediated by promoter hypermethylation, a 
mechanism described before in the context of oesophageal and colon cancer (94-96). 
	
	
Such a mechanism for the promotion of cancer cell invasiveness by AKAP12 (97). In line 
with this, AKAP12 inhibits cell proliferation (92, 98). In addition to AKAP12, other 
members of the AKAP family such as AKAP4 and AKAP9 are discussed as cancer 
markers (99-104). 
In the following sections we will first focus on the compartmentalization of 
cAMP maintained by AKAPs in the context of neuronal learning and memory processes 
related to neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s 
disease, Huntington’s disease, multiple sclerosis and Wallerian degeneration. Then, we 
will highlight our current knowledge about compartmentalized cAMP signalling networks 
in the context of obstructive pulmonary diseases such as chronic obstructive pulmonary 
disease and asthma, and whenever appropriate we will emphasize the effect of AKAP-
based multiprotein complexes.  
 
Lessons from neurons and neurodegenerative diseases  
In the following sections we will discuss the most recent findings on compartmentalized 
cAMP signalling to maintain proper neuron functions and to alleviate symptoms of 
neurodegenerative disease. In particular, we will highlight studies that focus on members 
of the AKAP family.  
 
Concept of neuronal cAMP compartmentalization: PKA and Epac 
Neurons represent highly polarized structures, displaying short, tapered dendrites and 
long, thin axons (105-107). In primary rat hippocampal neurons, Poo and colleagues 
demonstrated that LKB1 phosphorylation by PKA represents an early event in axonal 
differentiation, whereas Smurf1 phosphorylation by PKA directs selective neuronal 
degradation of Par6 or RhoA (106, 108). In rat dorsal root ganglion neurons, local cAMP 
levels regulate axonal guidance through the attraction and repulsion of axons, a process 
involving netrin-1 and myelin-associated glycoprotein (MAG) (109, 110). High cAMP 
levels during the embryonic stage regulate axonal guidance by Epac, whereas low 
cAMP levels during the postnatal stage result in growth cone repulsion by PKA (110). 
Local changes in cAMP determine hippocampus-dependent learning and 
memory stages such as acquisition, consolidation, retrieval, reconsolidation and 
extinction (111, 112). Since the pioneering work in Aplysia 30 years ago (113, 114), 
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Such a mechanism for the promotion of cancer cell invasiveness by AKAP12 (97). In line 
with this, AKAP12 inhibits cell proliferation (92, 98). In addition to AKAP12, other 
members of the AKAP family such as AKAP4 and AKAP9 are discussed as cancer 
markers (99-104). 
In the following sections we will first focus on the compartmentalization of 
cAMP maintained by AKAPs in the context of neuronal learning and memory processes 
related to neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s 
disease, Huntington’s disease, multiple sclerosis and Wallerian degeneration. Then, we 
will highlight our current knowledge about compartmentalized cAMP signalling networks 
in the context of obstructive pulmonary diseases such as chronic obstructive pulmonary 
disease and asthma, and whenever appropriate we will emphasize the effect of AKAP-
based multiprotein complexes.  
 
Lessons from neurons and neurodegenerative diseases  
In the following sections we will discuss the most recent findings on compartmentalized 
cAMP signalling to maintain proper neuron functions and to alleviate symptoms of 
neurodegenerative disease. In particular, we will highlight studies that focus on members 
of the AKAP family.  
 
Concept of neuronal cAMP compartmentalization: PKA and Epac 
Neurons represent highly polarized structures, displaying short, tapered dendrites and 
long, thin axons (105-107). In primary rat hippocampal neurons, Poo and colleagues 
demonstrated that LKB1 phosphorylation by PKA represents an early event in axonal 
differentiation, whereas Smurf1 phosphorylation by PKA directs selective neuronal 
degradation of Par6 or RhoA (106, 108). In rat dorsal root ganglion neurons, local cAMP 
levels regulate axonal guidance through the attraction and repulsion of axons, a process 
involving netrin-1 and myelin-associated glycoprotein (MAG) (109, 110). High cAMP 
levels during the embryonic stage regulate axonal guidance by Epac, whereas low 
cAMP levels during the postnatal stage result in growth cone repulsion by PKA (110). 
Local changes in cAMP determine hippocampus-dependent learning and 
memory stages such as acquisition, consolidation, retrieval, reconsolidation and 
extinction (111, 112). Since the pioneering work in Aplysia 30 years ago (113, 114), 
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several studies link cAMP and PKA to locally defined synaptic plasticity, learning and 
different memory stages (30, 112, 115-117).  
In addition, several recent genetic and pharmacological studies report on the 
role of Epac in a context-dependent fear-conditioning paradigm (118-125).  
 
Concept of compartmentalization of cAMP: AKAP5 
As outlined earlier, both PKA and Epac seem to sense local changes in cAMP to control 
neuronal development and differentiation, learning and memory. Compartmentalization 
of cAMP in the brain seems to be maintained primarily by AKAP5 (126). AKAP5 is 
regulated during neuronal development (127), and provides a platform to integrate 
neuronal cAMP signalling networks (30). Thus, AKAP5 most likely coordinates the fine 
tuning of cAMP by regulating the temporal and spatial events controlling cAMP levels. 
Indeed, a neuronal cAMP-sensing multiprotein complex maintained by AKAP5, PKA, 
Epac2 and PKB/Akt, controlled the survival protein kinase B/Akt pathway (30).  
 
AKAP5: Neurotransmission, learning and memory 
Binding of PKA to AKAPs alters synaptic protein phosphorylation and thereby controls 
synaptic plasticity and memory consolidation (126). In hippocampal neurons, AKAP5 
acts as a postsynaptic scaffold protein that also binds to phosphatase 2B/calcineurin 
(PP2B/CaN; also PPP3) (128) and PKC next to PKA protein (129, 130) (Figure 3). The 
postsynaptic AKAP5 localization is dependent on its association with the actin 
cytoskeleton, acidic phospholipids, and cadherins (131, 132). Binding of AKAP5 with 
membrane-associated guanylate kinase (MAGUK) is required for maturation of dendritic 
protrusions into large, dendritic spines with an increased density of synaptic AMPA 
receptors (127). The functional relation between AKAP5 and AMPA receptors may also 
be linked to the binding of AKAP5 to the MAGUK family member SAP-97 (133). AKAP5 
can also bind the postsynaptic density protein PSD-95 to regulate N-Methyl-D-aspartic 
acid (NMDA) receptors (134, 135) (Figure 3). Next to the interaction of AKAP5 with 
several members of the scaffold protein PSD family, binding of AKAP5 to cadherins may 
also influence synaptic plasticity mechanisms, a process implicated in the regulation of 
NMDA receptors (136) (Figure 3). 
	
	
 
Figure 3. Compartmentalization of cAMP in neurons in relation to neurodegenerative diseases. A, 
Illustration of cAMP compartmentalization with emphasize on AKAP5 and selected adaptor proteins in neurons 
and their alterations under pathological conditions including Alzheimer’s disease, Parkinson’s disease, 
Huntington’s disease, multiple sclerosis and Wallerian degeneration. B, An example of disrupted cAMP 
compartmentalization as it was shown that AKAP5 coordinated calcineurin (CaN) was required for AMPA receptor 
internalization and LTD, removal of the AKAP5 caused an impairment of this LTD. For further details, see text. 
 
AKAP5 directly interacts with the neuronal L-type calcium channel subunit 
Cav1.2 (137), and thereby forms a complex with AC, PKA and PP2A, and is, therefore, 
able to modulate Ca2+ signalling downstream of the β2-AR (138). Anchoring of 
PP2B/CaN to AKAP5 regulates internalization and rapid dephosphorylation of the AMPA 
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several studies link cAMP and PKA to locally defined synaptic plasticity, learning and 
different memory stages (30, 112, 115-117).  
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receptor, and most likely reflects a form of molecular and cellular memory associated 
with long-term depression (LTD) (Figure 3B) (134). Indeed, brain slices derived from 
adult AKAP5 knock-out mice display normal basal hippocampal spine density and 
synaptic transmission, but exhibit deficiency in LTD, learning and memory (127). 
Malenka and colleagues (139) reported that AKAP5 modulates LTD most likely through 
binding of AKAP5 to PSD-95, causing the release of PP2B/CaN, and subsequently 
enhances endocytosis of synaptic AMPA receptors. As a consequence, AKAP5 may 
leave the spine, and thereby contribute to the shrinkage of spines that accompanies LTD 
(139). Currently, the best genetic models for studying AKAP5 function are the Δ36 mice, 
which lack the PKA binding site at the C-terminus of AKAP5 (140), and AKAP5-deficient 
mice (141). Δ36 mice display both long-term potentiation and LTD defects. In contrast, 
the AKAP5 deficient mice exhibit only LTD defects. Such differences suggest that the 
most critical function of AKAP5 is most likely related to its interaction with PKA, to control 
the formation and/or maintenance of dendritic spines (142). It is clear that regulation of 
PKA signalling by AKAP5 is necessary to facilitate neurotransmission, learning and 
defined stages of the memory.  
Throughout the mouse brain, AKAP5 is widely distributed in regions linked to 
learning and memory in rodents, such as the cortex, the hippocampus and the amygdala 
(126, 143-145). Using contextual fear conditioning in mice, the expression of AKAP5 
protein was increased in the hippocampus in a late phase of memory consolidation of 
associative memory (117). Disruption of hippocampal AKAP–PKA interactions by st-
Ht31 or st-superAKAP-IS facilitates the extinction and impairs the consolidation of 
contextual fear memories, whereas acquisition and retrieval remain unchanged (30) 
(Figure 3). Disruption of AKAP–PKA interactions by st-Ht31 in the rat lateral amygdala 
impaired memory consolidation in auditory fear conditioning (126). Using the Morris 
water maze to study learning and spatial memory, AKAP5-deficient mice exhibit deficits 
in spatial memory retention most likely caused by delocalization of PKA and subsequent 
alterations in the local environment of cAMP signalling in the hippocampus (130). Taken 
together, the results from several recent studies illustrate the importance of AKAP5 for 
maintaining neuronal compartmentalized cAMP signalling to coordinate learning and 
memory. 
 
AKAP5: Lessons from Alzheimer’s disease  
As discussed earlier, cAMP in neurons is crucial for learning, memory and physiological 
events but it is not known how this system is altered under pathological 
	
	
neurodegenerative circumstances. Elucidating this is likely to provide mechanistic 
insights that may give some clues for the development of novel pharmacological tools. 
Ample evidence suggests that perturbation of local cAMP signalling contributes to the 
development and progression of neurodegenerative diseases. Here we focus on the role 
of the players discussed previously in the context of Alzheimer's disease.  
 Alzheimer’s disease is a neurodegenerative disease characterized by the 
progressive decline of cognitive function and memory, and is the fourth largest cause of 
death for people over 65 years of age (146). The disease is characterized by 
extracellular β-amyloid plaques, intracellular neurofibrillary tangles, cholinergic 
transmission defects and neuronal loss preferentially in the entorhinal cortex and 
hippocampus (146). As several inflammatory markers are up-regulated in Alzheimer’s 
disease, it is generally assumed that inflammation is linked to the pathogenesis of 
Alzheimer’s disease. Indeed, amyloid plaques seem to trigger inflammatory processes 
(147-150).  
Chronic infusion of lipopolysaccharide has been used as an experimental 
model to mimic certain aspects of Alzheimer’s disease (151). Chronic lipopolysaccharide 
infusion into the fourth ventricle of young rats induces brain inflammation and 
subsequently activation of microglial, a process accompanied by a reduction in the 
expression of adenosine A2B-receptors and cAMP (152). Mengod and colleagues (153) 
using in situ hybridization showed that at early stages of Alzheimer’s disease PDE4, in 
particular PDE4B, and PDE7 are up-regulated, while at later stages of Alzheimer’s 
disease PDE8 is upregulated (153). Both studies imply that progression of Alzheimer’s 
disease is associated with a limitation in cellular cAMP. 
Accumulating evidence suggests that Aβ-induced neurotoxicity alters NMDA 
receptor signalling through the cAMP response element-binding protein (CREB), a 
transcription involved in learning and memory processes (154). Moreover, CREB 
phosphorylation was reduced in the hippocampus of Alzheimer’s post-mortem brains 
(155). Intriguingly, Shelanski and colleagues showed that treatment of rat hippocampal 
neurons with Aβ peptides decreases the dissociation of PKA C and R subunits and 
thereby phosphorylation of downstream targets such as CREB (156). The PDE4 inhibitor 
rolipram promotes the dissociation of PKA’s C and R subunits and reverses inhibitory 
effects of Aβ peptides on CREB phosphorylation (156-158). As PKA-dependent 
signalling studied by CREB phosphorylation in the hippocampus of Alzheimer’s post-
mortem brains was reduced (155), Arima and colleagues proposed that CREB 
Processed on: 2-11-2016
506329-L-bw-Poppinga
39
Chapter 2	
	
receptor, and most likely reflects a form of molecular and cellular memory associated 
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neurodegenerative circumstances. Elucidating this is likely to provide mechanistic 
insights that may give some clues for the development of novel pharmacological tools. 
Ample evidence suggests that perturbation of local cAMP signalling contributes to the 
development and progression of neurodegenerative diseases. Here we focus on the role 
of the players discussed previously in the context of Alzheimer's disease.  
 Alzheimer’s disease is a neurodegenerative disease characterized by the 
progressive decline of cognitive function and memory, and is the fourth largest cause of 
death for people over 65 years of age (146). The disease is characterized by 
extracellular β-amyloid plaques, intracellular neurofibrillary tangles, cholinergic 
transmission defects and neuronal loss preferentially in the entorhinal cortex and 
hippocampus (146). As several inflammatory markers are up-regulated in Alzheimer’s 
disease, it is generally assumed that inflammation is linked to the pathogenesis of 
Alzheimer’s disease. Indeed, amyloid plaques seem to trigger inflammatory processes 
(147-150).  
Chronic infusion of lipopolysaccharide has been used as an experimental 
model to mimic certain aspects of Alzheimer’s disease (151). Chronic lipopolysaccharide 
infusion into the fourth ventricle of young rats induces brain inflammation and 
subsequently activation of microglial, a process accompanied by a reduction in the 
expression of adenosine A2B-receptors and cAMP (152). Mengod and colleagues (153) 
using in situ hybridization showed that at early stages of Alzheimer’s disease PDE4, in 
particular PDE4B, and PDE7 are up-regulated, while at later stages of Alzheimer’s 
disease PDE8 is upregulated (153). Both studies imply that progression of Alzheimer’s 
disease is associated with a limitation in cellular cAMP. 
Accumulating evidence suggests that Aβ-induced neurotoxicity alters NMDA 
receptor signalling through the cAMP response element-binding protein (CREB), a 
transcription involved in learning and memory processes (154). Moreover, CREB 
phosphorylation was reduced in the hippocampus of Alzheimer’s post-mortem brains 
(155). Intriguingly, Shelanski and colleagues showed that treatment of rat hippocampal 
neurons with Aβ peptides decreases the dissociation of PKA C and R subunits and 
thereby phosphorylation of downstream targets such as CREB (156). The PDE4 inhibitor 
rolipram promotes the dissociation of PKA’s C and R subunits and reverses inhibitory 
effects of Aβ peptides on CREB phosphorylation (156-158). As PKA-dependent 
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phosphorylation may serve as a molecular biomarker of ageing-related pathological 
processes (159), in particular of Alzheimer’s disease. 
In addition to PKA, recent studies indicate that Epac may also be linked to 
Alzheimer’s disease. Lezloualc’h and colleagues show that the Epac effector Rap1 
promotes the activation of Rac, and subsequently leads to the cleavage of the amyloid 
precursor protein (APP) and production of secreted APPα (sAPPα) (160). Rap1 can 
directly interact with STEF, a specific guanine exchanging factor (GEF) for Rac1, and 
this association is involved in the secretion of the sAPPα (161). Moreover, activation of 
the serotonin receptor of the subtype 4 increases sAPPα through Epac1/Rap1/Rac 
(162). It has been postulated that sAPPα acts as a memory-enhancer and 
neuroprotector (160, 162). Thus, production of sAPPα by Epac may reduce symptoms of 
Alzheimer’s disease. Indeed, in human brain regions associated with Alzheimer’s 
disease, Epac1 mRNA is up-regulated, which is accompanied by a down regulation of 
Epac2 mRNA (163).  
Next to Alzheimer’s disease, cAMP and its players are associated with others 
neurodegenerative disease such as Parkinson’s disease, Huntington’s disease, multiple 
sclerosis and Wallerian degeneration (Table 2). Several lines of evidence indicate that 
alterations in local cAMP dynamics might be caused by inhibition of PKA, up-regulation 
of a specific PDE subset, up-/down-regulation of Epacs, or a combination of these 
events. Persistent limitations in the cellular cAMP level, due to either defects in the 
cAMP-producing receptors and/or elevations of the cAMP-degrading PDEs, such as 
PDE4, seem to underpin the development and progression of neurodegenerative 
diseases (Table 2). Even though not yet being studied in detail in the context of 
neurodegenerative diseases, a central role for the AKAP family member AKAP5 might 
be envisaged due to its ability to interact with the β2-AR and/or PDE4 (164), and due to 
its ability to maintain neuronal cAMP compartmentalization.  
 
  
	
	
Table 2: cAMP compartmentalization in neurodegenerative diseases. For further details, see text. 
Pathology Modulator involved cAMP dependent effects References 
Alzheimer’s 
Disease 
PKA 
Reduced phosphorylation of CREB (157) 
Inactivation of PKA (156) 
Tau phosphorylation at Ser214 and Ser409 (242) 
Down regulation of A2B receptor/PKA signaling (152) 
EPAC sAPPα production via Epac1/Rap1/Rac (161) 
AKAPs AKAP79, associated with neurofibrillary pathology (242) 
PDEs 
PDE4, PDE4B and PDE7 upregulation at early stage of AD 
(153). 
PDE8 upregulation at later stage of AD 
Parkinson’s 
Disease 
PKA  
Down regulation of A2A receptor/PKA signaling (243) 
α-synuclein stimulates tau phosphorylation by PKA (244) 
PDEs PDE7 and PDE4 inhibition enhances neuroprotection (245, 246) 
Huntington’s 
Disease 
PKA  Decreased levels and CREB activation  (247, 248) 
PDEs 
Inhibition of PDE4 or PDE10A promotes neuroprotective 
effects 
(249-251) 
Multiple 
sclerosis 
PKA  
β2-AR deficient astrocytes produce less cAMP (252) 
Lipoic acid treatment increased PKA activity (253) 
PDEs 
Lovastatin treatment and inhibition of PDE4 promote 
neuroprotection and neurorepair 
(96) 
 
Airway smooth muscle and obstructive pulmonary diseases 
Chronic obstructive pulmonary disease (COPD) and asthma are both obstructive 
inflammatory airway diseases characterized by chronic inflammation, airway obstruction 
and airway remodelling, albeit with different aetiology and specific pathological features 
(165, 166). COPD is predicted to be the third-leading cause of death by disease 
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Airway smooth muscle and obstructive pulmonary diseases 
Chronic obstructive pulmonary disease (COPD) and asthma are both obstructive 
inflammatory airway diseases characterized by chronic inflammation, airway obstruction 
and airway remodelling, albeit with different aetiology and specific pathological features 
(165, 166). COPD is predicted to be the third-leading cause of death by disease 
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worldwide in 2020 (167). Airflow limitation in asthma is reversible with bronchodilators 
and associated with airway hyperresponsiveness, whereas airway obstruction in COPD 
is largely irreversible and lung function decline is progressive (166, 168-170). Airway 
smooth muscle cells contribute to disease symptoms in both asthma and COPD due to 
their multifunctional behavior that supports airway remodeling and airway obstruction, 
causing the limitation of airflow (171-173). 
Different classes of bronchodilators are used in practice: β2-AR agonists (β2-
agonists), muscarinic receptor antagonists (anticholinergics), individually or in 
combinations, with or without the addition of anti-inflammatory glucocorticosteroids (174-
178). The main targets for the therapeutic treatment of obstructive pulmonary diseases 
have a direct or indirect link to G protein-coupled receptor signalling, mainly to the β2-AR 
and the M3 muscarinic receptor. In obstructive airway diseases, increase in smooth 
muscle mass and hypercontractility cause severe limitations in the airflow. Airway 
smooth muscle cell growth is inhibited by several β2-agonists such as fenoterol and 
salbutamol (57, 179). Increased smooth muscle mass is believed to reduce the lumen 
size of the airways, a process associated with aberrant β2-AR signalling (180). Despite 
the fact that β2-agonists are generally well tolerated (181, 182), long term use of β2-
agonists caused variations in the treatment outcome in asthma and COPD patients, 
being either less efficacious in COPD patients or even leading to an increased incidence 
of asthma exacerbations and other markers of morbidity and mortality (183-186). 
Another treatment option in obstructive airway diseases is represented by PDE 
inhibition, for instance the selective PDE4 inhibitors rolipram and roflumilast (187-189). 
PDE inhibitors increase the cellular level of cAMP by preventing its degradation. 
Although both β2-agonists and PDE inhibitors show anti-inflammatory properties in vitro 
(190-192), a notable difference is seen in vivo. PDE4 inhibitors show anti-inflammatory 
properties in vivo, but largely lack airway smooth muscle relaxing properties. In contrast, 
β2-agonists show bronchorelaxing properties in vivo, but lack anti-inflammatory 
properties (187, 193). Possible explanations for this discrepancy are most likely β2-AR 
desensitization and/or biased signalling of the β2-AR towards ERK signalling (194, 195), 
features largely absent with PDE4 inhibitors due to their post-receptor mode of action. 
Both the process of β2-AR desensitization and biased signalling seem to be facilitated by 
scaffolding proteins such as AKAP5 and AKAP12 (196, 197) (Figure 1). Subcellular 
localized cAMP pools seem to cause differential biological effects upon scaffolding 
protein mediated targeting of either the β2-AR or PDEs.  
	
	
An innovative alternative is, therefore, urgently required to safeguard long term 
treatment of obstructive lung disorders. Compartmentalized cAMP signalling may 
provide a novel opportunity for pharmacological interventions. For example, targeting 
downstream of the β2-AR will most likely circumvent receptor desensitization. One might 
also expect that such strategies will increase treatment specificity, and thereby minimize 
unwanted side effects, by targeting only the desired cAMP pool. In the following section, 
the potential effect of compartmentalized cAMP signalling in the lung for further 
improvement of obstructive airway diseases will be discussed. 
 
A-kinase anchoring proteins: Signalling in the airway smooth muscle 
In the airway smooth muscle, the main signalling pathways that determine its 
functionality are receptors coupling to Gq or Gs proteins. The Gq protein-coupled receptor 
family is the M3 muscarinic receptor known to be activated by acetylcholine, and to be 
inhibited by anticholinergics such as tiotropium (178). After agonist binding, the Gαq 
subunit activates phospholipase C (PLC), thereby leading to the elevation in cellular 
calcium and activation of calcium/calmodulin-dependent myosin light chain (MLC), a 
process known to result in airway smooth muscle contraction (198, 199). Activation of 
PKC by diacylglycerol alters also the (de)phosphorylation of the MLC through several 
pathways and thereby contributes to the airway smooth muscle tone (198). Activation of 
the Gs protein-coupled receptors by drugs targeting the β2-AR, causes elevation of 
cAMP production via Gs and subsequent activation of ACs (Figure 4).  
Two members of the AKAP superfamily are known to interact with the β2-AR, 
AKAP5 and AKAP12. Whereas the association of AKAP5 with the β2-AR is constitutive 
(164, 200), agonist binding to the β2-AR increases the interaction of the receptor with 
AKAP12 (201). Despite the fact that AKAP5 and AKAP12 share many common features, 
no redundancy is seen between them with regard to this cellular response (197). AKAP5 
has been reported to switch the coupling of the β2-AR from Gs to Gi, a process most 
likely facilitated by a PKA-mediated phosphorylation of the receptor (164, 200, 202, 203) 
(Figure 1). It has been reported that coupling of the β2-AR to Gi leads to activation of 
ERK signalling (204). The ERK pathway is known to be linked to both proliferative and 
cytokine production pathways in airway smooth muscle (15, 16, 205, 206). In the context 
of obstructive pulmonary diseases, it is worthwhile to emphasize reports indicating that 
AKAP5 seems to determine the cell surface expression of the β2-AR by increasing the 
affinity of G-protein coupled receptor kinase 2 (GRK2) for βγ subunits of the G-proteins, 
causing their translocation to the membrane, leading to the desensitization and 
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being either less efficacious in COPD patients or even leading to an increased incidence 
of asthma exacerbations and other markers of morbidity and mortality (183-186). 
Another treatment option in obstructive airway diseases is represented by PDE 
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PDE inhibitors increase the cellular level of cAMP by preventing its degradation. 
Although both β2-agonists and PDE inhibitors show anti-inflammatory properties in vitro 
(190-192), a notable difference is seen in vivo. PDE4 inhibitors show anti-inflammatory 
properties in vivo, but largely lack airway smooth muscle relaxing properties. In contrast, 
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properties (187, 193). Possible explanations for this discrepancy are most likely β2-AR 
desensitization and/or biased signalling of the β2-AR towards ERK signalling (194, 195), 
features largely absent with PDE4 inhibitors due to their post-receptor mode of action. 
Both the process of β2-AR desensitization and biased signalling seem to be facilitated by 
scaffolding proteins such as AKAP5 and AKAP12 (196, 197) (Figure 1). Subcellular 
localized cAMP pools seem to cause differential biological effects upon scaffolding 
protein mediated targeting of either the β2-AR or PDEs.  
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AKAP5 and AKAP12. Whereas the association of AKAP5 with the β2-AR is constitutive 
(164, 200), agonist binding to the β2-AR increases the interaction of the receptor with 
AKAP12 (201). Despite the fact that AKAP5 and AKAP12 share many common features, 
no redundancy is seen between them with regard to this cellular response (197). AKAP5 
has been reported to switch the coupling of the β2-AR from Gs to Gi, a process most 
likely facilitated by a PKA-mediated phosphorylation of the receptor (164, 200, 202, 203) 
(Figure 1). It has been reported that coupling of the β2-AR to Gi leads to activation of 
ERK signalling (204). The ERK pathway is known to be linked to both proliferative and 
cytokine production pathways in airway smooth muscle (15, 16, 205, 206). In the context 
of obstructive pulmonary diseases, it is worthwhile to emphasize reports indicating that 
AKAP5 seems to determine the cell surface expression of the β2-AR by increasing the 
affinity of G-protein coupled receptor kinase 2 (GRK2) for βγ subunits of the G-proteins, 
causing their translocation to the membrane, leading to the desensitization and 
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internalization of the β2-AR (207) (Figure 1). In contrast, after desensitization, AKAP12 
is essential for the dephosphorylation, resensitization and recycling of the β2-AR back to 
the cell membrane (197, 201, 204). In addition, interaction of GRK2 with Ezrin (AKAP78) 
determines the β2-AR internalization (208) (Figure 1).  
 
 
Figure 4. Compartmentalization of cAMP in relation to airway smooth muscle functioning. Schematic 
illustration of central biological ASM functions, namely contraction, cytokine secretion and proliferation. 
Endogenous expression of AKAP5, AKAP12 and Ezrin (AKAP78) in ASM seems to maintain defined subcellular 
signalling compartments. Abbreviations not mentioned in the text; CaM, calmodulin; ROCK, Rho-kinase.  
	
Based on these findings, it is reasonable to assume that β2-AR functions are 
determined by the balance between AKAP5, AKAP12 and Ezrin (AKAP78) (Figure 1). 
Indeed, a recent study from Penn and colleagues reported on the expression of AKAP5, 
AKAP12 and Ezrin (AKAP78) in human airway smooth muscle cells (209). Penn and 
colleagues did not observe effects of Ht31 or AKAP-IS studying whole cell cAMP after 
stimulation with isoprenaline or the direct AC activator forskolin. However, using a cyclic 
nucleotide gated ion channel reporter the authors showed that local cAMP 
concentrations close to the near-membrane compartment were significantly and 
transiently increased (209). Using a combination of st-Ht31 and a PDE inhibitor cocktail, 
the authors demonstrated that disruption of PKA-AKAP interactions resulted in sustained 
AC activity (209). Mathematical models predicted that tethering of PKA to AKAP should 
cause a threefold increase in PKA at the β2-AR compartment, thereby decreasing input 
of the β2-AR acting as a negative feedback for AC and PDE activity (209). Indeed, direct 
inhibition of PKA with the protein kinase inhibitor (PKI) completely blunted the rapid 
	
	
decay of the cAMP signal over time (209). With multiple AKAPs possibly involved to 
create such PKA pool, utilization of tools recently described by Gold et al. (81) would be 
necessary to assess the individual contribution of each AKAP.  
In the following sections we will discuss the role of cAMP compartmentalization 
in some of the important features of chronic obstructive pulmonary diseases; contraction, 
inflammation and remodelling. Herein we will keep the focus on studies performed in 
airway smooth muscle.  
A-kinase anchoring proteins: Airway smooth muscle contraction 
Elevation of cAMP leads to the activation of both PKA and Epac and thereby modulates 
airway smooth muscle responses (15, 16). It is well established that PKA on its own 
deactivates MLC kinase and desensitizes the IP3 receptor, thereby functionally 
counteracting the PLC-PKC pathway. In our research group and by others, Epac has 
been identified as a novel factor being involved in the regulation of airway smooth 
muscle relaxation. Epac, acting most likely via its main effector Rap1, deactivates RhoA 
and up-regulates Rac1 activation, causing the balance to shift from phosphorylated MLC 
to non-phosphorylated MLC and thus to airway smooth muscle relaxation (210, 211) 
(Figure 4). Interestingly, Ezrin (AKAP78) is phosphorylated by Rho-regulated Rho-kinase 
and binds via its ezrin-radixin-moesin domain the Rho inhibitor Rho guanine-nucleotide-
dissociation inhibitor (RhoGDI) (212). Airway smooth muscle cells express both Epac 
and Ezrin (AKAP78) (209, 213). Thus deactivation of Rho by Epac might involve 
mechanisms driven by Ezrin (AKAP78) and RhoGDI.  
In a Madin-Darby canine kidney cell line, activated Ezrin (AKAP78) binds in a 
calcium dependent manner to Rac and thereby delayed membrane localization of E-
cadherin (214). Calcium underlies also cellular compartmentalization and cross-talk with 
cAMP, a process being facilitated by members of the AKAP family. For example, 
AKAP5, known to be involved in β2-AR desensitization as outlined earlier (Figure 1), 
interacts with calcineurin (215, 216) and calmodulin (217). Calmodulin competes with 
PKC in a Ca2+-dependent manner for binding to AKAP5 (218). More recently, AKAP12, 
known to be involved in β2-AR sensitivity (Figure 1), rapidly redistributes from the 
plasma membrane to the cytosol upon stimulation with calcium-elevating agents such 
ionomycin or thapsigargin (219). Moreover, it has been reported that AKAP12 displace 
PKA-RII from the membrane (219).  
A striking example of cooperativity between cAMP and calcium facilitated by 
AKAPs is shown for AKAP11 upon assembly of a complex that includes IQGAP1, 
GSK3β and PKA. It has been shown that binding of AKAP11 and IQGAP2 requires high 
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counteracting the PLC-PKC pathway. In our research group and by others, Epac has 
been identified as a novel factor being involved in the regulation of airway smooth 
muscle relaxation. Epac, acting most likely via its main effector Rap1, deactivates RhoA 
and up-regulates Rac1 activation, causing the balance to shift from phosphorylated MLC 
to non-phosphorylated MLC and thus to airway smooth muscle relaxation (210, 211) 
(Figure 4). Interestingly, Ezrin (AKAP78) is phosphorylated by Rho-regulated Rho-kinase 
and binds via its ezrin-radixin-moesin domain the Rho inhibitor Rho guanine-nucleotide-
dissociation inhibitor (RhoGDI) (212). Airway smooth muscle cells express both Epac 
and Ezrin (AKAP78) (209, 213). Thus deactivation of Rho by Epac might involve 
mechanisms driven by Ezrin (AKAP78) and RhoGDI.  
In a Madin-Darby canine kidney cell line, activated Ezrin (AKAP78) binds in a 
calcium dependent manner to Rac and thereby delayed membrane localization of E-
cadherin (214). Calcium underlies also cellular compartmentalization and cross-talk with 
cAMP, a process being facilitated by members of the AKAP family. For example, 
AKAP5, known to be involved in β2-AR desensitization as outlined earlier (Figure 1), 
interacts with calcineurin (215, 216) and calmodulin (217). Calmodulin competes with 
PKC in a Ca2+-dependent manner for binding to AKAP5 (218). More recently, AKAP12, 
known to be involved in β2-AR sensitivity (Figure 1), rapidly redistributes from the 
plasma membrane to the cytosol upon stimulation with calcium-elevating agents such 
ionomycin or thapsigargin (219). Moreover, it has been reported that AKAP12 displace 
PKA-RII from the membrane (219).  
A striking example of cooperativity between cAMP and calcium facilitated by 
AKAPs is shown for AKAP11 upon assembly of a complex that includes IQGAP1, 
GSK3β and PKA. It has been shown that binding of AKAP11 and IQGAP2 requires high 
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intracellular calcium levels (220, 221). At lower intracellular calcium, AKAP11-anchored 
PKA phosphorylates IQGAP2 and thereby leads to an increase in Rac binding. In the 
presence of inactive GSK3β, however, AKAP11 serves as a platform for the assembly of 
a complex between IQGAP and CLASP2 a plus-end microtubule tracking protein 
involved in microtubule polymerization. PKA phosphorylation of GSK3β and elevations in 
calcium cooperatively drive the formation of an IQGAP1-CLASP2. Both the IQGAP1-Rac 
and IQGAP1-CLASP2 complexes have been suggested to be involved in microtubule 
dynamics and cell motility (220, 221). AKAP11 was found to be expressed in airway 
smooth muscle (209). In addition, Epac not only interacts with AKAP5, but also with the 
microtubule network and with the calcium-elevating phospholipase C-epsilon (15). 
Future studies should point out if similar mechanisms contribute to airway smooth 
muscle contraction.  
 
A-kinase anchoring proteins: Airway smooth muscle inflammation 
Recently, we reported in human airway smooth muscle cells that direct pharmacological 
activation of PKA and Epac synergistically enhances Gq protein-coupled receptor-
induced release of the neutrophil chemoattractant interleukin-8 (IL-8) (213). Silencing of 
Epac expression decreased not only IL-8 release in response to Epac activation but also 
in response to PKA activation, and vice versa PKA inhibition by Rp-8-CPT-cAMPS 
reduced IL-8 release induced by both PKA and Epac (213). Using st-Ht31 to disrupt 
PKA-AKAP interactions (Figure 2A), preliminary results of our group suggest that PKA 
and Epac regulate the IL-8 release in an AKAP dependent manner.  
 Results from our research groups and others implicate that such close 
interconnectivity requires the presence of spatial regulation. AKAP5 was shown to be 
present in the same AKAP–PKA -Epac complex described before in neuronal cells (30). 
In a related study, we showed that induction of IL-8 release by cigarette smoke extract 
(CSE) was attenuated by the β2-agonist fenoterol, seemingly via Epac and PKA (222). 
Disturbance of AKAP-based multiprotein complexes might be expected due to the down 
regulation of Epac1 and members of the AKAP family by CSE (222, 223). Indeed, 
AKAP12 is down regulated in lung cancer (224). With AKAP5 and AKAP12 known to 
determine β2-AR functions (Figure 1), an important role for PKA and Epac localization 
close to G protein-coupled receptors in asthma and COPD could be imagined. This 
could explain the varying treatment outcomes seen for these bronchodilators in COPD 
(184-186).  
	
	
The underlying molecular mechanisms of the attenuation of IL-8 release by 
cAMP seem to be coordinated via parallel routes. Epac was shown to inhibit the NFκB 
translocation to the nucleus caused by CSE, and PKA counteracts CSE-induced ERK 
phosphorylation, both known to underlie IL-8 production (222, 225). Although limited 
knowledge is currently available on Epac compartmentalization, both NFκB and ERK are 
known to interact with proteins that anchor catalytic and/or regulatory PKA subunits, 
respectively (46, 47, 226, 227). Thus, it is tempting to speculate that a distinct subset of 
AKAP members mediate the anti-inflammatory properties of both PKA and Epac, a 
research topic open for future investigation. 
Our current knowledge implicates AKAPs as important factors of both 
inflammation and contraction. The question that remains: what role AKAPs play in 
airway remodelling? 
A-kinase anchoring proteins: Airway smooth muscle remodelling 
Another important functional feature of airway smooth muscle cells encompasses the 
existence of multiple phenotypes, a process reported to involve both PKA and Epac. 
Upon chronic exposure to stimuli such as growth factors, airway smooth muscle cells 
switch between a contractile and proliferative (synthetic) phenotype (172). Some 
researchers have suggested that airway smooth muscle proliferation is primarily 
inhibited by Epac, but not by PKA (228), while others state a more prominent role for 
PKA (57, 179). Recently, our research group demonstrated that pharmacological 
activation of either Epac or PKA prevented platelet-derived growth factor-induced 
hypocontractility of airway smooth muscle strips and airway smooth muscle proliferation, 
a process being accompanied by the inhibition of ERK1/2 (205, 206), suggesting a 
possible synergism between PKA and Epac. Our findings were strengthened by other 
studies in vascular smooth muscle cells (229). Here a concerted action of PKA and Epac 
inhibited serum-induced BrdU incorporation, Rb phosphorylation and the expression of 
cell cycle progression proteins, in a Rap1a-independent fashion (229).  
Several signalling pathways have been shown to be involved airway smooth 
muscle cell proliferation, including ERK1/2 (230) and phosphoinositide 3-kinase/Akt 
(179, 231). Until now, molecular interactions between the cAMP effectors PKA and Epac 
have been studied in great detail in non-pulmonary systems pointing to 
compartmentalization of both cAMP effectors via muscle specific mAKAP (29), via β2-AR 
associated AKAP5 (30) and via the cytoskeletal scaffolding-AKAP11 complex (232). 
Interestingly, AKAP11 was found to be expressed in airway smooth muscle using real-
time PCR (209). AKAP11 is not only able to bind PKA, but also GSK3, a kinase shown 
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AKAP members mediate the anti-inflammatory properties of both PKA and Epac, a 
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inflammation and contraction. The question that remains: what role AKAPs play in 
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Another important functional feature of airway smooth muscle cells encompasses the 
existence of multiple phenotypes, a process reported to involve both PKA and Epac. 
Upon chronic exposure to stimuli such as growth factors, airway smooth muscle cells 
switch between a contractile and proliferative (synthetic) phenotype (172). Some 
researchers have suggested that airway smooth muscle proliferation is primarily 
inhibited by Epac, but not by PKA (228), while others state a more prominent role for 
PKA (57, 179). Recently, our research group demonstrated that pharmacological 
activation of either Epac or PKA prevented platelet-derived growth factor-induced 
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possible synergism between PKA and Epac. Our findings were strengthened by other 
studies in vascular smooth muscle cells (229). Here a concerted action of PKA and Epac 
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(179, 231). Until now, molecular interactions between the cAMP effectors PKA and Epac 
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to be involved in expression of contractile proteins in airway smooth muscle (233), their 
proliferation (234, 235) and profibrotic signalling (236). Thus, AKAP11 driven cAMP 
compartmentalization may regulate airway smooth muscle remodelling.  
In summary, several lines of evidence point towards the logical conclusion that 
AKAP family members are most likely of key importance for cAMP compartmentalization 
and thereby signalling to maintain a fine-tuned control over structural lung cell 
responses. Future studies will surely add additional insights into our current knowledge 
of signal compartmentalization and perhaps cross-talk between calcium and cAMP in the 
lung.  
Outlook and Future perspectives 
Compartmentalization of cAMP by AKAP family members represents a highly 
specialized and dynamic process to fine-tune intracellular signalling. Disturbance of 
cAMP compartmentalization, either due to alterations in AKAP expression or complex 
composition with a variety of tools outlined herein, seems to profoundly regulate 
biological functions and thereby to contribute to neurodegenerative and obstructive lung 
diseases.  
Aging of the worldwide population will require further improvement of the 
management of chronic diseases. Notably, cAMP and its effectors seem to be critical in 
regulating several processes both in chronic brain and lung diseases. Next to PKA, Epac 
seems to act as a novel pharmacological target in both groups of diseases; however, the 
impact of Epac compared with PKA might be diverse and sometimes even conflicting. 
Members of the AKAP superfamily maintain cellular compartmentalization of cAMP 
primarily via direct interaction with PKA, a process now also linked to Epac. As AKAP 
bearing multiprotein complexes regulate receptor desensitization and are able to target 
simultaneously cAMP and calcium, the AKAP superfamily most likely represent an 
interesting novel pharmacological concept. In chronic obstructive pulmonary disease, 
targeting calcium-mediated bronchoconstriction and cAMP-mediated bronchorelaxation 
by one AKAP related drug might give an additional benefit above the current 
combination therapy with anticholinergics and β2-agonists (237). 
As outlined herein, the design of small molecule inhibitors seems to represent 
one of the most recent key findings in the field of AKAP research (88, 89). The AKAP–
PKA interaction has been also used as a template for drug design based on the ’Dock-
and-Lock Method‘ (238, 239). Here, a trivalent drug is created upon conjugation of two 
identical (pro-)drugs (e.g. interferon-alpha 2b (240)) to the PKA-RII dimer and another 
drug-(targeting) antibody to an AKAP peptide derived from the amphipathic helix (such 
	
	
as AKAP-IS) (238-240), a process being stabilized by cysteine residues allowing 
covalent ’locking‘ of the subunits via disulphide bridges. In theory it should be possible to 
combine any RII module with any AKAP-module (238, 239), the benefit of this method 
most likely should be envisaged for the creation of a diverse set of potential 
pharmacological drugs. 
 Within the AKAP research field, pharmacological tools focus on PKA-AKAP 
interactions and disruption of other interaction partners from the AKAP complexes. Until 
now, however, no reports focus on the disruption of AKAP-Epac complexes. Even 
though an increasing amount of evidence indicates that Epac interacts with AKAPs, and 
other scaffolds independently of PKA (15). These Rap-GEF interacting proteins might 
add another dimension to the concept of subcellular compartmentalization of cAMP, in 
particular in the context of the physiology and pathophysiology of biological functions.  
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Abstract  
 β2-agonists inhibitors can relieve chronic obstructive pulmonary disease (COPD) 
symptoms by stimulating cyclic AMP (cAMP) signaling. A-kinase anchoring proteins 
(AKAPs) compartmentalize cAMP signaling by establishing protein complexes. We 
previously reported that the β2-agonist fenoterol, direct activation of protein kinase A 
(PKA) and exchange factor directly activated by cAMP (Epac) decrease cigarette smoke 
extract (CSE)-induced release of neutrophil attractant interleukin-8 (IL-8) from human 
airway smooth muscle (ASM) cells. In the current study we tested the role of AKAPs in 
CSE-induced IL-8 release from ASM cells and assessed the effect of CSE on the 
expression levels of different AKAPs. We also studied mRNA and protein expression of 
AKAPs in lung tissue from COPD patients. Our data show that CSE exposure of ASM 
cells decreases AKAP5 and AKAP12, both capable of interacting with β2-adrenoceptors. 
In lung tissue of COPD patients, mRNA levels of AKAP5 and AKAP12 were decreased 
compared to lung tissue from controls. Using immunohistochemistry, we detected less 
AKAP5 protein in ASM of COPD GOLD stage II patients compared to control subjects. 
St-Ht31, which disrupts AKAP-PKA interactions, augmented CSE-induced IL-8 release 
from ASM cells and diminished its suppression by fenoterol, an effect mediated by 
disturbed ERK signaling. The modulatory role of AKAP-PKA interactions in the anti-
inflammatory effects of fenoterol in ASM cells and the decrease in expression of AKAP5 
and AKAP12 in response to cigarette smoke and in COPD patient lungs suggests that 
cigarette smoke-induced changes in AKAP5 and AKAP12 in COPD patients may affect 
efficacy of pharmacotherapy.  
 
Introduction 
Chronic obstructive pulmonary disease (COPD) is characterized by airway inflammation, 
with among others neutrophils, mucus hypersecretion, airway remodeling and by 
parenchymal tissue destruction (emphysema), all contributing to irreversible airflow 
limitation and accelerated lung function decline (1). Cigarette smoking is the main risk 
factor for the development of COPD (2). Smoking cessation is the most effective 
strategy to slow down the accelerated decline in lung function observed in the disease 
(3, 4), but it does not reverse the structural changes in the lungs. 
Pharmacological COPD management is mainly focused on the treatment of 
symptoms, including airway obstruction and inflammation. In COPD, mainstays for 
eliciting bronchodilation include inhaled anticholinergics or β2-agonists (4, 5). β2-agonists 
primarily act on airway smooth muscle (ASM) cells, increasing the intracellular 
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CSE-induced IL-8 release from ASM cells and assessed the effect of CSE on the 
expression levels of different AKAPs. We also studied mRNA and protein expression of 
AKAPs in lung tissue from COPD patients. Our data show that CSE exposure of ASM 
cells decreases AKAP5 and AKAP12, both capable of interacting with β2-adrenoceptors. 
In lung tissue of COPD patients, mRNA levels of AKAP5 and AKAP12 were decreased 
compared to lung tissue from controls. Using immunohistochemistry, we detected less 
AKAP5 protein in ASM of COPD GOLD stage II patients compared to control subjects. 
St-Ht31, which disrupts AKAP-PKA interactions, augmented CSE-induced IL-8 release 
from ASM cells and diminished its suppression by fenoterol, an effect mediated by 
disturbed ERK signaling. The modulatory role of AKAP-PKA interactions in the anti-
inflammatory effects of fenoterol in ASM cells and the decrease in expression of AKAP5 
and AKAP12 in response to cigarette smoke and in COPD patient lungs suggests that 
cigarette smoke-induced changes in AKAP5 and AKAP12 in COPD patients may affect 
efficacy of pharmacotherapy.  
 
Introduction 
Chronic obstructive pulmonary disease (COPD) is characterized by airway inflammation, 
with among others neutrophils, mucus hypersecretion, airway remodeling and by 
parenchymal tissue destruction (emphysema), all contributing to irreversible airflow 
limitation and accelerated lung function decline (1). Cigarette smoking is the main risk 
factor for the development of COPD (2). Smoking cessation is the most effective 
strategy to slow down the accelerated decline in lung function observed in the disease 
(3, 4), but it does not reverse the structural changes in the lungs. 
Pharmacological COPD management is mainly focused on the treatment of 
symptoms, including airway obstruction and inflammation. In COPD, mainstays for 
eliciting bronchodilation include inhaled anticholinergics or β2-agonists (4, 5). β2-agonists 
primarily act on airway smooth muscle (ASM) cells, increasing the intracellular 
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production of the second messenger cyclic AMP (cAMP) to induce ASM relaxation and 
bronchodilation (6). In addition to their role in regulating airway diameter, ASM cells also 
possess secretory and pro-inflammatory functions, and through this contribute to local 
chronic airway inflammation in COPD (7-10). Though anti-inflammatory effects of β2-
agonists in vitro are established (11, 12), the evidence for this in vivo is still under debate 
(13).  
Cyclic AMP induces its biological actions by activating various effectors, including 
protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac) (14, 15). 
Cyclic AMP and its effectors are under tight spatiotemporal control by a family of 
scaffolding proteins with over 50 members called A-kinase anchoring proteins (AKAPs) 
(Chapter 2) (16, 17). AKAPs regulate diverse cellular processes, including release of 
inflammatory cytokines from cardiomyocytes and alveolar macrophages (18, 19). For 
example, in alveolar macrophages AKAP10 is required for the potentiation of LPS-
induced IL-6 and IL-10 production by the cAMP-elevating agonist prostaglandin E2 
(PGE2) (18). Although less pronounced, AKAP11 also plays a modulatory role in the 
above-mentioned processes (18). 
Human ASM cells are known to express AKAP1–AKAP3, AKAP5, AKAP9–
AKAP13, MAP2B and Ezrin (20, 21). Inhibition of AKAP-PKA interactions using the PKA 
anchoring disruptor peptides, Ht31 and AKAP-IS, in human ASM cells extended the 
duration of the β2-agonist-induced cAMP signal at the plasma membrane (20). The 
functional role of AKAP-mediated compartmentalization in the lung, the effects of 
cigarette smoke exposure on AKAP expression, and the expression profile of AKAPs in 
lung diseases such as COPD are unknown. 
AKAP5 and AKAP12 directly interact with the β2-adrenoceptor (Chapter 2) (22-
25). Thus we hypothesized that alterations in AKAP5 and AKAP12 expression may 
affect the anti-inflammatory effects of β2-agonists on cigarette smoke-induced 
inflammatory responses. In the current study, we investigated AKAP expression in 
human ASM cells after exposure to cigarette smoke extract (CSE) as well as in lung 
tissue from COPD patients. We observed changes in AKAP5 and AKAP12 expression in 
COPD lungs as well as in cultured, CSE-exposed human ASM cells. Importantly, 
disruption of AKAP-PKA interactions prevented the anti-inflammatory properties of the 
β2-agonist fenoterol via disturbance of ERK phosphorylation.  
 
  
	
	
Materials and methods 
Cell culture – Human bronchial ASM cells obtained from three different healthy 
donors during lung transplant procedures, immortalized by stable ectopic expression of 
human telomerase reverse transcriptase (hTERT) as described previously (26) were 
used at passages 20-29. Primary human airway smooth muscle cells obtained as 
described previously (27) were used at passage 1-5. The cells were maintained in high 
glucose Dulbecco's modified Eagle's medium (DMEM) containing 10% heat-inactivated 
fetal calf serum supplemented with HEPES (25 mM), L-glutamine (2 mM), amphotericin 
B (1.5 μg/mL) and penicillin (100 U/ml)/streptomycin (100 μg/ml) in a humidified 
atmosphere at 37 °C in air/CO2 (95:5 % vol/vol). For primary ASM cells, the medium 
was supplemented with sodium pyruvate (1 mM), Gibco® MEM Non-Essential Amino 
Acids and gentamicin (45 µg/mL). 
Human lung tissue - To study possible differences in AKAP expression 
between patients with moderate and more severe COPD, we used tissue from COPD 
GOLD stage II and stage IV respectively. Lung tissue was collected from current and 
ex-smoking patients, using asymptomatic current and ex-smokers as a control group 
(for patient characteristics see Tables 1 and 2). Tissue from the control group and 
COPD GOLD stage II patients was derived from non-diseased lung tissue of patients 
undergoing resective surgery for pulmonary carcinoma, in controls without airway 
obstruction or chronic airway symptoms, such as cough and sputum production. 
Classification of COPD severity was based on the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) criteria (28). Tissue from GOLD IV patients was 
obtained from subjects undergoing surgery for lung transplantation. All tissue was 
collected according to the Research Code of the University Medical Center Groningen 
(http://www.rug.nl/umcg/onderzoek/researchcode/index) and national ethical and 
professional guidelines (“Code of conduct; Dutch federation of biomedical scientific 
societies”; htttp://www.federa.org). 
CSE preparation – CSE was prepared using 3R4F research cigarettes 
(Reference Cigarette Program, University of Kentucky; (29)) as described previously 
(30, 31). In short, two cigarettes were combusted using a peristaltic pump (Watson 
Marlow 323 E/D, Rotterdam, The Netherlands) in to 25 mL of serum free medium, this 
was designated 100% CSE and was diluted to 15% CSE using serum free medium. 
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donors during lung transplant procedures, immortalized by stable ectopic expression of 
human telomerase reverse transcriptase (hTERT) as described previously (26) were 
used at passages 20-29. Primary human airway smooth muscle cells obtained as 
described previously (27) were used at passage 1-5. The cells were maintained in high 
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atmosphere at 37 °C in air/CO2 (95:5 % vol/vol). For primary ASM cells, the medium 
was supplemented with sodium pyruvate (1 mM), Gibco® MEM Non-Essential Amino 
Acids and gentamicin (45 µg/mL). 
Human lung tissue - To study possible differences in AKAP expression 
between patients with moderate and more severe COPD, we used tissue from COPD 
GOLD stage II and stage IV respectively. Lung tissue was collected from current and 
ex-smoking patients, using asymptomatic current and ex-smokers as a control group 
(for patient characteristics see Tables 1 and 2). Tissue from the control group and 
COPD GOLD stage II patients was derived from non-diseased lung tissue of patients 
undergoing resective surgery for pulmonary carcinoma, in controls without airway 
obstruction or chronic airway symptoms, such as cough and sputum production. 
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CSE preparation – CSE was prepared using 3R4F research cigarettes 
(Reference Cigarette Program, University of Kentucky; (29)) as described previously 
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Marlow 323 E/D, Rotterdam, The Netherlands) in to 25 mL of serum free medium, this 
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Table 1: Characteristics of the study objects used for the gene expression. All values except number of 
subjects, gender and smoking status are expressed as median values with minimum and maximum range in 
parentheses. Ex-smoker: non-smoker for at least one year. FEV1% predicted: forced expiratory volume in 1 
second as percentage of predicted value. FVC: forced vital capacity. **P<0.01, ***P<0.001 compared to control 
group. +1 unknown value, ++=2 unknown values. Values are expressed as median values with minimum and 
maximum range in parentheses. Ex-smoker: non-smoker for at least one year. FEV1% predicted: forced 
expiratory volume in 1 second as percentage of predicted value. FVC: forced vital capacity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Characteristics of the control persons and patients whose lung tissues were used for the 
immunohistochemistry. All values except number of subjects and gender are expressed as median values with 
minimum and maximum range in parentheses. Only ex-smokers were included. FEV1% predicted: forced 
expiratory volume in 1 second as percentage of predicted value. FVC: forced vital capacity. *=p<0.05, 
***=p<0.001 compared to control group, $=p<0.05, $$$=p<0.001 compared to COPD stage II (Mann-Whitney U 
test). += 1 unknown, ++= 2 unknown 
 
 
 
 
 
 
 
 
 
 
 
  Subject groups 
Control COPD stage II COPD stage IV 
Number of subjects 5 5 5 
Age (years) 
57 
(46 - 67) 
71 
(49 - 80) 
58 
(55 - 61) 
Male/female 1/4 5/0 0/5 
Ex-smoker/current 
smoker 
3/2 4/1 5/0 
Pack years 
32 
(10 - 40)++ 
23 
(8.5 - 30)+ 
33 
(30 - 54) 
FEV1% predicted 
98.3 
(86.1 – 102.6) 
59.1 *** 
(54.6 – 61.1) 
16.8 *** 
(14.0 - 23,6) 
FEV1/FVC  
80.9 
(70,6 - 85,3) 
63.9 ** 
(45,7 - 71,1) 
25.7 *** 
(19,2 - 41,8) 
  Subject groups 
Control COPD stage II COPD stage IV 
Number of subjects 10 8 9 
Age (years) 
67 
(55-74) 
71* 
(58-80) 
58$ 
(50-66) 
Male/female 4/6 6/2 3/6 
Pack years 
15 
(1.5-65)++ 
36.5 
(10-44)+ 
26 
(18-38)+ 
FEV1% predicted 
97.1 
(63.7-121)++ 
65* 
(41.7-71)+ 
20.6***$$$ 
(13-36) 
FEV1/FVC  
73.6 
(64-86.2)+ 
63*** 
(45.7-64.1)+ 
36.8***$ 
(25-66) 
	
	
Cell stimulation - hTERT ASM cells were grown to confluence and growth was 
halted by exchanging the complete medium for serum-free medium for 24 hours. Cells 
were pre-treated with 50 μM st-Ht31 (Promega, Madison, MT, USA) to disrupt AKAP-
PKA interactions (Chapter 2) (32, 33), for 20 min prior to stimulation with 15% CSE in 
serum-free medium. Control cultures were pre-treated with vehicle alone. When used, 
fenoterol (0.001 – 0.1 µM), the PKA activator 6-Bnz-cAMP (6-Bnz; 500 μM) or the Epac-
activator 8-pCPT-2′-O-Me-cAMP (8-pCPT; 100 µM) were added 10 minutes after the 
addition of st-Ht31. The action of these cAMP analogues has previously been 
characterized in this system (30). Cells were stimulated with 15% CSE for different time 
points: 10 min for VASP phosphorylation, 1 h for ERK phosphorylation, 2 h for nuclear 
factor-κB (NF-κB) translocation and 24 h for AKAP mRNA and protein expression and 
ELISA measurements of IL-8. Serum-free medium (vehicle) served as control for all 
experiments, as st-Ht31P, the commonly used control for st-Ht31, has been reported to 
be a direct inhibitor of PKA (34). In addition, st-Ht31P decreased cell viability in a dose-
dependent manner (Figure 6E), rendering st-Ht31P invalid as a control in this set-up, 
and in line with previous observations from our group (31). 
RII overlay - RII overlay assay was performed as described previously (35, 36). 
In short, proteins were subjected to SDS-PAGE, transferred to PVDF membranes and 
incubated in RII blocking buffer (5% milk powder, 0.1% BSA, 0.1% sodium azide in 
PBS) for three hours at room temperature. The membranes were incubated with [γ32P]-
labeled PKA RIIα subunits in fresh RII blocking buffer overnight at room temperature. 
Membranes were washed twice with blocking buffer and twice with PBS (10 min each). 
Binding of [γ32P]-RII subunits was visualized by autoradiography using a STORM 830 
Scanner (Molecular Dynamics).  
Western blot - Cells were lysed in RIPA lysis buffer (containing 0.5 mM 
phenylmethylsulphonyl fluoride, 0.1 mM sodium orthovanadate, 1 mM sodium fluoride, 
3.5 µM β-glycerolphosphate, 1 mM EDTA, 1% Triton X-100 (v/v), 0.1% sodium dodecyl 
sulphate (w/v), 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 µg/µL soybean trypsin 
inhibitor, 1,43 µg/µL aprotinin and 0.8 mM benzamidin) followed by sonication. Samples 
for detection of AKAP9 (#611518; BD Biosciences), AKAP12 (ab87067; Abcam), Ezrin 
(Ab4069; Abcam), AKAP5 (sc-6442; Santa Cruz Biotechnology), AKAP8 (sc-10766; 
Santa Cruz Biotechnology), (phospho)VASP (#3112; Cell Signaling Technology) or 
(phospho)ERK (#9101 and #9102; Cell Signaling Technology) expression were 
subjected to SDS-PAGE. Immunoblotting with primary antibodies (dilution 1:500 for 
AKAPs antibodies, 1:1000 for the VASP antibody, 1:2000 for ERK antibodies) was done 
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Cell stimulation - hTERT ASM cells were grown to confluence and growth was 
halted by exchanging the complete medium for serum-free medium for 24 hours. Cells 
were pre-treated with 50 μM st-Ht31 (Promega, Madison, MT, USA) to disrupt AKAP-
PKA interactions (Chapter 2) (32, 33), for 20 min prior to stimulation with 15% CSE in 
serum-free medium. Control cultures were pre-treated with vehicle alone. When used, 
fenoterol (0.001 – 0.1 µM), the PKA activator 6-Bnz-cAMP (6-Bnz; 500 μM) or the Epac-
activator 8-pCPT-2′-O-Me-cAMP (8-pCPT; 100 µM) were added 10 minutes after the 
addition of st-Ht31. The action of these cAMP analogues has previously been 
characterized in this system (30). Cells were stimulated with 15% CSE for different time 
points: 10 min for VASP phosphorylation, 1 h for ERK phosphorylation, 2 h for nuclear 
factor-κB (NF-κB) translocation and 24 h for AKAP mRNA and protein expression and 
ELISA measurements of IL-8. Serum-free medium (vehicle) served as control for all 
experiments, as st-Ht31P, the commonly used control for st-Ht31, has been reported to 
be a direct inhibitor of PKA (34). In addition, st-Ht31P decreased cell viability in a dose-
dependent manner (Figure 6E), rendering st-Ht31P invalid as a control in this set-up, 
and in line with previous observations from our group (31). 
RII overlay - RII overlay assay was performed as described previously (35, 36). 
In short, proteins were subjected to SDS-PAGE, transferred to PVDF membranes and 
incubated in RII blocking buffer (5% milk powder, 0.1% BSA, 0.1% sodium azide in 
PBS) for three hours at room temperature. The membranes were incubated with [γ32P]-
labeled PKA RIIα subunits in fresh RII blocking buffer overnight at room temperature. 
Membranes were washed twice with blocking buffer and twice with PBS (10 min each). 
Binding of [γ32P]-RII subunits was visualized by autoradiography using a STORM 830 
Scanner (Molecular Dynamics).  
Western blot - Cells were lysed in RIPA lysis buffer (containing 0.5 mM 
phenylmethylsulphonyl fluoride, 0.1 mM sodium orthovanadate, 1 mM sodium fluoride, 
3.5 µM β-glycerolphosphate, 1 mM EDTA, 1% Triton X-100 (v/v), 0.1% sodium dodecyl 
sulphate (w/v), 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 µg/µL soybean trypsin 
inhibitor, 1,43 µg/µL aprotinin and 0.8 mM benzamidin) followed by sonication. Samples 
for detection of AKAP9 (#611518; BD Biosciences), AKAP12 (ab87067; Abcam), Ezrin 
(Ab4069; Abcam), AKAP5 (sc-6442; Santa Cruz Biotechnology), AKAP8 (sc-10766; 
Santa Cruz Biotechnology), (phospho)VASP (#3112; Cell Signaling Technology) or 
(phospho)ERK (#9101 and #9102; Cell Signaling Technology) expression were 
subjected to SDS-PAGE. Immunoblotting with primary antibodies (dilution 1:500 for 
AKAPs antibodies, 1:1000 for the VASP antibody, 1:2000 for ERK antibodies) was done 
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overnight at 4 °C. Blots were incubated with secondary antibody (1:2000 A9044 or 
A0545; Sigma-Aldrich). Signals were detected with chemiluminescence reagents 
according to the manufacturer's protocol. GAPDH (1:2000; sc-47724; Santa Cruz 
Biotechnology) served as a control for equal loading. Blots were quantified using 
ImageJ. 
Real time PCR - After 24 hours, total RNA was isolated using the NucleoSpin® 
RNA II isolation kit (Machery-Nagel) and cDNA was obtained using the Reverse 
Transcription System (A3500, Promega) following the manufacturers’ instructions. This 
cDNA was used as a template for quantitative real time PCR for AKAP5 (Forward; 5’-
GACGCCCTACGTTGATCT-3’, Reverse; 5’- GAAATGCCCAGTTTCTCTATG-3’), and 
AKAP12 (Forward; 5’-CAAGCACAGGAGGAGTTACAG-3’, Reverse; 5’- 
CTGGTCTTCCAAACAGACAATG-3’) using the PIXO™ Real-Time PCR (Helixis, 
Carlsbad, CA, USA). Relative quantifications of gene expression were normalized 
against 18S expression (Forward; 5’-CGCCGCTAGAGGTGAAATTC-3’, Reverse; 5’- 
TTGGCAAATGCTTTCGCTC-3’). 
Immunohistochemistry –3 micron sections from paraffin embedded lung tissue 
from COPD patients and control subjects (Table 2) were deparaffinized and antigen 
retrieval was performed in a Pascal pressure cooker (DakoCytomation, Inc. Carpinteria, 
USA) using preheated 0.1 mM Tris/HCl buffer for 15 minutes at 125 ºC. Endogenous 
peroxidase was blocked with 0.3% H2O2 in PBS for 30 minutes. Mouse monoclonal 
antibodies against AKAP5 (sc-17772, Santa Cruz; 1:25), AKAP12 (ab87067, Abcam; 
1:25) or Ezrin [3C12] (ab4069, Abcam; 1:25) in PBS containing 1% BSA were used as a 
first antibody and incubated overnight at 4°C. Incubation time of the secondary antibody 
(rabbit-α-mouse 1:100) and third antibody (goat-α-rabbit 1:100) in 1% Human AB serum 
in 1% BSA/PBS was 30 minutes. Visualization was performed by 0.1% 3.3’-
diaminobenzidine staining for 10 minutes. Sections were counterstained with 
haematoxylin for 3 minutes. Semi-quantitative evaluation of the intensity of the staining 
in ASM or total tissue was performed by two persons by independent identification of 
the intensity of the staining in four classes: [0] no, [1] low, [2] medium and [3] strong.  
Measurements of IL-8 and cell viability - IL-8 was measured in cell 
supernatants using an ELISA kit (PeliKine compact™; Sanquin, Amsterdam, The 
Netherlands) according to the manufacturer’s instructions. After removal of the media, 
the cells were washed twice with PBS, and viability was determined using the 
AlamarBlue® method (30). 
	
	
Immunofluorescence - Cells were seeded on coverslips, and after 24 hours put 
to serum free conditions overnight, they were stimulated for 2 hours. After stimulation 
cells were fixed in 3% paraformaldehyde (PFA) for 15 minutes, subsequently 3% PFA 
and 0.3% Triton X-100 were added. Blocking was performed (1% BSA and 2% donkey 
serum in CytoTBS-T for 1 h) followed by incubating in a humidifying chamber with the 
primary antibody against p65 (1:20 in blocking solution) at 4 °C. Nuclei were stained 
with a Hoechst staining (1:10000). ProLong Gold antifade reagent was added to mount 
the cells before cells were visualized. Co-localization of p65 with nuclear staining was 
quantified using Tissuefaxs (TissueGnostics GmbH). 
Data processing and statistical analysis - Normal distribution was determined 
using the Shapiro Wilk Shapiro–Wilk test and if normal distribution was determined, 
differences between two groups were compared by paired sampled T-test, when looking 
at cell culture experiments, unless stated otherwise. A Kruskal–Wallis one-way analysis 
of variance followed by Mann-Whitney U test was used when comparing patient 
material. A two tailed p-value <0.05 was considered as statistically significant. All tests 
were performed using SPSS 22.0 for Windows. 
 
Results  
In order to investigate AKAP expression in hTERT ASM cells we initially carried out RII 
overlay assays. Protein samples from the cells were separated by SDS-PAGE, blotted 
onto nitrocellulose and overlaid with radioactively labelled regulatory RIIα subunits of 
PKA that bind to AKAPs on the nitrocellulose membranes ((35-37); Figure 1A). Pre-
incubation of RIIα subunits with the peptide AKAP18δ-L314E, (L314E), which, like the 
st-Ht31 peptide (37), binds with subnanomolar affinity to the AKAP-binding site of RII 
subunits to abolish AKAP-RII interactions, abrogated binding of RIIα to AKAPs (Figure 
1A, right panel). This confirms that AKAP detection carried out in the presence of the 
inactive control peptide, AKAP18δ-PP, was specific (Figure 1A, left panel). The 
molecular weights of the detected proteins correspond to those of several known 
AKAPs, and subsequent Western blotting identified AKAP5, AKAP8, AKAP9, AKAP12 
and Ezrin in hTERT ASM cells (Figure 1B). In the RII overlay, exposure to CSE altered 
the AKAP protein pattern with most AKAP signals, being reduced (Figure 1A). Using 
immunoblotting, the effects of CSE exposure on the protein expression of the identified 
AKAPs were compared (Figure 1C). AKAP5, AKAP9 and AKAP12 were decreased 
whereas Ezrin expression was increased, and AKAP8 was not affected. 
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overnight at 4 °C. Blots were incubated with secondary antibody (1:2000 A9044 or 
A0545; Sigma-Aldrich). Signals were detected with chemiluminescence reagents 
according to the manufacturer's protocol. GAPDH (1:2000; sc-47724; Santa Cruz 
Biotechnology) served as a control for equal loading. Blots were quantified using 
ImageJ. 
Real time PCR - After 24 hours, total RNA was isolated using the NucleoSpin® 
RNA II isolation kit (Machery-Nagel) and cDNA was obtained using the Reverse 
Transcription System (A3500, Promega) following the manufacturers’ instructions. This 
cDNA was used as a template for quantitative real time PCR for AKAP5 (Forward; 5’-
GACGCCCTACGTTGATCT-3’, Reverse; 5’- GAAATGCCCAGTTTCTCTATG-3’), and 
AKAP12 (Forward; 5’-CAAGCACAGGAGGAGTTACAG-3’, Reverse; 5’- 
CTGGTCTTCCAAACAGACAATG-3’) using the PIXO™ Real-Time PCR (Helixis, 
Carlsbad, CA, USA). Relative quantifications of gene expression were normalized 
against 18S expression (Forward; 5’-CGCCGCTAGAGGTGAAATTC-3’, Reverse; 5’- 
TTGGCAAATGCTTTCGCTC-3’). 
Immunohistochemistry –3 micron sections from paraffin embedded lung tissue 
from COPD patients and control subjects (Table 2) were deparaffinized and antigen 
retrieval was performed in a Pascal pressure cooker (DakoCytomation, Inc. Carpinteria, 
USA) using preheated 0.1 mM Tris/HCl buffer for 15 minutes at 125 ºC. Endogenous 
peroxidase was blocked with 0.3% H2O2 in PBS for 30 minutes. Mouse monoclonal 
antibodies against AKAP5 (sc-17772, Santa Cruz; 1:25), AKAP12 (ab87067, Abcam; 
1:25) or Ezrin [3C12] (ab4069, Abcam; 1:25) in PBS containing 1% BSA were used as a 
first antibody and incubated overnight at 4°C. Incubation time of the secondary antibody 
(rabbit-α-mouse 1:100) and third antibody (goat-α-rabbit 1:100) in 1% Human AB serum 
in 1% BSA/PBS was 30 minutes. Visualization was performed by 0.1% 3.3’-
diaminobenzidine staining for 10 minutes. Sections were counterstained with 
haematoxylin for 3 minutes. Semi-quantitative evaluation of the intensity of the staining 
in ASM or total tissue was performed by two persons by independent identification of 
the intensity of the staining in four classes: [0] no, [1] low, [2] medium and [3] strong.  
Measurements of IL-8 and cell viability - IL-8 was measured in cell 
supernatants using an ELISA kit (PeliKine compact™; Sanquin, Amsterdam, The 
Netherlands) according to the manufacturer’s instructions. After removal of the media, 
the cells were washed twice with PBS, and viability was determined using the 
AlamarBlue® method (30). 
	
	
Immunofluorescence - Cells were seeded on coverslips, and after 24 hours put 
to serum free conditions overnight, they were stimulated for 2 hours. After stimulation 
cells were fixed in 3% paraformaldehyde (PFA) for 15 minutes, subsequently 3% PFA 
and 0.3% Triton X-100 were added. Blocking was performed (1% BSA and 2% donkey 
serum in CytoTBS-T for 1 h) followed by incubating in a humidifying chamber with the 
primary antibody against p65 (1:20 in blocking solution) at 4 °C. Nuclei were stained 
with a Hoechst staining (1:10000). ProLong Gold antifade reagent was added to mount 
the cells before cells were visualized. Co-localization of p65 with nuclear staining was 
quantified using Tissuefaxs (TissueGnostics GmbH). 
Data processing and statistical analysis - Normal distribution was determined 
using the Shapiro Wilk Shapiro–Wilk test and if normal distribution was determined, 
differences between two groups were compared by paired sampled T-test, when looking 
at cell culture experiments, unless stated otherwise. A Kruskal–Wallis one-way analysis 
of variance followed by Mann-Whitney U test was used when comparing patient 
material. A two tailed p-value <0.05 was considered as statistically significant. All tests 
were performed using SPSS 22.0 for Windows. 
 
Results  
In order to investigate AKAP expression in hTERT ASM cells we initially carried out RII 
overlay assays. Protein samples from the cells were separated by SDS-PAGE, blotted 
onto nitrocellulose and overlaid with radioactively labelled regulatory RIIα subunits of 
PKA that bind to AKAPs on the nitrocellulose membranes ((35-37); Figure 1A). Pre-
incubation of RIIα subunits with the peptide AKAP18δ-L314E, (L314E), which, like the 
st-Ht31 peptide (37), binds with subnanomolar affinity to the AKAP-binding site of RII 
subunits to abolish AKAP-RII interactions, abrogated binding of RIIα to AKAPs (Figure 
1A, right panel). This confirms that AKAP detection carried out in the presence of the 
inactive control peptide, AKAP18δ-PP, was specific (Figure 1A, left panel). The 
molecular weights of the detected proteins correspond to those of several known 
AKAPs, and subsequent Western blotting identified AKAP5, AKAP8, AKAP9, AKAP12 
and Ezrin in hTERT ASM cells (Figure 1B). In the RII overlay, exposure to CSE altered 
the AKAP protein pattern with most AKAP signals, being reduced (Figure 1A). Using 
immunoblotting, the effects of CSE exposure on the protein expression of the identified 
AKAPs were compared (Figure 1C). AKAP5, AKAP9 and AKAP12 were decreased 
whereas Ezrin expression was increased, and AKAP8 was not affected. 
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Immunofluorescence microscopic analyses revealed similar effects of CSE on AKAP5, 
AKAP12 and Ezrin levels (Figure 1D).  
To assess whether similar changes in AKAP expression are also seen upon 
long-term cigarette smoke exposure in COPD patients, we studied mRNA expression of 
the different AKAPs in lung tissue. We observed that the mRNA levels of AKAP5 
(Figure 2A) and AKAP12 (Figure 2B) were lower in COPD patients with both GOLD 
stages II and IV compared to control subjects. No significant differences in AKAP5 or 
AKAP12 expression were seen between GOLD stage II and IV patients. To study 
whether the reduced mRNA levels of AKAP5 and AKAP12 in lung tissue of COPD 
patients could be the result of cigarette smoke exposure, we studied the effect of CSE 
on AKAP5 and AKAP12 mRNA levels in primary ASM cells. Indeed, in all primary ASM 
cell lines tested, AKAP5 and AKAP12 mRNA was reduced upon CSE exposure (Figure 
2C).  
We next assessed AKAP protein immunoreactivity in lung sections from COPD patients 
and control subjects, all of which are ex-smokers (Table 2). Consistent with a recent 
report for AKAP9 expression (31), AKAP5, AKAP12 (Figure 3A & 4A) and Ezrin (Figure 
5) exhibited prominent immunoreactivity in the epithelium. In the ASM layer, Ezrin was 
not detected (received a score of 0), but strong immunoreactivity for AKAP5 and 
AKAP12 was evident (Figure 3A & 4A, white arrows). 
AKAP5 in the ASM showed a decrease in the COPD stage II samples versus 
control samples and but was similar to controls in specimens from COPD stage IV 
donors (p<0.05 and p=0.09 respectively, Figure 5B). AKAP12 was not significantly 
different in the COPD stages II and IV versus controls (Figure 4B).  
We next examined functional implications for altered AKAP expression in CSE-
exposed ASM cells and ASM from lungs of subjects with COPD. In agreement with our 
previous findings (30), CSE induced IL-8 release from hTERT ASM cells, with the levels 
in cell culture supernatant being increased by 77±21% compared to basal levels in 
untreated cultures (P<0.01, Figure 6A & B). Cell viability was unaffected (Figure 6C & 
D). We found that CSE-induced IL-8 release was dose-dependently attenuated by the 
β2-agonist, fenoterol, with a maximum reduction of 50% being reached with 0.1 µM 
fenoterol (p<0.01; Figure 6A). The PKA activator 6-Bnz (500 μM) also reduced CSE-
induced IL-8 release by about 50% (Figure 6B). Similarly, as we observed previously 
(30), selective pharmacological activation of Epac with 8-pCPT (100 μM) decreased 
CSE-induced IL-8 release (p=0.07, Figure 6B).  
 
	
	
	
Figure 1: Cigarette smoke extract (CSE) changes the expression of several AKAPs in human ASM. (A) RII-
overlay for the detection of AKAPs before and after 24 h of CSE treatment (15 %). Pre-incubation with peptide 
AKAP18δ-L314E (L314E), which binds to regulatory RII subunits of PKA and thereby blocks the interaction of the 
radioactive RII subunits with the AKAPs on the membrane, served as a control to confirm the specificity of the 
signals. The peptide AKAP18δ-PP (PP), which does not bind RII subunits, does not interfere with the interaction 
of the labeled RII subunits and the AKAPs on the membrane. (B) Expression of AKAP5 (AKAP79), AKAP12 
(AKAP250, Gravin), AKAP8 (AKAP95), AKAP9 (AKAP450, AKAP350, Yotiao) and Ezrin (AKAP78) were 
confirmed using immunoblotting. (C, D) AKAP expression was studied by immunoblotting and 
immunofluorescence before and after treatment with 15% CSE for 24 h. Results are expressed as means ±SEM, 
n = 3-6 separate experiments. *p<0.05, **p<0.01 compared to unstimulated controls. 
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Immunofluorescence microscopic analyses revealed similar effects of CSE on AKAP5, 
AKAP12 and Ezrin levels (Figure 1D).  
To assess whether similar changes in AKAP expression are also seen upon 
long-term cigarette smoke exposure in COPD patients, we studied mRNA expression of 
the different AKAPs in lung tissue. We observed that the mRNA levels of AKAP5 
(Figure 2A) and AKAP12 (Figure 2B) were lower in COPD patients with both GOLD 
stages II and IV compared to control subjects. No significant differences in AKAP5 or 
AKAP12 expression were seen between GOLD stage II and IV patients. To study 
whether the reduced mRNA levels of AKAP5 and AKAP12 in lung tissue of COPD 
patients could be the result of cigarette smoke exposure, we studied the effect of CSE 
on AKAP5 and AKAP12 mRNA levels in primary ASM cells. Indeed, in all primary ASM 
cell lines tested, AKAP5 and AKAP12 mRNA was reduced upon CSE exposure (Figure 
2C).  
We next assessed AKAP protein immunoreactivity in lung sections from COPD patients 
and control subjects, all of which are ex-smokers (Table 2). Consistent with a recent 
report for AKAP9 expression (31), AKAP5, AKAP12 (Figure 3A & 4A) and Ezrin (Figure 
5) exhibited prominent immunoreactivity in the epithelium. In the ASM layer, Ezrin was 
not detected (received a score of 0), but strong immunoreactivity for AKAP5 and 
AKAP12 was evident (Figure 3A & 4A, white arrows). 
AKAP5 in the ASM showed a decrease in the COPD stage II samples versus 
control samples and but was similar to controls in specimens from COPD stage IV 
donors (p<0.05 and p=0.09 respectively, Figure 5B). AKAP12 was not significantly 
different in the COPD stages II and IV versus controls (Figure 4B).  
We next examined functional implications for altered AKAP expression in CSE-
exposed ASM cells and ASM from lungs of subjects with COPD. In agreement with our 
previous findings (30), CSE induced IL-8 release from hTERT ASM cells, with the levels 
in cell culture supernatant being increased by 77±21% compared to basal levels in 
untreated cultures (P<0.01, Figure 6A & B). Cell viability was unaffected (Figure 6C & 
D). We found that CSE-induced IL-8 release was dose-dependently attenuated by the 
β2-agonist, fenoterol, with a maximum reduction of 50% being reached with 0.1 µM 
fenoterol (p<0.01; Figure 6A). The PKA activator 6-Bnz (500 μM) also reduced CSE-
induced IL-8 release by about 50% (Figure 6B). Similarly, as we observed previously 
(30), selective pharmacological activation of Epac with 8-pCPT (100 μM) decreased 
CSE-induced IL-8 release (p=0.07, Figure 6B).  
 
	
	
	
Figure 1: Cigarette smoke extract (CSE) changes the expression of several AKAPs in human ASM. (A) RII-
overlay for the detection of AKAPs before and after 24 h of CSE treatment (15 %). Pre-incubation with peptide 
AKAP18δ-L314E (L314E), which binds to regulatory RII subunits of PKA and thereby blocks the interaction of the 
radioactive RII subunits with the AKAPs on the membrane, served as a control to confirm the specificity of the 
signals. The peptide AKAP18δ-PP (PP), which does not bind RII subunits, does not interfere with the interaction 
of the labeled RII subunits and the AKAPs on the membrane. (B) Expression of AKAP5 (AKAP79), AKAP12 
(AKAP250, Gravin), AKAP8 (AKAP95), AKAP9 (AKAP450, AKAP350, Yotiao) and Ezrin (AKAP78) were 
confirmed using immunoblotting. (C, D) AKAP expression was studied by immunoblotting and 
immunofluorescence before and after treatment with 15% CSE for 24 h. Results are expressed as means ±SEM, 
n = 3-6 separate experiments. *p<0.05, **p<0.01 compared to unstimulated controls. 
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Figure 2: Expression of AKAP5 and AKAP12 mRNA is altered in COPD patients and by CSE in vitro. 
Expression of (A) AKAP5 and (B) AKAP12 was measured in lung tissue of subjects without COPD, COPD GOLD 
stages II or IV (n=5 each group). See Table 1 for characteristics of the subjects. (C) Gene expression of AKAP5 
and AKAP12 were measured in primary airway smooth muscle cells after exposure to 15% CSE for 24 h, each 
data point reflects a separate donor. Results are expressed as individual data points with the median of the 
separate experiments. *p<0.05, **p<0.01 compared to unstimulated control subjects (A & B) or basal controls (C). 
 
	
Figure 3: Expression of AKAP5 in COPD patients and control subjects. AKAP5 protein expression was 
analyzed by immunohistochemistry in lung tissue from COPD patients and control subjects. A representative 
image of a control patient is shown (A). Bars indicate 100 µm. (B) Semi-quantification of expression in the ASM of 
COPD versus control patients. See Table 2 for details of the patients, all individuals were ex-smokers. White 
arrows indicate smooth muscle. Results are expressed as individual data points for each patient with the median 
of the separate experiments, *p<0.05. 
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To determine the role of AKAP-PKA interactions in CSE-induced IL-8 release and in the 
inhibitory effects of the β2-agonist fenoterol, the PKA activator 6-Bnz, and the Epac 
activator 8-pCPT, we next measured the impact of the cell-permeant PKA anchoring 
disruptor peptide, st-Ht31. The control peptide st-Ht31P could not be used as a control, 
since it caused death of the ASM cells (Figure 6E), which is in line with observations in 
human bronchial epithelial cells (31). Treatment with st-Ht31 (50 μM) did not affect 
viability of the hTERT ASM under any condition (Figure 6C), while it caused a small but 
significant increase of IL-8 release under basal conditions, and markedly augmented IL-
8 release from CSE-exposed ASM cells (p<0.05 both; Figure 6A & B). In addition, 
disrupting AKAP-PKA interactions with st-Ht31 significantly reversed the inhibitory 
effects of the β2-agonist fenoterol on CSE-induced IL-8 release by about 50% (Figure 
6A), and the presence of fenoterol could not prevent the augmentation of IL-8 release 
that was induced by st-Ht31 in CSE-exposed cultures. We also studied the effect of the 
peptide in the presence of the PKA activator 6-Bnz, which fully activates PKA 
throughout the cell beyond any compartmental restrictions. 6-Bnz significantly reduced 
IL-8 release and disruption of AKAP-PKA interactions with st-Ht31 did not reverse the 
suppressive effects of 6-Bnz on CSE-induced IL-8 release (Figure 6B); this further 
supports the notion that AKAP-PKA interactions are required for the inhibitory effect of 
cAMP on IL-8.  
	
Figure 4: Expression of AKAP12 in COPD patients and control subjects. AKAP12 protein expression was 
analyzed by immunohistochemistry in lung tissue from COPD patients and control subjects. A representative 
picture of a control patient is shown (A). Bars indicate 100 µm. (B) Semi-quantification of expression in the ASM of 
COPD versus control patients. See Table 2 for details of the patients, all individuals were ex-smokers. White 
arrows indicate smooth muscle. Results are expressed as individual data points for each patient with the median 
of the separate experiments.  
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Figure 2: Expression of AKAP5 and AKAP12 mRNA is altered in COPD patients and by CSE in vitro. 
Expression of (A) AKAP5 and (B) AKAP12 was measured in lung tissue of subjects without COPD, COPD GOLD 
stages II or IV (n=5 each group). See Table 1 for characteristics of the subjects. (C) Gene expression of AKAP5 
and AKAP12 were measured in primary airway smooth muscle cells after exposure to 15% CSE for 24 h, each 
data point reflects a separate donor. Results are expressed as individual data points with the median of the 
separate experiments. *p<0.05, **p<0.01 compared to unstimulated control subjects (A & B) or basal controls (C). 
 
	
Figure 3: Expression of AKAP5 in COPD patients and control subjects. AKAP5 protein expression was 
analyzed by immunohistochemistry in lung tissue from COPD patients and control subjects. A representative 
image of a control patient is shown (A). Bars indicate 100 µm. (B) Semi-quantification of expression in the ASM of 
COPD versus control patients. See Table 2 for details of the patients, all individuals were ex-smokers. White 
arrows indicate smooth muscle. Results are expressed as individual data points for each patient with the median 
of the separate experiments, *p<0.05. 
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To determine the role of AKAP-PKA interactions in CSE-induced IL-8 release and in the 
inhibitory effects of the β2-agonist fenoterol, the PKA activator 6-Bnz, and the Epac 
activator 8-pCPT, we next measured the impact of the cell-permeant PKA anchoring 
disruptor peptide, st-Ht31. The control peptide st-Ht31P could not be used as a control, 
since it caused death of the ASM cells (Figure 6E), which is in line with observations in 
human bronchial epithelial cells (31). Treatment with st-Ht31 (50 μM) did not affect 
viability of the hTERT ASM under any condition (Figure 6C), while it caused a small but 
significant increase of IL-8 release under basal conditions, and markedly augmented IL-
8 release from CSE-exposed ASM cells (p<0.05 both; Figure 6A & B). In addition, 
disrupting AKAP-PKA interactions with st-Ht31 significantly reversed the inhibitory 
effects of the β2-agonist fenoterol on CSE-induced IL-8 release by about 50% (Figure 
6A), and the presence of fenoterol could not prevent the augmentation of IL-8 release 
that was induced by st-Ht31 in CSE-exposed cultures. We also studied the effect of the 
peptide in the presence of the PKA activator 6-Bnz, which fully activates PKA 
throughout the cell beyond any compartmental restrictions. 6-Bnz significantly reduced 
IL-8 release and disruption of AKAP-PKA interactions with st-Ht31 did not reverse the 
suppressive effects of 6-Bnz on CSE-induced IL-8 release (Figure 6B); this further 
supports the notion that AKAP-PKA interactions are required for the inhibitory effect of 
cAMP on IL-8.  
	
Figure 4: Expression of AKAP12 in COPD patients and control subjects. AKAP12 protein expression was 
analyzed by immunohistochemistry in lung tissue from COPD patients and control subjects. A representative 
picture of a control patient is shown (A). Bars indicate 100 µm. (B) Semi-quantification of expression in the ASM of 
COPD versus control patients. See Table 2 for details of the patients, all individuals were ex-smokers. White 
arrows indicate smooth muscle. Results are expressed as individual data points for each patient with the median 
of the separate experiments.  
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In contrast, we observed that increased IL-8 release induced by st-Ht31 in CSE-
exposed cells was refractory to treatment with the Epac activator, 8-pCPT (Figure 6B). 
IL-8 release induced by CSE involves nuclear translocation of the NF-κB 
subunit, p65, which is regulated by Epac (30). In a manner similar to TNFα (used as 
positive control), CSE caused nuclear translocation of p65 (Figure 7). As seen for IL-8 
release, CSE-induced p65 nuclear translocation was unaffected by the addition of st-
Ht31 (Figure 7, quantifications not shown). PKA activity, as measured by VASP 
phosphorylation (30) was not affected by st-Ht31 suggesting that disruption of AKAP-
PKA complexes by st-Ht31 does not profoundly alter basal or CSE-induced total cellular 
PKA activity (Figure 8A). Interestingly, CSE alone did induce a significant increase in 
VASP phosphorylation (Figure 8A). There is evidence that direct activation of PKA 
attenuated CSE-induced IL-8 release by inhibiting ERK1/2 phosphorylation (30). In line 
with the effect of st-Ht31 to increase basal IL-8 release, we also observed that st-Ht31 
increased basal phosphorylation of ERK1/2 (Figure 8B). CSE-induced phosphorylation 
of ERK1/2 was not affected by st-Ht31. However, the peptide did give a trend towards 
prevention of the inhibitory effect of fenoterol on CSE-induced ERK1/2 phosphorylation 
(Figure 8B, p=0.078), similar to the effect of st-Ht31 without CSE stimulation (Figure 
8B). Collectively, these data suggest an important role for AKAP-PKA interactions in the 
regulation of ASM mediated inflammatory responses.  
 
Discussion 
In the current study we describe the expression of a subset of AKAPs that are differently 
affected by CSE exposure in ASM cells. In particular, the expression level of AKAP5, 
which is an important regulator of β2-AR sensitivity (22-24, 38), was significantly 
reduced, suggesting a mechanism that could link cigarette smoking and COPD 
pathogenesis (25). We show that mRNA for AKAP5 and AKAP12 is reduced in lung 
tissue obtained from COPD patients, and using immunohistochemistry and observed a 
significant decrease of AKAP5 protein in COPD stage II lung specimens. Disruption of 
AKAP-PKA interaction with st-Ht31 increased basal and CSE-induced IL-8 release from 
ASM cells and prevented the inhibitory effect of the β2-agonist, fenoterol, on IL-8 
secretion, i.e. prevented fenoterol’s anti-inflammatory effect. This indicates that the 
inhibitory effect of fenoterol at least in part depends on AKAP-PKA interactions. 
Inhibition of AKAP-PKA interactions is associated with a disruption of the inhibitory 
action of fenoterol on ERK phosphorylation. These data indicate that CSE-induced 
downregulation of AKAPs may promote airway inflammation and may reduce the 
	
	
regulatory effect of β2-agonists on CSE-induced airway inflammation. Our study is the 
first to link AKAPs to cigarette smoke-evoked inflammatory responses in ASM cells.  
Previously, we had demonstrated that CSE-induced IL-8 release from human 
ASM cells is prevented by treatment with fenoterol as well as by selective activation of 
the cAMP effectors PKA and Epac (30). Epac activation had less pronounced effects on 
CSE-induced IL-8 release compared to PKA activation. The more limited effectiveness 
of Epac activation with 8-pCPT is most likely due to a reduction of Epac1 expression that 
can be induced by CSE (30, 39). We reported earlier that activation of PKA inhibits CSE-
induced IL-8 release by suppressing ERK1/2 phosphorylation (30). To analyze the 
potential involvement of AKAPs in the reduction of CSE-induced IL-8 release by 
fenoterol/PKA, we used the AKAP-PKA interaction inhibitor st-Ht31, demonstrating that 
AKAPs are required for spatial coordination of PKA activity that suppresses ERK1/2 via 
β2-adrenoceptors. CSE-induced phosphorylation of ERK1/2 was not affected by st-Ht31, 
possibly because the phospho-ERK1/2 signal was already at its maximum. With the 
observation that the CSE-induced IL-8 release, in contrast to ERK1/2 phosphorylation, 
CSE-induced IL-8 release is further enhanced with the addition of st-Ht31 most likely, it 
is possible that another AKAP-PKA sensitive pathway is involved in the IL-8 release. For 
example other reportsstudies have identified that p38- and JNK as-induced signaling 
pathways that can contribute toregulate the release of IL-8 (40), and that these kinases 
could also be affected by PKA. 
A role for AKAPs in coordinating the duration of cAMP production after 
stimulation of the β2-adrenoceptor has been shown in several cell types, including ASM 
cells transfected with a cyclic nucleotide gated ion channel-based reporter (20). In that 
study, disruptors of AKAP-PKA interactions, Ht31 and AKAP-IS, did not cause a change 
in whole cell cAMP accumulation after stimulation with the β2-agonist isoprenaline or 
forskolin, a direct activator of cAMP producing adenylyl cyclases (41). However, the 
duration of the transient local cAMP signal measured at the plasma membrane was 
significantly sustained by AKAP-PKA interaction disruptors (20). It was shown that 
AKAP12 is responsible for resensitization and recycling of the β2-adrenoceptor after 
treatment with isoproterenol, whereas AKAP5 is responsible for PKA mediated β2-
adrenoceptor phosphorylation and subsequent switching from the cAMP pathway to β-
arrestin-ERK1/2 signaling (22, 23, 25, 38, 42). Therefore, the altered expression of 
AKAP5 after exposure to CSE and in COPD might have important consequences for 
ERK1/2 in IL-8 signaling.  
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Figure 5: Expression of Ezrin expression in lung tissue of COPD patients and control subjects. Ezrin 
protein expression was analyzed by immunohistochemistry in lung tissue from COPD patients and control 
subjects. (A) Representative pictures are shown. Bars indicate 200 µm. (B) Semi-quantification of the signals was 
independently performed in duplicate by two persons for COPD versus control patients. See Table 2 for details of 
the patients, all individuals were ex-smokers. Results are expressed as individual data points for each patient with 
the median of the separate experiments, *p<0.05, control patients versus COPD patients. 
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Figure 6: AKAPs coordinate CSE-induced IL-8 release from hTERT ASM. (A) IL-8 release was measured 
using ELISA after 24 h exposure to 15% CSE in the absence or presence of st-Ht31, fenoterol, (B) IL-8 release 
was measured using ELISA after 24 h exposure to 15% CSE in the absence or presence of 6-Bnz-cAMP or 8-
pCPT-2’-O-Me-cAMP. (C) Cell viability was tested after 24 h using alamarBlue®. (D) The cells were incubated 
with the peptide st-Ht31P in the indicated concentrations for 24 h (n=3). The AKAP-PKA interaction disruptor 
peptide st-Ht31 (50 µM) was added 20 min. before the addition of fenoterol, 8-pCPT or 6-Bnz, CSE was added 25 
min. after this (n=4-15). *p<0.05, **p<0.01, ***p<0.001 compared to unstimulated control or as indicated. 
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We observed that CSE causes a downregulation of AKAP5 and AKAP12 mRNA 
and protein in both immortalized and primary ASM cells, suggesting a novel mechanism 
for CSE influences on β2-adrenoceptor-directed cell functions. Since st-Ht31 reduces the 
anti-inflammatory effects of fenoterol, CSE-induced alterations in AKAP expression may 
contribute to increased IL-8 release from ASM. We also observed the downregulation of 
AKAP5 and AKAP12 mRNA in lung tissue from COPD patients, suggesting roles of 
these AKAPs in β2-adrenoceptor responses. Previously, it was observed in BeWo 
trophoblast cells that a common pathway may regulate expression of AKAP5 and 
AKAP12 protein and mRNA, which is different from that of AKAP8 mRNA regulation 
(43). Along these lines, in the current study, we observed that CSE reduced AKAP5 and 
AKAP12 mRNA expression, while AKAP8 was not affected.  
In addition to ASM, we observed high expression of AKAP5 and AKAP12 in 
airway epithelium. Recently, we showed (31), in contrast to our current findings in ASM 
cells, that expression of AKAP5 and AKAP12 is not significantly altered by CSE in 
bronchial epithelial cells in vitro. In bronchial epithelial cells, AKAPs (presumably 
AKAP9), are involved in maintaining cell-cell contacts and the epithelial barrier function 
by interaction with the adhesion molecule E-cadherin (31). The observed dysregulation 
of AKAP expression after CSE exposure could contribute to an increased inflammatory 
response as seen in COPD (1). In line with this, we report here that disturbing AKAP 
functioning using st-Ht31 increased the IL-8 release.  
Dysfunction of cAMP compartmentalization and local PKA signaling occurs in 
various diseases including cardiac and neurological diseases (Chapter 2) (44, 45), and 
here we show this also may play a role in COPD. The observed dysregulation of the 
expression of AKAPs that are important in β2-adrenoceptor regulation may pave the way 
to novel pharmacological approaches for the treatment of COPD. In summary, the 
current study demonstrates that AKAPs, in particular their interactions with PKA, are 
involved in the regulation of pro-inflammatory responses, specifically IL-8 release by 
ASM. In addition, we show that AKAP5 and AKAP12, which can regulate β2-
adrenoceptor sensitivity, are dysregulated upon CSE exposure and in COPD patients. 
Therefore, there is a potential for regulating inflammatory responses and possibly β2-
adrenoceptor functioning by pharmacological targeting of AKAPs. 
 
	
	
	
	
Figure 7: Disruption of AKAP-PKA interactions does not affect the NF-κB pathway. Using 
immunofluorescence, nuclear translocation of p65 was visualized after 2 h of exposure to 15% CSE in the 
absence or presence of st-Ht31, using TNF-α as a positive control. Representative pictures of 3 independent 
experiments are shown. Bars indicate 10 µm.  
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Figure 8: Disruption of AKAP-PKA interactions inhibits fenoterol-induced inhibition of ERK 
phosphorylation, without affecting PKA activation. (A) PKA activity was determined using the phosphorylation 
of VASP at Ser157 after 10 min exposure to 15% CSE in the absence or presence of st-Ht31. (B) Phosphorylation 
of ERK1/2 was visualized after 1 h of 15% CSE exposure in the absence or presence of st-Ht31. Protein 
phosphorylation was corrected for total protein loaded in each lane either by taking the ratio of the density of the 
phosphorylated-protein against the sum of the phosphorylated and non-phosphorylated protein (A) or the ratio of 
the phosphorylated protein against total protein (B). *p<0.05, **p<0.01 statistically significant differences, 
compared to unstimulated control.	 
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phosphorylated-protein against the sum of the phosphorylated and non-phosphorylated protein (A) or the ratio of 
the phosphorylated protein against total protein (B). *p<0.05, **p<0.01 statistically significant differences, 
compared to unstimulated control.	 
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Abstract  
A major hallmark of chronic obstructive pulmonary disease (COPD) is the infiltration and 
activation of inflammatory cells, particularly neutrophils, macrophages, and lymphocytes. 
Recently, it has been shown that A-kinase anchoring proteins (AKAPs) regulate the 
release of the neutrophil attractant IL-8. This study focuses on AKAP5 and AKAP12, 
which were found previously to be lower expressed in lung biopsies from COPD patients 
compared to non-COPD patients. We exposed wildtype, AKAP5-/- and AKAP12-/- mice to 
air or cigarette smoke for four days followed by measuring KC (IL-8 homologue) release 
and inflammatory cells in bronchoalveolar lavage (BAL). In wildtype mice, cigarette 
smoke exposure decreased AKAP5 and AKAP12 gene expression, and resulted in 
increased KC levels and neutrophil counts in BAL. In AKAP5-/- mice, this inflammatory 
effect was aggravated in cigarette smoke-exposed without affecting these parameters in 
the air-exposed mice. In AKAP12-/- mice, KC levels were similar to wildtype mice in both 
the air-exposed and cigarette smoke-exposed groups. However, AKAP12-/- mice had 
increased numbers of neutrophils, macrophages and lymphocytes in BAL fluid compared 
to wildtype mice in the air-exposed group, with no further increase upon cigarette smoke 
exposure. In conclusion, our data indicate that AKAP12 suppresses infiltration of 
inflammatory cells at baseline, whereas AKAP5 specifically suppresses cigarette smoke-
induced KC-mediated neutrophilia. Although the mechanism of action needs to be 
elucidated, this indicates that cigarette smoke-induced downregulation of these AKAPs 
may result in the development of neutrophilic airway inflammation. 
 
Introduction 
Chronic obstructive pulmonary disease (COPD) is a devastating lung disorder mainly 
caused by cigarette smoke that - according to the World Health Organization - will 
become the third leading cause of death worldwide by 2030. Underlying pathogenic 
processes include infiltration and activation of inflammatory cells, particularly neutrophils, 
macrophages and lymphocytes (1, 2).  
The second messenger cyclic AMP (cAMP), which is produced upon activation 
of the β2-adrenoceptor, has anti-inflammatory effects and is an important target in the 
anti-inflammatory treatment of COPD using phosphodiesterase (PDE) inhibitors that 
effectively suppress neutrophil recruitment to the lung (3). By hydrolyzing cAMP, PDEs 
prevent the diffusion of cAMP and create local compartments, which are important to 
allow a tight control of cAMP signaling events throughout the cell. In addition to PDE 
phosphodiesterase, compartmentalization of cAMP involves the scaffolding proteins A-
kinase anchoring proteins (AKAPs). We and others have shown previously by means of 
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air or cigarette smoke for four days followed by measuring KC (IL-8 homologue) release 
and inflammatory cells in bronchoalveolar lavage (BAL). In wildtype mice, cigarette 
smoke exposure decreased AKAP5 and AKAP12 gene expression, and resulted in 
increased KC levels and neutrophil counts in BAL. In AKAP5-/- mice, this inflammatory 
effect was aggravated in cigarette smoke-exposed without affecting these parameters in 
the air-exposed mice. In AKAP12-/- mice, KC levels were similar to wildtype mice in both 
the air-exposed and cigarette smoke-exposed groups. However, AKAP12-/- mice had 
increased numbers of neutrophils, macrophages and lymphocytes in BAL fluid compared 
to wildtype mice in the air-exposed group, with no further increase upon cigarette smoke 
exposure. In conclusion, our data indicate that AKAP12 suppresses infiltration of 
inflammatory cells at baseline, whereas AKAP5 specifically suppresses cigarette smoke-
induced KC-mediated neutrophilia. Although the mechanism of action needs to be 
elucidated, this indicates that cigarette smoke-induced downregulation of these AKAPs 
may result in the development of neutrophilic airway inflammation. 
 
Introduction 
Chronic obstructive pulmonary disease (COPD) is a devastating lung disorder mainly 
caused by cigarette smoke that - according to the World Health Organization - will 
become the third leading cause of death worldwide by 2030. Underlying pathogenic 
processes include infiltration and activation of inflammatory cells, particularly neutrophils, 
macrophages and lymphocytes (1, 2).  
The second messenger cyclic AMP (cAMP), which is produced upon activation 
of the β2-adrenoceptor, has anti-inflammatory effects and is an important target in the 
anti-inflammatory treatment of COPD using phosphodiesterase (PDE) inhibitors that 
effectively suppress neutrophil recruitment to the lung (3). By hydrolyzing cAMP, PDEs 
prevent the diffusion of cAMP and create local compartments, which are important to 
allow a tight control of cAMP signaling events throughout the cell. In addition to PDE 
phosphodiesterase, compartmentalization of cAMP involves the scaffolding proteins A-
kinase anchoring proteins (AKAPs). We and others have shown previously by means of 
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AKAP-PKA complex disruption using st-Ht31 or silencing RNAs against different AKAPs 
that AKAPs can inhibit the release of inflammatory mediators such as neutrophil 
attractant interleukin-8 (IL-8) (Chapter 3) (4, 5).  
Previously, we have shown that AKAP5 (AKAP79/150) and AKAP12 
(Gravin/SSeCKS) expression is decreased in bronchial biopsies of COPD patients and 
in cigarette smoke extract-treated airway smooth muscle cells coinciding with an 
increase in IL-8 release (Chapter 3). Others have shown that AKAP12 is not down – but 
upregulated in the presence of pro-inflammatory mediators, including in lung 
homogenates from mice after intraperitoneal injection of lipopolysaccharide, and 
lipopolysaccharide-induced AKAP12 has been shown to mediate cytokine (i.e. TNF-α, 
IL-1β) release from astrocytes (6-10). While AKAP12 is involved in β2-adrenoceptor 
resensitization, AKAP5 is known to regulate β2-adrenoceptor desensitization. Little is 
known about the regulation of inflammatory processes by AKAP5; however, it has been 
identified as a regulating gene in a quantitative trait locus involving neutrophil 
recruitment in a murine model of chemically-induced peritonitis (11). We hypothesized 
that the lower AKAP5 and AKAP12 expression found in COPD patients acts to increase 
neutrophilic airway inflammation. For this aim we used an acute in vivo model of 
pulmonary inflammation, and exposed wildtype, AKAP5-/- and AKAP12-/- mice to air or 
cigarette smoke. . 
 
Materials and methods 
Animals and animal model – Female C57BL/6 wildtype, AKAP5-/- (12) and 
AKAP12-/- (13) mice were used for all experiments. Mice were exposed to the smoke of 
filter-free Kentucky 3R4F research cigarettes (Tobacco Research Institute, University of 
Kentucky, Lexington, KY, USA) by whole-body exposure in a 6L Perspex box, as 
described previously (14, 15). On day 1, mice were exposed to the smoke of 1 cigarette 
in the morning and 3 cigarettes in the afternoon. On day 2, 3 and 4, mice were exposed 
to the smoke of 5 cigarettes in the morning and 5 cigarettes in the afternoon (Figure 
1A). Control animals were exposed to air. Air- and cigarette smoke-exposed wildtype 
mice were included in every experiment to minimize variability. 16 h after the last 
cigarette smoke exposure, animals were euthanized by subcutaneously injecting a mix 
of ketamine (40 mg/kg) and dormitor (0.5 mg/kg) after which the lungs were immediately 
lavaged. Animals were housed conventionally under a 12 h light–dark cycle and 
received food and water ad libitum. All experiments were performed in accordance with 
	
	
the national guidelines and approved by the University of Groningen Institutional Animal 
Care and Use Committee (Groningen, the Netherlands). 
Genotyping and mRNA expression - DNA was isolated from mouse ear using 
the NucleoSpin Tissue kit (Machery Nagel, Düren, Germany), according to the 
manufacturer’s instructions. Using the primers listed in Table 1, we amplified the DNA 
using HotStar Taq Master Mix (Qiagen, Valencia, CA, USA). To verify complete 
knockdown of AKAP5 and AKAP12, the samples were loaded on a 1% agarose gel to 
identify DNA products. RNA from each mouse was collected from frozen lung using 
Nucleospin RNA II kit (Machery Nagel), according to the manufacturer’s instructions. 
cDNA was prepared from RNA followed by real-time quantitative PCR (RT-qPCR; 
Westburg, Leusden, The Netherlands) using the forward and reverse primers listed in 
Table 1. RT-qPCR was performed in duplicate using SYBR Green (Roche) with 
denaturation at 94°C for 30 s, annealing at 59°C for 30 s and extension at 72°C for 30 s 
for 40 cycles followed by 10 min at 72°C. Expression of all target genes mRNA analyzed 
using LinRegPCR software version 2013.1 (16). Data were expressed in arbitrary units 
as ratio of the starting concentration (N0) of each gene of interest corrected to the 
geometric mean of the N0 of two reference genes (18s and Gapdh). 
Analysis of bronchoalveolar lavage (BAL) fluid - After euthanizing the mice, the 
lungs were gently lavaged using a tracheal cannula with 1 mL PBS containing 5% 
bovine serum albumin and protease inhibitors (cØmplete mini Cat # 11 836 153 001, 
Roche Diagnostics GmbH, Mannheim Germany) and another four times with 1 mL PBS. 
Cells from all fractions were collected by centrifugation (200 g, 10 min, 4°C). 
Supernatants of the first wash step were collected for analysis of KC (CXCL1) levels 
using a DuoSet ELISA (DY453-05, R&D systems), according to the manufacturer’s 
protocol. For each animal, BAL cells of the different fractions were combined, 
resuspended in 500 µL PBS, and total cell numbers were determined. After determining 
total cell numbers, 5*105 cells were spun on microscope slides coated with PBS 
containing 3% BSA. Cytospins were stained with May-Grünwald Giemsa (Sigma, St. 
Louis, MO, USA), and neutrophil, macrophage and lymphocyte numbers were 
determined by differential cell counting of 400 cells in duplicate. 
Data processing and statistical analysis - Results are presented as individual data 
points with the median. Outliers were removed from the analysis. Graphs were prepared 
using Prism 5.0 and statistics were performed using SPSS 23.0. Normal distribution was 
determined using a Kolmogorov-Smirnov test for normality. Statistical analysis was 
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performed by means of one-way ANOVA and/or independent T-tests as mentioned. p-
values < 0.05 were considered statistically significant. 
 
Table 1: Primer sequences for the primers used for RT-qPCR analysis and genotyping. 
 
 
Results  
Cigarette smoke exposure reduces AKAP5 and AKAP12 expression – Previously, we 
published that AKAP5 and AKAP12 expression decreased after exposure to cigarette 
smoke extract in airway smooth muscle cells (Chapter 3). To confirm this in vivo, we 
exposed mice to cigarette smoke for four days (Figure 1A). After cigarette smoke 
exposure, wildtype mice showed reduced mRNA expression of AKAP5 (p<0.05), with the 
same trend for AKAP12 mRNA (p=0.06) compared to air-exposed mice (Figure 1B). To 
assess the functional impact of the deficiency of AKAP5 and AKAP12 in cigarette 
smoke-induced airway inflammation, we used AKAP5-/- and AKAP12-/- mice, which were 
shown to express no mRNA of the respective knockout gene (Figure 2A, B). The 
AKAP12-/- mice showed also a significant 3-fold reduction of AKAP5 expression 
compared to wildtype mice (p<0.05; Figure 2B). AKAP5 expression in the AKAP12-/- 
mice was reduced to similar levels as by cigarette smoke exposure in wildtype mice and 
it was not further decreased by cigarette smoke in AKAP12-/- mice (Data not shown). 
AKAP12-/- mRNA expression was unaffected in AKAP5-/- mice.  
 
Primer FW (5'à3') REV (5'à3') 
RT-qPCR       
AKAP12 Akap12 TCCACGTCCAAGAGGAAAGC CTTTGGATGCTGATTCGCCG  
AKAP5 Akap5 GACGATCTGGGTTGGGCTTC  TCCCTTCTCGTCCTTCGTCT  
18s 18s CGCGGTTCTATTTTGTTGGT AGTCGGCATCGTTTATGGTC 
GAPDH Gapdh AACTTTGGCATTGTGGAAGG ACACATTGGGGGTAGGAACA  
  
  
Genotyping PCR 
   
AKAP12 
WT2-R CTC TGA CCT CAT GCA TTC 
WT2-L GTG GAG ATG CTG TCC TCT CAG 
399 Neo-F GCC TCT GTT CCA CAT ACA CTT CAT TC 
TL657-F GTC GCT ACC ATT ACC AGT TGG TCT 
399 Ex2-R CTC TTT TCT CCG GGC TAA TAC TCT GT 
AKAP5 Akap5 AGACCAGCGTTTCTGAG TTCCTGTGTGTCACAAG 
AKAP5-/- Akap5-Neomycin TCGCATGATTGAACAAG AAGCACGAGGAAGCGGT 
	
	
	
 
Figure 1: Cigarette smoke reduced mRNA expression of AKAP5 and AKAP12. (A) Graphical representation 
of the experimental model for pulmonary inflammation with the amount of cigarettes (5 min/cigarette) in the 
morning and afternoon (# Cigs) of the corresponding day (Days). 16 h after the last smoke exposure a 
bronchoalveolar lavage was performed and lungs were harvested for lung tissue homogenates for mRNA 
isolation. (B) AKAP5 and AKAP12 gene expression in wildtype mice exposed to cigarette smoke. Data is shown 
as individual data points with the median and was analyzed using an independent sample T-test; *=p<0.05. 
 
 
Figure 2: Characterization of the AKAP5 and AKAP12 knockout mice. Gene expression of (A) AKAP5 and (B) 
AKAP12 in lung tissue homogenates depicted as N0 corrected for the geometric mean of the N0 for 18S and 
GAPDH, each dot represents an individual mouse with the median. Data was analyzed using an independent 
sample T-test; *=p<0.05, ***=p<0.001. 
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performed by means of one-way ANOVA and/or independent T-tests as mentioned. p-
values < 0.05 were considered statistically significant. 
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AKAP knockout mice show distinct inflammatory responses – We studied the 
effect of AKAP5 and AKAP12 knockout on the level of the murine homologue of IL-8, the 
neutrophil attractant KC, in BAL upon air – and cigarette smoke exposure. At baseline, 
KC levels measured in BAL fluid from the different groups showed no differences. 
Cigarette smoke exposure induced an increase in KC release in all groups, with the 
AKAP5-/- mice showing a significantly higher increase compared to wildtype and 
AKAP12-/- mice (Figure 3). Differential cell counts showed that cigarette smoke 
increases the number of neutrophils, but not of macrophages and lymphocytes in BAL 
fluid from wildtype mice (Figure 4). Similar to the KC effects, AKAP5-/- showed an 
exacerbated response to cigarette smoke exposure with a higher influx of neutrophils 
(Figure 4B, p< 0.001). In the AKAP12-/- mice, neutrophil numbers were already 
increased compared to wildtype mice in the air-exposed mice (Figure 4B, p<0.01), and 
were not further increased in the cigarette smoke exposed group. Total inflammatory cell 
numbers (Figure 4A, p<0.001), as well as the number of macrophages (Figure 4C, 
p<0.01) and lymphocytes (Figure 4D, p=0.06), were also increased in the air exposed 
AKAP12-/- mice. Cigarette smoke exposure decreased the macrophage count only in the 
AKAP12-/- mice (Figure 4C).  
In the wildtype – and the AKAP5-/- mice, KC release and neutrophil counts 
showed a strong positive correlation in mice exposed to air or cigarette smoke (Figure 
5A, B), which could not be observed in the AKAP12-/- mice (Figure 5C).  
 Together, our data show that loss of AKAP5 and AKAP12 expression increases 
pulmonary inflammation in vivo, by increasing cigarette smoke-induced KC release and 
by enhancing inflammatory cell infiltration at baseline, respectively.  
 
	
	
 
Figure 3: Cigarette smoke induced KC release in BAL fluid was exacerbated in AKAP5-/- mice. BAL fluid 
was collected from and measured KC levels were measured by ELISA. Data are presented as individual values of 
the different mice with the median. Data were analyzed using independent sample T-test. *=p<0.05, ***=p<0.001. 
 
Discussion 
AKAP5 and AKAP12 are two well-characterized AKAPs with several shared interaction 
partners (Chapter 2). The current study aimed to unravel the role of AKAP5 and 
AKAP12 in regulating inflammatory processes in the lung in vivo, using knockout mice. 
We hypothesized that the lower AKAP5 and AKAP12 expression found in COPD 
patients may lead to aggravated neutrophilic airway inflammation. We demonstrate that 
AKAP5 and AKAP12 mRNA expression is reduced in the lungs of mice exposed to 
cigarette smoke for four days, in line with findings from in vitro studies and from lung 
tissue of COPD patients with a lower AKAP5 and AKAP12 expression compared to non-
COPD controls with a similar smoking history (Chapter 3). In addition, we used AKAP5-/- 
– and AKAP12-/-mice, where we confirmed total knockout of AKAP5 and AKAP12, 
respectively. We observed that AKAP5 and AKAP12 deficiency aggravated airway 
inflammation. In AKAP5-/- mice, the cigarette-smoke induced increase in KC levels and 
neutrophil counts was significantly increased, while AKAP deficiency resulted in 
increased numbers of neutrophils, and to a lesser extent also increased numbers of 
macrophages and lymphocytes, in the lungs at baseline.  
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Figure 4: AKAP12-/- mice show increased inflammatory cell numbers in air-exposed mice and AKAP5-/- in 
cigarette smoke-exposed mice. Infiltration of inflammatory cells were determined by two independent 
observants in BAL fluid of wildtype –, AKAP5-/- – and AKAP12-/- mice exposed to air or cigarette smoke for 4 days. 
(A) total cells, (B) neutrophils, (C) macrophages and (D) lymphocytes were determined in the BAL fluid. Data are 
presented as individual animals with the median. Data were analyzed using two-way ANOVA: Individual 
comparisons were made using an independent sample T-test. *=p<0.05, **=p<0.01, **=p<0.001.  
 
We observed that AKAP5 gene expression was reduced to some extent in the 
AKAP12-/- mice, indicating a regulatory role for AKAP12 in the expression of AKAP5. Not 
much is known about regulation of AKAP5 expression, but an overlap with AKAP12 has 
been shown before in BeWo trophoblasts, where forskolin can induce both AKAP5 and 
AKAP12 expression (17). A link between the cigarette smoke-induced downregulation of 
AKAP5 and AKAP12 has not been investigated previously. Given the observed 
regulation of AKAP5 by AKAP12 in our study, the loss of AKAP12 expression upon 
cigarette exposure may offer a plausible mechanism for the cigarette smoke-induced 
reduction of AKAP5 expression. However, the magnitude of reduction of AKAP5 was 
stronger than that of AKAP12, suggesting that the cigarette smoke-induced reduction in 
AKAP5 is, at least partly, independent of the downregulation of AKAP12. Vice versa, 
AKAP5-/- mice did not display reduced expression of AKAP12, indicating that the 
interactive regulation of expression levels appears to be regulated by AKAP12 only. 
Although it is tempting to speculate that the effects of AKAP12-/- on the inflammatory 
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parameters are (in part) by the observed reduction of AKAP5, this is unlikely given the 
observed distinct inflammatory responses in the AKAP5-/- and AKAP12-/- mice, with only 
AKAP5-/- mice showing increased KC levels after smoke exposure.  
The cigarette smoke-induced reduction in AKAP5 and AKAP12 expression was 
accompanied by an increase in KC levels in the BAL and neutrophilic lung inflammation. 
Our findings in the AKAP5-/- mice indicate that AKAP5 regulates cigarette smoke-
induced release of neutrophil attractant KC, and that its loss results in increased 
sensitivity to cigarette smoke. There was a strong correlation between KC levels in BAL 
and neutrophil counts upon cigarette smoke exposure in wildtype and AKAP5-/- mice, 
suggesting that the recruitment of neutrophils is, at least in part, mediated by the release 
of KC. These results in AKAP5-/- mice are in line with our previous in vitro findings, 
demonstrating an increase of cigarette smoke extract-induced IL-8 release when 
inhibiting AKAP-PKA interactions (Chapter 3). To the best of our knowledge, the specific 
role of AKAP5 in the regulation of inflammatory processes is still unknown. Our group 
has previously shown that the cAMP effector Epac, which is known to bind AKAP5 (18), 
can decrease cigarette smoke extract induced IL-8 release from airway smooth muscle 
cells (19). In this way, loss of AKAP5 expression could lead to loss of this regulatory 
effect, resulting in an increase in IL-8 release from smooth muscle cells. However, Epac 
knockout mice did not show similar effects on KC release in a similar cigarette smoke 
mouse model (15), rendering Epac-mediated effects an unlikely explanation. AKAP5 is 
mainly known for its role in synaptic transmissions in the brain, and learning and memory 
(Chapter 2). It is also known that AKAP5 binds to the β2-adrenoceptor, regulating its 
sensitivity and potentially cAMP production inside the cell (Chapter 2). In addition to the 
cAMP pathway, AKAP5 is known to bind several components of the intracellular calcium 
pathway (20-23) which could be another way to IL-8 release (24). The exact 
mechanisms of AKAP5-regulated IL-8 release and neutrophil attraction upon cigarette 
smoke exposure in vivo will require further investigation though.  
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AKAP5-/- mice showing increased KC levels after smoke exposure.  
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accompanied by an increase in KC levels in the BAL and neutrophilic lung inflammation. 
Our findings in the AKAP5-/- mice indicate that AKAP5 regulates cigarette smoke-
induced release of neutrophil attractant KC, and that its loss results in increased 
sensitivity to cigarette smoke. There was a strong correlation between KC levels in BAL 
and neutrophil counts upon cigarette smoke exposure in wildtype and AKAP5-/- mice, 
suggesting that the recruitment of neutrophils is, at least in part, mediated by the release 
of KC. These results in AKAP5-/- mice are in line with our previous in vitro findings, 
demonstrating an increase of cigarette smoke extract-induced IL-8 release when 
inhibiting AKAP-PKA interactions (Chapter 3). To the best of our knowledge, the specific 
role of AKAP5 in the regulation of inflammatory processes is still unknown. Our group 
has previously shown that the cAMP effector Epac, which is known to bind AKAP5 (18), 
can decrease cigarette smoke extract induced IL-8 release from airway smooth muscle 
cells (19). In this way, loss of AKAP5 expression could lead to loss of this regulatory 
effect, resulting in an increase in IL-8 release from smooth muscle cells. However, Epac 
knockout mice did not show similar effects on KC release in a similar cigarette smoke 
mouse model (15), rendering Epac-mediated effects an unlikely explanation. AKAP5 is 
mainly known for its role in synaptic transmissions in the brain, and learning and memory 
(Chapter 2). It is also known that AKAP5 binds to the β2-adrenoceptor, regulating its 
sensitivity and potentially cAMP production inside the cell (Chapter 2). In addition to the 
cAMP pathway, AKAP5 is known to bind several components of the intracellular calcium 
pathway (20-23) which could be another way to IL-8 release (24). The exact 
mechanisms of AKAP5-regulated IL-8 release and neutrophil attraction upon cigarette 
smoke exposure in vivo will require further investigation though.  
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Figure 5: Correlation between KC release and neutrophil count is absent in AKAP12-/- mice. Combining the 
data of corresponding mice from both air – and smoke-exposed groups from figures 3 and 4, correlation was 
determined using Pearson for normal distributed data and Spearman for non-normal distributed data.  
	
	
Lung neutrophils, macrophages, and lymphocytes positively correlate with the 
severity of COPD (25). Our study shows that AKAP12-/- mice have increased numbers 
for all these cell types, particularly neutrophils, at baseline, indicating that AKAP12 acts 
to suppress inflammation in the lung under basal conditions. Therefore, the decreased 
expression of AKAP12 after cigarette smoking may contribute to the inflammation seen 
in COPD, although it does not further increase the sensitivity to cigarette smoke.  
We did not observe a correlation between KC release and neutrophils in the 
lungs of AKAP12-/- mice, suggesting the involvement of other chemokines or another 
mechanism, e.g. increased cell survival, in the increase in neutrophils as well as 
macrophages and lymphocytes in AKAP12-/- mice. From the brain it is known that there 
AKAP12-positive cells are involved in the formation of a structure which traps various 
immune cells (26), leading to prolonged inflammatory infiltration after ischemic stroke in 
AKAP12-/- mice (26). Similarly, AKAP12 positive cells in the lung could also be involved 
in the removal of inflammatory cells, causing an increase of inflammatory cells infiltrating 
tissue in AKAP12 deficient mice. As AKAP12 is also known to regulate cellular 
senescence and proliferation (27, 28), it may also affect the proliferation of inflammatory 
cells, thereby regulating their numbers in the lung.  
In conclusion, AKAP5 and AKAP12 exhibit anti-inflammatory roles in the lungs. 
AKAP12 suppresses pulmonary inflammation under basal conditions, whereas AKAP5 
suppresses cigarette smoke-induced inflammation. Given their distinct anti-inflammatory 
roles, AKAP5 and AKAP12 could be key players in the development of COPD as their 
expression is lower in lung tissue from COPD patients compared to non-COPD controls 
(Chapter 3).  
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Abstract  
Alleviation of bronchoconstriction in obstructive respiratory diseases is achieved using 
bronchodilators such as the cAMP-elevating β2-agonists. We showed recently that A-
kinase anchoring proteins (AKAPs) regulate anti-inflammatory properties of the β2-
agonist fenoterol. AKAPs scaffold the cAMP effector protein kinase A (PKA) as well as 
other enzymes and receptors to specific intracellular compartments. We have shown 
that AKAP5 and AKAP12 are lower expressed in lung tissue of COPD patients. AKAP5 
and AKAP12 have been implicated in regulating the β2-adrenoceptor expression in the 
plasma membrane. Therefore, we hypothesized that a loss of AKAP5 and/or AKAP12 
might affect the responsiveness of airway smooth muscle to β2-agonists. Pre-incubation 
with the global AKAP-PKA interaction inhibitor st-Ht31, but not the control peptide st-
Ht31P, caused a significant rightward shift of the fenoterol-induced relaxation of 
methacholine-induced tone in guinea pig tracheal open-ring preparations. Tracheal 
preparations obtained from AKAP12-/- mice, but not AKAP5-/-, showed a significant 
decrease in maximal β2-agonist-induced relaxation compared to wildtype mice, without 
significantly affecting the pD2-value. β2-Adrenoceptor Ser355/Ser356 phosphorylation 
was reduced in the lungs of AKAP12-/- mice compared to wildtype. However, β2-agonist-
induced desensitization of the β2-adrenoceptor was not altered in AKAP5-/- or AKAP12-/- 
mice compared to wildtype mice. In conclusion, AKAPs, particularly AKAP12, contribute 
to a proper β2-adrenoceptor functioning. Therefore, the loss of AKAP12 as seen in 
COPD patients may lead to a reduced therapeutic efficacy of β2-agonists in these 
patients.  
 
Introduction 
The regulation of airway constriction is a result of a balance between contractile and 
relaxing molecular pathways. The main regulators of airway tone are that of intracellular 
Ca2+ - causing smooth muscle contraction by increasing the phosphorylation of myosin 
light chain - and cyclic AMP (cAMP) - leading to smooth muscle relaxation by decreasing 
the phosphorylation of the myosin light chain (1). cAMP-elevating agents, most notably 
β2-agonists, are potent inhibitors of bronchial constriction in obstructive pulmonary 
diseases. Classically, protein kinase a (PKA) is considered the main cAMP effector 
involved in β2-agonist-induced airway smooth muscle relaxation (1, 2).  
 In recent years another dimension to cAMP signaling has been discovered in 
the form of A-kinase anchoring proteins (AKAPs), proteins that scaffold PKA and other 
proteins involved in (the regulation of) cAMP responses, including exchange protein 
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Abstract  
Alleviation of bronchoconstriction in obstructive respiratory diseases is achieved using 
bronchodilators such as the cAMP-elevating β2-agonists. We showed recently that A-
kinase anchoring proteins (AKAPs) regulate anti-inflammatory properties of the β2-
agonist fenoterol. AKAPs scaffold the cAMP effector protein kinase A (PKA) as well as 
other enzymes and receptors to specific intracellular compartments. We have shown 
that AKAP5 and AKAP12 are lower expressed in lung tissue of COPD patients. AKAP5 
and AKAP12 have been implicated in regulating the β2-adrenoceptor expression in the 
plasma membrane. Therefore, we hypothesized that a loss of AKAP5 and/or AKAP12 
might affect the responsiveness of airway smooth muscle to β2-agonists. Pre-incubation 
with the global AKAP-PKA interaction inhibitor st-Ht31, but not the control peptide st-
Ht31P, caused a significant rightward shift of the fenoterol-induced relaxation of 
methacholine-induced tone in guinea pig tracheal open-ring preparations. Tracheal 
preparations obtained from AKAP12-/- mice, but not AKAP5-/-, showed a significant 
decrease in maximal β2-agonist-induced relaxation compared to wildtype mice, without 
significantly affecting the pD2-value. β2-Adrenoceptor Ser355/Ser356 phosphorylation 
was reduced in the lungs of AKAP12-/- mice compared to wildtype. However, β2-agonist-
induced desensitization of the β2-adrenoceptor was not altered in AKAP5-/- or AKAP12-/- 
mice compared to wildtype mice. In conclusion, AKAPs, particularly AKAP12, contribute 
to a proper β2-adrenoceptor functioning. Therefore, the loss of AKAP12 as seen in 
COPD patients may lead to a reduced therapeutic efficacy of β2-agonists in these 
patients.  
 
Introduction 
The regulation of airway constriction is a result of a balance between contractile and 
relaxing molecular pathways. The main regulators of airway tone are that of intracellular 
Ca2+ - causing smooth muscle contraction by increasing the phosphorylation of myosin 
light chain - and cyclic AMP (cAMP) - leading to smooth muscle relaxation by decreasing 
the phosphorylation of the myosin light chain (1). cAMP-elevating agents, most notably 
β2-agonists, are potent inhibitors of bronchial constriction in obstructive pulmonary 
diseases. Classically, protein kinase a (PKA) is considered the main cAMP effector 
involved in β2-agonist-induced airway smooth muscle relaxation (1, 2).  
 In recent years another dimension to cAMP signaling has been discovered in 
the form of A-kinase anchoring proteins (AKAPs), proteins that scaffold PKA and other 
proteins involved in (the regulation of) cAMP responses, including exchange protein 
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directly activated by cAMP (Epac) and β2-adrenoceptors (3-5).To date, more than 50 
AKAP family members have been identified, all bringing PKA to different compartments 
within the cell, thus playing a role in various cellular functions such as cell cycle 
regulation (6) and inflammation (Chapter 3) (7). Of these different AKAP family 
members, AKAP5 and AKAP12 have in particular been shown to be crucial regulators of 
β-adrenergic signaling, facilitating the signal transduction to cAMP effectors and to 
further downstream targets (Chapters 2 and 3). In addition, we have shown reduced 
expression of AKAP5 and AKAP12 in lung tissue of COPD patients (Chapter 3). 
AKAP5 may switch β2-adrenergic signaling from Gs to Gi via PKA-mediated 
phosphorylation of the receptor (8-11). In addition, AKAP5 increases the affinity of 
GPCR kinase 2 (GRK2) for βγ subunits of the heterotrimeric G-proteins (12). GRK2 
phosphorylates the β2-adrenoceptor at Ser355/356 leading to desensitization and 
internalization of the receptor (12). After internalization, AKAP12 seems to be important 
to dephosphorylate the receptor leading to its recycling back to the membrane (13-15). 
Thus, AKAP5 and AKAP12 play distinct roles in the process of de/resensitization. 
However, the role of these AKAPs in the regulation of β2-adrenoceptor function in airway 
smooth muscle is currently unknown.  
Here we studied the involvement of AKAP5 and AKAP12 in β2-adrenoceptor-
mediated airway smooth muscle relaxation.  
 
Materials and methods 
Animals – All experiments were performed in accordance with the national 
guidelines and approved by the University of Groningen Institutional Animal Care and 
Use Committee. Outbred specific pathogen-free male Dunkin Hartley guinea pigs 
(Harlan-Hillcrest, UK) were used. The animals were killed by experimental concussion 
followed by rapid exsanguination. The trachea was removed from the larynx to the 
bronchi and rapidly placed in a Krebs--Henseleit (KH) solution (composition in mM: 
NaCl 117.50; KCl 5.60; MgSO4 1.18; CaCl2 2.52; NaH2PO4 1.28; NaHCO3 25.0 and D-
glucose 5.50; pH 7.4) at 37°C, gassed with 95% O2 and 5% CO2.  
C57BL/6 WT animals, AKAP5-/- (16, 17) and AKAP12-/- (18) mice were 
euthanized using a mixture of O2/CO2 for 5 minutes, and tracheae were obtained and 
transferred to KH solution at room temperature, gassed with 95% O2 and 5% CO2. Per 
mouse, 2 tracheal preparations of two cartilage rings were prepared, maintained at 
37°C, and used for experiments.  
	
	
Relaxation studies – After removal of serosal connective tissue, single guinea 
pig tracheal open-ring preparations were mounted in a 20-mL organ bath connected to 
an isometric force-displacement transducer (Grass FT03) using surgical wire. The 
resting tension was adjusted to 0.5 g as described before (19). After a 60 min 
equilibration period with three washes, the preparations were contracted with cumulative 
administration of methacholine (10-7 – 10-4 M), followed by thorough washout. 
Thereafter, basal tone was assessed using isoprenaline (10-7 M) and tension was re-
adjusted to 0.5 g followed by washout. Subsequently, the preparations were contracted 
with methacholine (10-7 – 10-4 M). After three additional washouts, tracheal preparations 
were pre-incubated without (control) or with the PKA-AKAP interaction inhibitor st-Ht31 
(50 µM) or the control peptide st-Ht31P (50 µM) for 30 min. The tissue was pre-
contracted with methacholine (10-6 M), followed by a cumulative concentration response 
curve with the β2-agonist fenoterol in 0.5 log increments (10-10 – 10-5.5 M). After 
washout, basal tone was re-assessed using isoprenaline (10-5 M). Per animal, each 
experimental condition was performed in duplicate.  
Murine tracheal preparations were mounted in a 5-mL DMT Myograph with a 
preload of 0.5 g. After a 60 min equilibration period with three washes, the preparations 
were contracted with cumulative administration of methacholine (10-7 – 10-4 M), followed 
by thorough washout. Rings were incubated with or without 10-6 M β2-agonist fenoterol 
for 60 min and tension was set using 10-6 M methacholine followed by a cumulative 
concentration response curves made with the β2-agonist isoprenaline in 0.5 log 
increments (10-10 – 10-5 M). Isoprenaline was used in mice, because there is a β1-
adrenoceptor-mediated component in airway smooth muscle relaxation in mice (20). 
Desensitization protocols – One hour (early response) should be sufficient to 
get full desensitization of the β2-adrenoceptor (21). However, there is a known 
difference in β2-agonist-induced desensitization depending on the intrinsic efficacy of 
the ligand, which disappears over time (22). Therefore we also included a 24 h protocol 
(late response). In the early response and in the late response desensitization protocol 
testing, tracheal preparations were incubated for 1 h or 24 h, respectively, with or 
without 10-6 M of the β2-agonist fenoterol in Dulbecco’s Modified Eagle’s Medium 
(Invitrogen Cat # 42430-082) in a 37°C incubator. Rings were mounted in a 5-mL DMT 
Myograph with a preload of 0.5 g. After equilibration, tension was set using 10-6 M 
methacholine followed by a cumulative concentration response curves made with the β-
agonist isoprenaline in 0.5 log increments (10-10 – 10-5 M).  
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glucose 5.50; pH 7.4) at 37°C, gassed with 95% O2 and 5% CO2.  
C57BL/6 WT animals, AKAP5-/- (16, 17) and AKAP12-/- (18) mice were 
euthanized using a mixture of O2/CO2 for 5 minutes, and tracheae were obtained and 
transferred to KH solution at room temperature, gassed with 95% O2 and 5% CO2. Per 
mouse, 2 tracheal preparations of two cartilage rings were prepared, maintained at 
37°C, and used for experiments.  
	
	
Relaxation studies – After removal of serosal connective tissue, single guinea 
pig tracheal open-ring preparations were mounted in a 20-mL organ bath connected to 
an isometric force-displacement transducer (Grass FT03) using surgical wire. The 
resting tension was adjusted to 0.5 g as described before (19). After a 60 min 
equilibration period with three washes, the preparations were contracted with cumulative 
administration of methacholine (10-7 – 10-4 M), followed by thorough washout. 
Thereafter, basal tone was assessed using isoprenaline (10-7 M) and tension was re-
adjusted to 0.5 g followed by washout. Subsequently, the preparations were contracted 
with methacholine (10-7 – 10-4 M). After three additional washouts, tracheal preparations 
were pre-incubated without (control) or with the PKA-AKAP interaction inhibitor st-Ht31 
(50 µM) or the control peptide st-Ht31P (50 µM) for 30 min. The tissue was pre-
contracted with methacholine (10-6 M), followed by a cumulative concentration response 
curve with the β2-agonist fenoterol in 0.5 log increments (10-10 – 10-5.5 M). After 
washout, basal tone was re-assessed using isoprenaline (10-5 M). Per animal, each 
experimental condition was performed in duplicate.  
Murine tracheal preparations were mounted in a 5-mL DMT Myograph with a 
preload of 0.5 g. After a 60 min equilibration period with three washes, the preparations 
were contracted with cumulative administration of methacholine (10-7 – 10-4 M), followed 
by thorough washout. Rings were incubated with or without 10-6 M β2-agonist fenoterol 
for 60 min and tension was set using 10-6 M methacholine followed by a cumulative 
concentration response curves made with the β2-agonist isoprenaline in 0.5 log 
increments (10-10 – 10-5 M). Isoprenaline was used in mice, because there is a β1-
adrenoceptor-mediated component in airway smooth muscle relaxation in mice (20). 
Desensitization protocols – One hour (early response) should be sufficient to 
get full desensitization of the β2-adrenoceptor (21). However, there is a known 
difference in β2-agonist-induced desensitization depending on the intrinsic efficacy of 
the ligand, which disappears over time (22). Therefore we also included a 24 h protocol 
(late response). In the early response and in the late response desensitization protocol 
testing, tracheal preparations were incubated for 1 h or 24 h, respectively, with or 
without 10-6 M of the β2-agonist fenoterol in Dulbecco’s Modified Eagle’s Medium 
(Invitrogen Cat # 42430-082) in a 37°C incubator. Rings were mounted in a 5-mL DMT 
Myograph with a preload of 0.5 g. After equilibration, tension was set using 10-6 M 
methacholine followed by a cumulative concentration response curves made with the β-
agonist isoprenaline in 0.5 log increments (10-10 – 10-5 M).  
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 Western blot – Mouse lungs were pulverized under liquid nitrogen, followed by 
sonication in SDS lysis buffer (composition: 62.5 mM Tris, 69.4 mM SDS, pH 6.8) 
supplemented with 10 μg/mL aprotinin, 10 μg/mL leupeptin, 10 μg/mL pepstatin, 1 mM 
Na3VO4, 1 mM NaF and 3.5 μM β-glycerolphosphate. Samples for detection of 
phosphorylated β2-adrenoceptor (Ser 355/ Ser 356) (sc-22191-R; Santa Cruz 
Biotechnology) expression were subjected to SDS-PAGE. Immunoblotting with primary 
antibodies (dilution 1:5000) was done overnight at 4°C. β-actin (1:10.000; A5441; 
Sigma-Aldrich) served as a control for equal loading. Blots were incubated with 
secondary antibody (1:5000 A9044 or A0545; Sigma-Aldrich), for 1 h at room 
temperature. Signals were detected with chemiluminescence reagents according to the 
manufacturer's protocol (PerkinElmer). Blots were quantified using ImageJ. 
Data processing and statistical analysis - Isometrically recorded contractile 
responses to methacholine were expressed in grams developed tension. Isoprenaline-
induced relaxation responses, in the absence or presence of the st-Ht31, were 
expressed as a percentage of the maximal methacholine-induced contraction. Results 
are presented as means±standard error of the mean (SEM) of the indicated number of 
experiments. Curves were fitted using Prism 5.0. The values provided by the Prism 
software were used for β2-agonist sensitivity (pD2) and maximal response (Emax). 
Statistical analysis was performed by means of one-way ANOVA followed by a Tukey 
post-hoc test. p-values < 0.05 were considered statistically significant. 
 
Results  
AKAPs, particularly AKAP12, coordinate responsiveness to β2-agonists – To assess the 
role of AKAPs in responsiveness for β2-agonist-induced airway smooth muscle 
relaxation, we studied the effect of the non-selective AKAP-PKA interaction inhibitor st-
Ht31 on guinea pig tracheal open ring preparations. Fenoterol-induced relaxation of pre-
contracted guinea pig tracheal open-ring preparations (pD2: 8.0±0.2) was shifted 
rightward by pre-incubation with the non-selective AKAP-PKA interaction inhibitor st-
Ht31 (pD2: 7.5±0.1, p<0.05 compared to control and st-Ht31P), without affecting the 
maximal relaxation (Emax; Figure 1). By contrast, fenoterol-induced relaxation was not 
affected by pre-incubation with the control peptide st-Ht31P (pD2: 7.9±0.1; Figure 1 and 
Table 1).  
 
	
	
 
Figure 1: Disrupting AKAP-PKA interactions decreases the sensitivity towards β2-agonists. Isometric 
cumulative concentration relaxation curves of guinea pig tracheal open-ring preparations pre-contracted with 
methacholine (MCh) flowing incubation without (control) or with the AKAP-PKA interaction inhibitor st-Ht31 (50 
µM) or the control peptide st-Ht31P (50 µM) for 30 minutes. Data represent mean ± SEM of 4 independent 
experiments in duplicate. Data was analyzed using a one-way ANOVA followed by a Tukey post-hoc (see also 
Table 1). 
The involvement of AKAP5 and AKAP12 in β-agonist-induced relaxation was 
studied in knock out mice using isoprenaline. There was no significant difference in 
methacholine-induced contraction between the genotypes (WT: 0.6±0.1g; AKAP5-/-: 
0.5±0.2g and AKAP12-/-: 0.6±0.1 g). In contrast to guinea pigs, and in line with other 
studies (23), mouse tracheal preparations did not reach full relaxation upon β-agonist 
incubation. Interestingly, tracheal preparations obtained from AKAP12-/- mice had a 
decreased maximal isoprenaline-induced relaxation (Emax: 56.9±1.1%) compared to 
wildtype (Emax: 70.5±1.9%, p<0.01) and AKAP5-/- mice (Emax: 66.6±3.5%, p<0.05; Figure 
2). Isoprenaline-induced relaxation of tracheal rings of AKAP12-/- mice pre-contracted 
with methacholine showed a small, but non-significant rightward shift of the curve (pD2: 
7.6±0.1) compared to wildtype (pD2: 7.8±0.1; Figure 2) and AKAP5-/- mice (pD2: 7.8±0.1; 
Figure 2).  
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Biotechnology) expression were subjected to SDS-PAGE. Immunoblotting with primary 
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are presented as means±standard error of the mean (SEM) of the indicated number of 
experiments. Curves were fitted using Prism 5.0. The values provided by the Prism 
software were used for β2-agonist sensitivity (pD2) and maximal response (Emax). 
Statistical analysis was performed by means of one-way ANOVA followed by a Tukey 
post-hoc test. p-values < 0.05 were considered statistically significant. 
 
Results  
AKAPs, particularly AKAP12, coordinate responsiveness to β2-agonists – To assess the 
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relaxation, we studied the effect of the non-selective AKAP-PKA interaction inhibitor st-
Ht31 on guinea pig tracheal open ring preparations. Fenoterol-induced relaxation of pre-
contracted guinea pig tracheal open-ring preparations (pD2: 8.0±0.2) was shifted 
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cumulative concentration relaxation curves of guinea pig tracheal open-ring preparations pre-contracted with 
methacholine (MCh) flowing incubation without (control) or with the AKAP-PKA interaction inhibitor st-Ht31 (50 
µM) or the control peptide st-Ht31P (50 µM) for 30 minutes. Data represent mean ± SEM of 4 independent 
experiments in duplicate. Data was analyzed using a one-way ANOVA followed by a Tukey post-hoc (see also 
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The involvement of AKAP5 and AKAP12 in β-agonist-induced relaxation was 
studied in knock out mice using isoprenaline. There was no significant difference in 
methacholine-induced contraction between the genotypes (WT: 0.6±0.1g; AKAP5-/-: 
0.5±0.2g and AKAP12-/-: 0.6±0.1 g). In contrast to guinea pigs, and in line with other 
studies (23), mouse tracheal preparations did not reach full relaxation upon β-agonist 
incubation. Interestingly, tracheal preparations obtained from AKAP12-/- mice had a 
decreased maximal isoprenaline-induced relaxation (Emax: 56.9±1.1%) compared to 
wildtype (Emax: 70.5±1.9%, p<0.01) and AKAP5-/- mice (Emax: 66.6±3.5%, p<0.05; Figure 
2). Isoprenaline-induced relaxation of tracheal rings of AKAP12-/- mice pre-contracted 
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Figure 2: Genetic deletion of AKAP12, but not of AKAP5, decreases β2-agonist-induced relaxation. 
Isometric cumulative concentration relaxation curves of tracheal preparations obtained from wildtype, AKAP5-/- 
and AKAP12-/- mice pre-contracted with methacholine (MCh). Data represent mean ± SEM of 5 mice. Data was 
analyzed using a one-way ANOVA followed by a Tukey post-hoc (see also Table 2). 
 
AKAP5 and AKAP12 do not coordinate β2-agonist-induced desensitization – 
AKAP5 and AKAP12 have been suggested to regulate β2-agonist sensitivity by 
coordinating desensitization and resensitization of the β2-adrenoceptor, respectively 
(Chapter 2). To study whether β2-agonist-induced desensitization of the β2-adrenoceptor 
is indeed mediated by AKAP5 and AKAP12 in airway smooth muscle, tracheal rings 
were pre-treated with 10-6 M fenoterol for 1 h (to study early reduction in β2-agonist 
sensitivity) and for 24 h (to study the late response upon prolonged β2-agonist 
treatment), (21). After 1 h incubation, fenoterol induced a small rightward shift of the 
relaxation curve in tracheal rings of wildtype mice (pD2: 7.5±0.1 vs 7.7±0.0; Figure 3A), 
without reaching significance. This was maintained to similar magnitudes in AKAP12-/- 
(pD2: 7.5±0.1 vs 7.6±0.1) and in AKAP5-/- mice (pD2: 7.4±0.1 vs 7.6±0.2), all without 
reaching significance (Figure 3B,C), indicating that short term treatment with fenoterol is 
insufficient to observe possible effects of AKAP5 and AKAP12 on β2-adrenoceptor 
desensitization. 
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Figure 3: Genetic deletion of AKAP5 or AKAP12 does not affect β2-agonist-induced desensitization. 
Isometric cumulative relaxation curve of wildtype (A, D) , AKAP5-/- (B, E) and AKAP12-/- (C, F) mouse tracheal 
rings pre-contracted with methacholine (MCh) after treatment with 10-6 M of the β2-agonist fenoterol for 1 h (A–C) 
or 24 h (D–F). Data represent mean ± SEM of 5 mice. Data was analyzed using a one-way ANOVA followed by a 
Tukey post-hoc (D-F) (see also Table 2). 
 
The maximal relaxation induced by isoprenaline in the tracheal preparations 
that had been incubated for 24 h in media alone (control group) was reduced for all three 
groups (wildtype, AKAP5-/- and AKAP12-/-) compared to their respective controls in the 
basal relaxation experiment and the short term desensitization protocol (Table 2). After 
24 h of pre-incubation with fenoterol, the maximum relaxation induced by isoprenaline 
was further reduced compared to control in the wildtype animals (Emax: 52.4±4.5% 
(control) vs 31.5±4.0% (fenoterol); p<0.001, Figure 3D). Similar effects were found in 
tracheal preparations obtained from AKAP5-/- (Emax: 49.6±1.0% (control) vs 34.2±1.4% 
(fenoterol); p<0.01, Figure 3E). The maximal response of the control group of the 
AKAP12-/- mice (Emax: 34.1±2.1%) was lower than that of the wildtype and the AKAP5-/- 
mice (Figure 3D-F, Table 2). Similar to the effects observed in the WT and AKAP5-/- 
mice, 24 h pre-treatment with fenoterol decreased the maximal response to isoprenaline 
in the AKAP12-/- mice (Emax: 22.2±1.2%; p<0.05, Figure 3F, Table 2). These results 
indicate that AKAP5 and AKAP12 do not affect β2-agonist-induced desensitization in 
murine airway smooth muscle, but that AKAP12 might play a role in basal maintenance 
of receptor functioning. 
AKAP12 is involved in phosphorylation of the β2-adrenoceptor – The process of 
GRK2-induced β2-adrenoceptor desensitization starts with the phosphorylation of 
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Figure 2: Genetic deletion of AKAP12, but not of AKAP5, decreases β2-agonist-induced relaxation. 
Isometric cumulative concentration relaxation curves of tracheal preparations obtained from wildtype, AKAP5-/- 
and AKAP12-/- mice pre-contracted with methacholine (MCh). Data represent mean ± SEM of 5 mice. Data was 
analyzed using a one-way ANOVA followed by a Tukey post-hoc (see also Table 2). 
 
AKAP5 and AKAP12 do not coordinate β2-agonist-induced desensitization – 
AKAP5 and AKAP12 have been suggested to regulate β2-agonist sensitivity by 
coordinating desensitization and resensitization of the β2-adrenoceptor, respectively 
(Chapter 2). To study whether β2-agonist-induced desensitization of the β2-adrenoceptor 
is indeed mediated by AKAP5 and AKAP12 in airway smooth muscle, tracheal rings 
were pre-treated with 10-6 M fenoterol for 1 h (to study early reduction in β2-agonist 
sensitivity) and for 24 h (to study the late response upon prolonged β2-agonist 
treatment), (21). After 1 h incubation, fenoterol induced a small rightward shift of the 
relaxation curve in tracheal rings of wildtype mice (pD2: 7.5±0.1 vs 7.7±0.0; Figure 3A), 
without reaching significance. This was maintained to similar magnitudes in AKAP12-/- 
(pD2: 7.5±0.1 vs 7.6±0.1) and in AKAP5-/- mice (pD2: 7.4±0.1 vs 7.6±0.2), all without 
reaching significance (Figure 3B,C), indicating that short term treatment with fenoterol is 
insufficient to observe possible effects of AKAP5 and AKAP12 on β2-adrenoceptor 
desensitization. 
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Figure 3: Genetic deletion of AKAP5 or AKAP12 does not affect β2-agonist-induced desensitization. 
Isometric cumulative relaxation curve of wildtype (A, D) , AKAP5-/- (B, E) and AKAP12-/- (C, F) mouse tracheal 
rings pre-contracted with methacholine (MCh) after treatment with 10-6 M of the β2-agonist fenoterol for 1 h (A–C) 
or 24 h (D–F). Data represent mean ± SEM of 5 mice. Data was analyzed using a one-way ANOVA followed by a 
Tukey post-hoc (D-F) (see also Table 2). 
 
The maximal relaxation induced by isoprenaline in the tracheal preparations 
that had been incubated for 24 h in media alone (control group) was reduced for all three 
groups (wildtype, AKAP5-/- and AKAP12-/-) compared to their respective controls in the 
basal relaxation experiment and the short term desensitization protocol (Table 2). After 
24 h of pre-incubation with fenoterol, the maximum relaxation induced by isoprenaline 
was further reduced compared to control in the wildtype animals (Emax: 52.4±4.5% 
(control) vs 31.5±4.0% (fenoterol); p<0.001, Figure 3D). Similar effects were found in 
tracheal preparations obtained from AKAP5-/- (Emax: 49.6±1.0% (control) vs 34.2±1.4% 
(fenoterol); p<0.01, Figure 3E). The maximal response of the control group of the 
AKAP12-/- mice (Emax: 34.1±2.1%) was lower than that of the wildtype and the AKAP5-/- 
mice (Figure 3D-F, Table 2). Similar to the effects observed in the WT and AKAP5-/- 
mice, 24 h pre-treatment with fenoterol decreased the maximal response to isoprenaline 
in the AKAP12-/- mice (Emax: 22.2±1.2%; p<0.05, Figure 3F, Table 2). These results 
indicate that AKAP5 and AKAP12 do not affect β2-agonist-induced desensitization in 
murine airway smooth muscle, but that AKAP12 might play a role in basal maintenance 
of receptor functioning. 
AKAP12 is involved in phosphorylation of the β2-adrenoceptor – The process of 
GRK2-induced β2-adrenoceptor desensitization starts with the phosphorylation of 
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Ser355/Ser356 (24). The basal phosphorylation of these β2-adrenoceptor residues was 
significantly decreased in lung tissue from AKAP12-/- (12.0±6.7%) compared to wildtype 
(100.0±50.6%, p<0.001) and AKAP5-/- (76.3±31.0%, p<0.01, Figure 4). Together, these 
data indicate that AKAP12 is involved in GRK-mediated phosphorylation of the β2-
adrenoceptor.  
 
 
Discussion 
This study shows that AKAPs, particularly AKAP12, play a role in the responsiveness of 
airway smooth muscle to β2-agonists. Our data demonstrate that AKAP12 is crucial for 
maintaining a normal β2-adrenoceptor-mediated bronchodilatory response and is 
involved in regulating GRK-mediated phosphorylation of the β2-adrenoceptor.  
Following agonist stimulation of the β2-adrenoceptor, adenylyl cyclase is 
activated leading subsequently to an increase in intracellular levels of the second 
messenger cAMP, which induces airway smooth muscle relaxation by activation of PKA 
(2). We now demonstrate that AKAPs play an important regulatory role in this β2-
adrenoceptor-mediated airway smooth muscle relaxation, which can, at least in part, be 
attributed to AKAP12. Incubation with the global PKA-AKAP interaction inhibitor st-Ht31 
decreased β-agonist potency in guinea pig tracheal open ring preparations, presumably 
by disrupting binding of downstream effectors including PKA to AKAPs, demonstrating 
that one or more AKAP(s) mediate(s) β-adrenoceptor-mediated relaxation. To identify 
the AKAP protein(s) responsible for this effect, β2-agonist-induced relaxation studies 
were performed using tracheal preparations from wildtype, AKAP5-/- – and AKAP12-/ 
mice. Murine AKAP12-/-, not AKAP5-/-, tracheal rings showed a decrease in the β-agonist 
efficacy (Emax) but not the potency (pD2), suggesting a decrease in the post-receptor 
response. Since there is no significant change in potency in AKAP12-/-, this suggests 
that there might be more AKAPs important in β2-agonist-induced relaxation. 
Others have shown that AKAP12 is one of the highest expressed AKAPs in the 
airway smooth muscle and that disrupting AKAP function with st-Ht31 prolongs β2-
agonist-induced cAMP signaling (25). This prolongation was suggested by others to 
work via the inhibition of AKAP12, presumably by affecting PDE4D activity (26). 
However, assuming that it is AKAP12 that mediates the abrogation of cAMP signaling at 
the membrane, this would predict an increased β2-agonist-induced cAMP signaling when 
AKAP12 is removed. Based on our data we hypothesize that although the β2-
adrenoceptor is able to elevate cAMP in the absence of AKAP12, elevated cAMP levels  
	
	
 
Figure 4: Genetic deletion of AKAP12 decreases β2-adrenoceptor phosphorylation. (A) Representative 
western blot of β2-adrenoceptor phosphorylation at GRK sites Ser355/Ser356 (p-β2-AR). (B) Quantification of 
western blot analysis, p-β2-AR is corrected for equal loading using β-actin. Data is represented as % of average 
wildtype, lines represent median. *p<0.05, **p<0.01 compared to wildtype, one-way ANOVA followed by a Tukey 
post-hoc. 
 
are not sensed by PKA due to the lack of AKAP12. In support, although both AKAP5 and 
AKAP12 regulate β2-adrenoceptor-mediated cAMP levels (27), only AKAP12 regulated 
β2-agonist-induced airway smooth muscle relaxation in our study.  
Next to the cellular cAMP production and degradation, uncoupling and 
desensitization of the β2-adrenoceptor after β-agonist stimulation should be considered. 
The receptor can be phosphorylated by various kinases, including PKA, PKC or GRK. 
GRK-mediated phosphorylation leads to sequestration and proteasomal degradation, or 
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Ser355/Ser356 (24). The basal phosphorylation of these β2-adrenoceptor residues was 
significantly decreased in lung tissue from AKAP12-/- (12.0±6.7%) compared to wildtype 
(100.0±50.6%, p<0.001) and AKAP5-/- (76.3±31.0%, p<0.01, Figure 4). Together, these 
data indicate that AKAP12 is involved in GRK-mediated phosphorylation of the β2-
adrenoceptor.  
 
 
Discussion 
This study shows that AKAPs, particularly AKAP12, play a role in the responsiveness of 
airway smooth muscle to β2-agonists. Our data demonstrate that AKAP12 is crucial for 
maintaining a normal β2-adrenoceptor-mediated bronchodilatory response and is 
involved in regulating GRK-mediated phosphorylation of the β2-adrenoceptor.  
Following agonist stimulation of the β2-adrenoceptor, adenylyl cyclase is 
activated leading subsequently to an increase in intracellular levels of the second 
messenger cAMP, which induces airway smooth muscle relaxation by activation of PKA 
(2). We now demonstrate that AKAPs play an important regulatory role in this β2-
adrenoceptor-mediated airway smooth muscle relaxation, which can, at least in part, be 
attributed to AKAP12. Incubation with the global PKA-AKAP interaction inhibitor st-Ht31 
decreased β-agonist potency in guinea pig tracheal open ring preparations, presumably 
by disrupting binding of downstream effectors including PKA to AKAPs, demonstrating 
that one or more AKAP(s) mediate(s) β-adrenoceptor-mediated relaxation. To identify 
the AKAP protein(s) responsible for this effect, β2-agonist-induced relaxation studies 
were performed using tracheal preparations from wildtype, AKAP5-/- – and AKAP12-/ 
mice. Murine AKAP12-/-, not AKAP5-/-, tracheal rings showed a decrease in the β-agonist 
efficacy (Emax) but not the potency (pD2), suggesting a decrease in the post-receptor 
response. Since there is no significant change in potency in AKAP12-/-, this suggests 
that there might be more AKAPs important in β2-agonist-induced relaxation. 
Others have shown that AKAP12 is one of the highest expressed AKAPs in the 
airway smooth muscle and that disrupting AKAP function with st-Ht31 prolongs β2-
agonist-induced cAMP signaling (25). This prolongation was suggested by others to 
work via the inhibition of AKAP12, presumably by affecting PDE4D activity (26). 
However, assuming that it is AKAP12 that mediates the abrogation of cAMP signaling at 
the membrane, this would predict an increased β2-agonist-induced cAMP signaling when 
AKAP12 is removed. Based on our data we hypothesize that although the β2-
adrenoceptor is able to elevate cAMP in the absence of AKAP12, elevated cAMP levels  
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western blot of β2-adrenoceptor phosphorylation at GRK sites Ser355/Ser356 (p-β2-AR). (B) Quantification of 
western blot analysis, p-β2-AR is corrected for equal loading using β-actin. Data is represented as % of average 
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alternatively, the receptor is dephosphorylated by PP2A and recycled back to the 
membrane (28, 29). It has been postulated that AKAP5 and AKAP12 play an important 
role in this cycle of β2-adrenoceptor (de)sensitization (Chapter 2). GRK-mediated 
phosphorylation of the β2-adrenoceptor was previously shown to be augmented by an 
AKAP5-PKA complex in HEK293 cells (12). However, in our study using intact tracheal 
preparations only a small decrease in GRK-mediated phosphorylation of Ser355/356-β2-
adrenoceptor in AKAP5-/- lungs was observed, which failed to reach statistical 
significance. 
In contrast, our study did find a strong reduction in Ser355/356 phosphorylation of 
the β2-adrenoceptor in AKAP12-/- lungs, which would decrease association of β-arrestin 
with the β2-adrenoceptor as seen before (30). Decreased phosphorylation of the β2-
adrenoceptor was found before in cardiomyocytes of mice expressing a truncated form 
of AKAP12, although this study did not specify which phospho-site was affected (31). In 
these cardiomyocytes, decreased phosphorylation of the β2-adrenoceptor was 
associated with increased cardiac contraction at baseline as well as after β-adrenoceptor 
stimulation (31), suggesting enhanced receptor signaling when AKAP12 function is 
disrupted. Interestingly, in these cardiomyocytes no change in cAMP concentration or 
PKA activity was observed compared to wildtype cardiomyocytes (31). However, when 
challenging the airway smooth muscle with st-Ht31 others also only found a change in 
cAMP directly beneath the membrane, not in the whole cell (25).  
In the current study, decreased phosphorylation of the β2-adrenoceptor was 
associated with decreased β-agonist responsiveness in AKAP12-/- mice, indicating that 
the reduced responsiveness towards β-agonists is not the result of increased receptor 
phosphorylation but rather another mechanism. This would further support the 
hypothesis that the changes in airway responsiveness to β-agonists in the AKAP12-/- 
mice are caused by changes downstream of the β2-adrenoceptor-mediated cAMP 
production. Others have previously shown that AKAP12 knock down in A431 cells 
prevents the β2-adrenoceptor from going into clathrin coated pits induced by GRK2 and 
β-arrestin (30). AKAP12 knock down not only delayed desensitization of the β2-
adrenoceptor, but also its resensitization, which is presumably related to PKC bound to 
AKAP12 (30). In the current study, neither AKAP12 nor AKAP5 was involved in β-
agonist-induced desensitization, as the knock out mice were similarly subject to agonist-
induced desensitization following long term pre-treatment with fenoterol as the wildtype 
mice. At least for the AKAP12-/-, these findings can potentially be explained, by changes 
in dynamics of both de- and resensitization as observed in A431 cells (30). By changing 
	
	
both de- and resensitization a loss of AKAP12 could perhaps give a net effect of zero 
change.  
We have previously shown that cigarette smoke exposure decreases the 
expression of AKAP5 and AKAP12 in airway smooth muscle cells (Chapter 3). Since 
others have shown that precision cut lung slices exposed to cigarette smoke have 
impaired β-agonist responsiveness (32), it is tempting to speculate that this impaired β-
agonist responsiveness is – at least in part – due to impairment of AKAP12 function. Our 
data also suggest that the lower expression of AKAP12 as seen in lung tissue of COPD 
patients compared to non-COPD patients (Chapter 3) may possibly lead to a reduced 
therapeutic efficacy of β2-adrenoceptor agonists in these patients. Therefore, we 
hypothesize that elevations in AKAP12 expression and/or function may serve as a 
potential drug target to improve therapeutic efficacy of β2-adrenoceptor agonists.  
In conclusion, AKAPs, in particular AKAP12, mediate β2-agonist induced tracheal 
smooth muscle relaxation, suggesting that pharmacological treatment of COPD patients 
with β2-agonists can potentially benefit from AKAP12-targeted treatments.  
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associated with increased cardiac contraction at baseline as well as after β-adrenoceptor 
stimulation (31), suggesting enhanced receptor signaling when AKAP12 function is 
disrupted. Interestingly, in these cardiomyocytes no change in cAMP concentration or 
PKA activity was observed compared to wildtype cardiomyocytes (31). However, when 
challenging the airway smooth muscle with st-Ht31 others also only found a change in 
cAMP directly beneath the membrane, not in the whole cell (25).  
In the current study, decreased phosphorylation of the β2-adrenoceptor was 
associated with decreased β-agonist responsiveness in AKAP12-/- mice, indicating that 
the reduced responsiveness towards β-agonists is not the result of increased receptor 
phosphorylation but rather another mechanism. This would further support the 
hypothesis that the changes in airway responsiveness to β-agonists in the AKAP12-/- 
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agonist-induced desensitization, as the knock out mice were similarly subject to agonist-
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both de- and resensitization a loss of AKAP12 could perhaps give a net effect of zero 
change.  
We have previously shown that cigarette smoke exposure decreases the 
expression of AKAP5 and AKAP12 in airway smooth muscle cells (Chapter 3). Since 
others have shown that precision cut lung slices exposed to cigarette smoke have 
impaired β-agonist responsiveness (32), it is tempting to speculate that this impaired β-
agonist responsiveness is – at least in part – due to impairment of AKAP12 function. Our 
data also suggest that the lower expression of AKAP12 as seen in lung tissue of COPD 
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therapeutic efficacy of β2-adrenoceptor agonists in these patients. Therefore, we 
hypothesize that elevations in AKAP12 expression and/or function may serve as a 
potential drug target to improve therapeutic efficacy of β2-adrenoceptor agonists.  
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Table 1: Effects of st-Ht31 on β2-agonist-induced relaxation in guinea pig tracheal open ring preparations. 
Data represented as means(±SEM) of N experiments. *p<0.05 compared to the control and the st-Ht31P group 
using a one-way ANOVA followed by a Tukey post-hoc. 
 Control st-Ht31 st-Ht31P 
Emax (%) 98.6 (±0.3) 95.8 (±2.1) 99.5 (±0.8) 
pD2 (–log M) 8.0 (±0.2) 7.5 (±0.1)* 7.9 (±0.1) 
N 4 4 4 
 
Table 2: Effects of AKAP5-/- and AKAP12-/- on β2-agonist-induced relaxation of mouse tracheal 
preparations under basal conditions and after short term (1 h) and long term (24 h) pre-treatment with 
fenoterol. Data represented as means(±SEM) of N experiments. **p<0.01; ***p<0.001 compared to wildtype 
control group, $p<0.01 compared to AKAP5-/- control group, #p<0.05; ##p<0.01; ###p<0.001 compared to 24h 
control group of respective genotype using a one-way ANOVA followed by a Tukey post-hoc. 
No  
pre-treatment 
Wild type AKAP5-/- AKAP12-/- 
Emax (%) 
70.5 
(±1.9) 
66.6 
(±3.5) 
56.9**$ 
(±1.1) 
pD2 (–log M) 
7.8 
(±0.1) 
7.8 
(±0.1) 
7.6 
(±0.1) 
N 5 5 5 
1h  
pre-treatment 
Wild type AKAP5-/- AKAP12-/- 
Control Fenoterol Control Fenoterol Control Fenoterol 
Emax (%) 
67.6 
(±4.8) 
65.4 
(±2.9) 
76.3 
(±1.6) 
71.7 (±3.5) 
63.4 
(±8.8) 
59.6 
(±7.5) 
pD2 (–log M) 
7.7 
(±0.0) 
7.5 
(±0.1) 
7.6 
(±0.2) 
7.4 
(±0.1) 
7.6 
(±0.1) 
7.5 
(±0.1) 
N 5 5 5 5 5 5 
24h  
pre-treatment 
Wild type AKAP5-/- AKAP12-/- 
Control Fenoterol Control Fenoterol Control Fenoterol 
Emax (%) 
52.4 
(±4.5) 
31.5### 
(±4.0) 
49.6 
(±1.0) 
34.2## 
(±1.4) 
34.1***$$ 
(±2.1) 
22.2# 
(±1.2) 
pD2 (–log M) 
7.7 
(±0.07) 
7.8 
(±0.2) 
7.6 
(±0.1) 
7.6 
(±0.1) 
7.5 
(±0.1) 
7.6 
(±0.1) 
N 4 4 5 5 5 5 
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Table 1: Effects of st-Ht31 on β2-agonist-induced relaxation in guinea pig tracheal open ring preparations. 
Data represented as means(±SEM) of N experiments. *p<0.05 compared to the control and the st-Ht31P group 
using a one-way ANOVA followed by a Tukey post-hoc. 
 Control st-Ht31 st-Ht31P 
Emax (%) 98.6 (±0.3) 95.8 (±2.1) 99.5 (±0.8) 
pD2 (–log M) 8.0 (±0.2) 7.5 (±0.1)* 7.9 (±0.1) 
N 4 4 4 
 
Table 2: Effects of AKAP5-/- and AKAP12-/- on β2-agonist-induced relaxation of mouse tracheal 
preparations under basal conditions and after short term (1 h) and long term (24 h) pre-treatment with 
fenoterol. Data represented as means(±SEM) of N experiments. **p<0.01; ***p<0.001 compared to wildtype 
control group, $p<0.01 compared to AKAP5-/- control group, #p<0.05; ##p<0.01; ###p<0.001 compared to 24h 
control group of respective genotype using a one-way ANOVA followed by a Tukey post-hoc. 
No  
pre-treatment 
Wild type AKAP5-/- AKAP12-/- 
Emax (%) 
70.5 
(±1.9) 
66.6 
(±3.5) 
56.9**$ 
(±1.1) 
pD2 (–log M) 
7.8 
(±0.1) 
7.8 
(±0.1) 
7.6 
(±0.1) 
N 5 5 5 
1h  
pre-treatment 
Wild type AKAP5-/- AKAP12-/- 
Control Fenoterol Control Fenoterol Control Fenoterol 
Emax (%) 
67.6 
(±4.8) 
65.4 
(±2.9) 
76.3 
(±1.6) 
71.7 (±3.5) 
63.4 
(±8.8) 
59.6 
(±7.5) 
pD2 (–log M) 
7.7 
(±0.0) 
7.5 
(±0.1) 
7.6 
(±0.2) 
7.4 
(±0.1) 
7.6 
(±0.1) 
7.5 
(±0.1) 
N 5 5 5 5 5 5 
24h  
pre-treatment 
Wild type AKAP5-/- AKAP12-/- 
Control Fenoterol Control Fenoterol Control Fenoterol 
Emax (%) 
52.4 
(±4.5) 
31.5### 
(±4.0) 
49.6 
(±1.0) 
34.2## 
(±1.4) 
34.1***$$ 
(±2.1) 
22.2# 
(±1.2) 
pD2 (–log M) 
7.7 
(±0.07) 
7.8 
(±0.2) 
7.6 
(±0.1) 
7.6 
(±0.1) 
7.5 
(±0.1) 
7.6 
(±0.1) 
N 4 4 5 5 5 5 
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Abstract 
A-kinase anchoring proteins (AKAPs) AKAP5 and AKAP12 enhance β2-adrenoceptor 
recycling in airway smooth muscle cells, and their mRNA expression in airway smooth 
muscle cells is lowered by cigarette smoke extract. We assessed the association 
between single nucleotide polymorphisms (SNPs) in AKAP5 and AKAP12 and β2-
agonist responsiveness and comparing current and never-smoking asthmatics. One 
AKAP5 SNP and four AKAP12 SNPs have the minor allele associated with decreased 
and increased β2-agonist responsiveness, respectively, in current versus never smokers. 
The minor alleles of one AKAP5 and 10 AKAP12 SNPs correlated with increased gene 
expression in lung tissue. The minor allele of one AKAP12 SNP associated with both 
decreased gene expression and increased β2-agonist responsiveness in current 
smokers. In conclusion, AKAP5 and especially AKAP12 variants associate with β2-
agonist responsiveness	 differentially in current smokers compared to never-smokers. 
Cigarette smoke decreased AKAP5 and AKAP12 mRNA expression could therefore 
have an impact on therapeutic efficacy of β2-agonists. 
 
Introduction 
Asthmatics that are (ex-)smoker show an altered inflammatory response with less 
eosinophils and more neutrophils in their sputum and blood compared to never-smoking 
asthmatics.(1) In addition, cigarette smoking is associated with worsening of symptoms. 
Important in the treatment symptoms in asthmatics are inhaled β2-agonists. They are 
also used to test lung function reversibility, a diagnostic test in which the improvement in 
forced expiratory volume in one second (FEV1) after the administration of an inhaled β2-
agonist is measured. β2-agonists stimulate the β2-adrenoceptor, leading to cyclic AMP 
signaling, a process coordinated by scaffolding proteins of the A-kinase anchoring 
protein (AKAP) family. AKAP5 and AKAP12 bind β2-adrenoceptors and increase 
recycling.(2) Expression of AKAP5 and AKAP12 mRNA is reduced in cultured airway 
smooth muscle cells after cigarette smoke-extract exposure.(3) Since AKAP5 and 
AKAP12 increase β2-adrenoceptor recycling (2) and smokers have less β2-agonist-
induced reversibility of decreased FEV1 than never-smokers,(4) we studied the 
association of genetic variations in AKAP5 and AKAP12 with β2-agonist responsiveness 
and if this association interacts with smoking status (in current and never smoking 
asthma patients).  
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Abstract 
A-kinase anchoring proteins (AKAPs) AKAP5 and AKAP12 enhance β2-adrenoceptor 
recycling in airway smooth muscle cells, and their mRNA expression in airway smooth 
muscle cells is lowered by cigarette smoke extract. We assessed the association 
between single nucleotide polymorphisms (SNPs) in AKAP5 and AKAP12 and β2-
agonist responsiveness and comparing current and never-smoking asthmatics. One 
AKAP5 SNP and four AKAP12 SNPs have the minor allele associated with decreased 
and increased β2-agonist responsiveness, respectively, in current versus never smokers. 
The minor alleles of one AKAP5 and 10 AKAP12 SNPs correlated with increased gene 
expression in lung tissue. The minor allele of one AKAP12 SNP associated with both 
decreased gene expression and increased β2-agonist responsiveness in current 
smokers. In conclusion, AKAP5 and especially AKAP12 variants associate with β2-
agonist responsiveness	 differentially in current smokers compared to never-smokers. 
Cigarette smoke decreased AKAP5 and AKAP12 mRNA expression could therefore 
have an impact on therapeutic efficacy of β2-agonists. 
 
Introduction 
Asthmatics that are (ex-)smoker show an altered inflammatory response with less 
eosinophils and more neutrophils in their sputum and blood compared to never-smoking 
asthmatics.(1) In addition, cigarette smoking is associated with worsening of symptoms. 
Important in the treatment symptoms in asthmatics are inhaled β2-agonists. They are 
also used to test lung function reversibility, a diagnostic test in which the improvement in 
forced expiratory volume in one second (FEV1) after the administration of an inhaled β2-
agonist is measured. β2-agonists stimulate the β2-adrenoceptor, leading to cyclic AMP 
signaling, a process coordinated by scaffolding proteins of the A-kinase anchoring 
protein (AKAP) family. AKAP5 and AKAP12 bind β2-adrenoceptors and increase 
recycling.(2) Expression of AKAP5 and AKAP12 mRNA is reduced in cultured airway 
smooth muscle cells after cigarette smoke-extract exposure.(3) Since AKAP5 and 
AKAP12 increase β2-adrenoceptor recycling (2) and smokers have less β2-agonist-
induced reversibility of decreased FEV1 than never-smokers,(4) we studied the 
association of genetic variations in AKAP5 and AKAP12 with β2-agonist responsiveness 
and if this association interacts with smoking status (in current and never smoking 
asthma patients).  
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Methods 
The cohort used for this study consisted of 281 asthma patients referred to the asthma 
clinic at Beatrixoord Hospital in Haren, the Netherlands, that were part of a larger GWAS 
study.(5-7) Reversibility of FEV1 (i.e. ((FEV1 after β2-agonist – FEV1 before β2-agonist)/ 
FEV1 predicted)*100%) was tested after administration of 800 μg salbutamol (albuterol) 
by pressurized metered dose inhaler with a spacer. Smoking status was determined 
using a standardized modified form of the British Medical Society Respiratory 
Questionnaire.(8) Genotyping was performed using the Illumina 317 Chip (Illumina Inc, 
San Diego, CA) and the Illumina 370 Duo Chip. A genome wide association study was 
performed in 229 subjects of this population with reversibility data available and we 
focused here on single nucleotide polymorphisms (SNPs) in the AKAP5 and AKAP12 
genes for their association with FEV1 reversibility. The study was approved by the 
medical ethics committee of the University Medical Center Groningen and all participants 
gave written, informed consent. 
The association between the SNPs and reversibility was tested using linear 
regression models with adjustment for age and sex. All SNPs were tested in a dominant 
genetic model (heterozygous and homozygous subjects were pooled) due to the number 
of patients per group. The analyses were stratified by smoking defined as never smoking 
versus current smoking (ex-smokers were excluded). In addition, the interaction between 
smoking and SNPs were tested using a linear regression model with adjustment for age 
and sex and including the SNP, current smoking and their interaction. 
We assessed if the selected SNPs were cis-acting eQTLs in a lung tissue 
database established by the lung eQTL consortium (Universities of Groningen, Laval 
and British Columbia), as described previously.(9)  
 
Results 
Of the 229 subjects where the genome wide association study was performed, we 
excluded 75 ex-smokers and of the included subjects, 92 were never smokers (42.4% 
male; 49.8±8.4 years) and 62 were current smokers (72.6% male; 49.5±8.2 years). 
Current smokers tended to have lower FEV1 reversibility than never smokers 
(11.0±8.4% vs 13.6±7.2% p=0.054) (supplementary table 1).  
Three SNPs in AKAP5 were available and 34 SNPs in AKAP12 
(supplementary table 2). FEV1 reversibility after β2-agonist treatment was associated 
with one SNP (rs745686) in the promoter of AKAP5 and two SNPs (rs6557123, 
rs2251681) in intron 2 of AKAP12 in asthmatics with no history of smoking (table 1). In 
	
	
smoking asthmatics, four SNPs in AKAP12 were associated with β2-agonist-induced 
FEV1 reversibility (table 1). Interaction analysis showed one SNP in AKAP5 and four 
SNPs in AKAP12 differentially associated with β2-agonist-induced FEV1 reversibility in 
current smokers compared to never-smokers (table 1).  
The lung eQTL dataset, analyzing 183 SNPs around AKAP12 and 52 SNPs around 
AKAP5, showed one SNP associated with AKAP5 gene expression and 11 SNPs 
associated with AKAP12 gene expression (table 2). 
 
Discussion 
We hypothesized that genetic variants in AKAP5 and AKAP12 are associated with 
decreased β2-agonist responsiveness, due to their roles in β2-adrenoceptor recycling, (2) 
and that this association may differ between smoking and non-smoking asthmatics given 
the reducing effect of cigarette smoke on their expression.(3) Indeed, several SNPs in 
AKAP5 and AKAP12 associated with β2-agonist responsiveness of which one in the 
AKAP5 and four in the AKAP12 gene showed a positive interaction with smoking status. 
The minor allele of one of these SNPs (rs7757002) also associated with AKAP12 
decreased gene expression.  
One missense mutation in exon 5 of the AKAP12 gene associated with β2-
agonist-induced reversibility of FEV1 (rs13212161 E [Glu] ⇒ G [Gly]). This SNP is in 
complete linkage disequilibrium (r2 = 1) with two other missense mutations (rs12201388 
E [Glu] ⇒ K [Lys], rs34713284 V [Val] ⇒ M [Met]). Our data suggest that the amino acids 
changed by these SNPs play an important role in AKAP12 functioning, probably by 
maintaining a secondary protein structure necessary for protein-protein interactions. 
Importantly, one of these SNPs (rs13212161) causes a mutation in the suggested β2-
adrenoceptor binding domain.(10) Thus, exon 5 of AKAP12 seems to be important for 
proper binding to β2-adrenoceptors and subsequent reversibility of FEV1. 
The minor allele of another SNP (rs7757002) is associated with lower AKAP12 
expression and a higher reversibility of FEV1 after β2-agonist treatment. The latter finding 
is unexpected as AKAP12 increases β2-adrenoceptor recycling back to the 
membrane,(3) suggesting increased β2-agonist responsiveness. In contrast, the minor 
allele of a SNP in the promotor region of AKAP5 (rs745686) only associated with β2-
agonist responsiveness in never-smoking asthmatics, although it is not associated with 
gene expression.  
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Methods 
The cohort used for this study consisted of 281 asthma patients referred to the asthma 
clinic at Beatrixoord Hospital in Haren, the Netherlands, that were part of a larger GWAS 
study.(5-7) Reversibility of FEV1 (i.e. ((FEV1 after β2-agonist – FEV1 before β2-agonist)/ 
FEV1 predicted)*100%) was tested after administration of 800 μg salbutamol (albuterol) 
by pressurized metered dose inhaler with a spacer. Smoking status was determined 
using a standardized modified form of the British Medical Society Respiratory 
Questionnaire.(8) Genotyping was performed using the Illumina 317 Chip (Illumina Inc, 
San Diego, CA) and the Illumina 370 Duo Chip. A genome wide association study was 
performed in 229 subjects of this population with reversibility data available and we 
focused here on single nucleotide polymorphisms (SNPs) in the AKAP5 and AKAP12 
genes for their association with FEV1 reversibility. The study was approved by the 
medical ethics committee of the University Medical Center Groningen and all participants 
gave written, informed consent. 
The association between the SNPs and reversibility was tested using linear 
regression models with adjustment for age and sex. All SNPs were tested in a dominant 
genetic model (heterozygous and homozygous subjects were pooled) due to the number 
of patients per group. The analyses were stratified by smoking defined as never smoking 
versus current smoking (ex-smokers were excluded). In addition, the interaction between 
smoking and SNPs were tested using a linear regression model with adjustment for age 
and sex and including the SNP, current smoking and their interaction. 
We assessed if the selected SNPs were cis-acting eQTLs in a lung tissue 
database established by the lung eQTL consortium (Universities of Groningen, Laval 
and British Columbia), as described previously.(9)  
 
Results 
Of the 229 subjects where the genome wide association study was performed, we 
excluded 75 ex-smokers and of the included subjects, 92 were never smokers (42.4% 
male; 49.8±8.4 years) and 62 were current smokers (72.6% male; 49.5±8.2 years). 
Current smokers tended to have lower FEV1 reversibility than never smokers 
(11.0±8.4% vs 13.6±7.2% p=0.054) (supplementary table 1).  
Three SNPs in AKAP5 were available and 34 SNPs in AKAP12 
(supplementary table 2). FEV1 reversibility after β2-agonist treatment was associated 
with one SNP (rs745686) in the promoter of AKAP5 and two SNPs (rs6557123, 
rs2251681) in intron 2 of AKAP12 in asthmatics with no history of smoking (table 1). In 
	
	
smoking asthmatics, four SNPs in AKAP12 were associated with β2-agonist-induced 
FEV1 reversibility (table 1). Interaction analysis showed one SNP in AKAP5 and four 
SNPs in AKAP12 differentially associated with β2-agonist-induced FEV1 reversibility in 
current smokers compared to never-smokers (table 1).  
The lung eQTL dataset, analyzing 183 SNPs around AKAP12 and 52 SNPs around 
AKAP5, showed one SNP associated with AKAP5 gene expression and 11 SNPs 
associated with AKAP12 gene expression (table 2). 
 
Discussion 
We hypothesized that genetic variants in AKAP5 and AKAP12 are associated with 
decreased β2-agonist responsiveness, due to their roles in β2-adrenoceptor recycling, (2) 
and that this association may differ between smoking and non-smoking asthmatics given 
the reducing effect of cigarette smoke on their expression.(3) Indeed, several SNPs in 
AKAP5 and AKAP12 associated with β2-agonist responsiveness of which one in the 
AKAP5 and four in the AKAP12 gene showed a positive interaction with smoking status. 
The minor allele of one of these SNPs (rs7757002) also associated with AKAP12 
decreased gene expression.  
One missense mutation in exon 5 of the AKAP12 gene associated with β2-
agonist-induced reversibility of FEV1 (rs13212161 E [Glu] ⇒ G [Gly]). This SNP is in 
complete linkage disequilibrium (r2 = 1) with two other missense mutations (rs12201388 
E [Glu] ⇒ K [Lys], rs34713284 V [Val] ⇒ M [Met]). Our data suggest that the amino acids 
changed by these SNPs play an important role in AKAP12 functioning, probably by 
maintaining a secondary protein structure necessary for protein-protein interactions. 
Importantly, one of these SNPs (rs13212161) causes a mutation in the suggested β2-
adrenoceptor binding domain.(10) Thus, exon 5 of AKAP12 seems to be important for 
proper binding to β2-adrenoceptors and subsequent reversibility of FEV1. 
The minor allele of another SNP (rs7757002) is associated with lower AKAP12 
expression and a higher reversibility of FEV1 after β2-agonist treatment. The latter finding 
is unexpected as AKAP12 increases β2-adrenoceptor recycling back to the 
membrane,(3) suggesting increased β2-agonist responsiveness. In contrast, the minor 
allele of a SNP in the promotor region of AKAP5 (rs745686) only associated with β2-
agonist responsiveness in never-smoking asthmatics, although it is not associated with 
gene expression.  
	
06
Processed on: 2-11-2016
506329-L-bw-Poppinga
128
Chapter 6
 
Ta
bl
e 
1:
 A
ss
oc
ia
tio
n 
be
tw
ee
n 
ge
no
ty
pe
s 
an
d 
FE
V
1 
re
ve
rs
ib
ili
ty
 i
n 
as
th
m
at
ic
 p
ro
ba
nd
s 
w
ith
 n
o 
hi
st
or
y 
of
 s
m
ok
in
g 
vs
 c
ur
re
nt
 s
m
ok
er
s.
 O
nl
y 
re
su
lts
 f
or
 s
ig
ni
fic
an
tly
 
as
so
ci
at
ed
 S
N
P
s 
ar
e 
sh
ow
n.
 A
na
ly
se
s 
w
ith
 p
<0
.0
5 
ar
e 
de
pi
ct
ed
 in
 b
ol
d.
 M
A
F:
 m
in
or
 a
lle
le
 f
re
qu
en
cy
, 
W
T:
 W
ild
ty
pe
 (
ho
m
oz
yg
ou
s 
fo
r 
m
aj
or
 a
lle
le
), 
H
z/
H
m
: 
H
et
er
oz
yg
ou
s 
or
 
H
om
oz
yg
ou
s 
fo
r m
in
or
 a
lle
le
, H
tz
: H
et
er
oz
yg
ou
s,
 *
M
aj
or
 a
lle
le
 fi
rs
t 
	  
 
 
N
ev
er
 s
m
ok
in
g 
as
th
m
at
ic
s 
(n
 =
 9
2)
 
 
C
ur
re
nt
 s
m
ok
in
g 
as
th
m
at
ic
s 
(n
 =
 6
2)
 
 
C
ur
re
nt
 v
s 
ne
ve
r s
m
ok
in
g 
 
 
 
FE
V
1 r
ev
er
si
bi
lit
y 
M
ea
n 
(S
D
) 
R
eg
re
ss
io
n 
an
al
ys
is
 
 
FE
V
1 r
ev
er
si
bi
lit
y 
M
ea
n 
(S
D
) 
R
eg
re
ss
io
n 
an
al
ys
is
 
 
In
te
ra
ct
io
n 
an
al
ys
is
 
 
A
lle
le
s*
 
M
A
F 
W
t 
H
z/
H
m
 
B
et
a 
(S
E
) 
P
 
 
W
t 
H
z/
H
m
 
B
et
a 
(S
E
) 
P
 
 
B
et
a 
(S
E
) 
P
 
A
K
A
P
5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
rs
74
56
86
 
A
/G
 
0.
34
 
11
.9
 (6
.4
) 
14
.8
 (7
.5
) 
3.
0 
(1
.5
) 
.0
5 
 
13
.1
 (9
.9
) 
9.
7 
(7
.0
) 
-3
.6
 (2
.2
) 
.1
0 
 
-6
.7
 (2
.5
) 
.0
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
K
A
P
12
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
rs
65
57
12
3 
A
/G
 
0.
39
 
16
.0
 (7
.1
) 
11
.9
 (6
.8
) 
-4
.0
 (1
.5
) 
<.
01
 
 
12
.7
 (9
.4
) 
10
.0
 (7
.7
) 
-3
.1
 (2
.3
) 
.1
8 
 
0.
7 
(2
.6
) 
.7
7 
rs
22
51
68
1 
C
/T
 
0.
13
 
12
.6
 (6
.5
) 
16
.8
 (8
.5
) 
4.
1 
(1
.7
) 
.0
2 
 
10
.6
 (7
.4
) 
12
.6
 (1
1.
2)
 
2.
7 
(2
.8
) 
.3
3 
 
-1
.3
 (3
.0
) 
.6
7 
rs
77
57
00
2 
G
/A
 
0.
09
 
13
.6
 (6
.6
) 
13
.3
 (9
.5
) 
-0
.5
 (2
.0
) 
.8
1 
 
9.
8 
(7
.3
) 
17
.4
 (1
0.
7)
 
7.
6 
(2
.8
) 
<.
01
 
 
7.
9 
(3
.3
) 
.0
2 
rs
77
71
98
6 
A
/G
 
0.
09
 
13
.7
 (6
.6
) 
13
.0
 (9
.4
) 
-0
.6
 (1
.9
) 
.7
4 
 
10
.0
 (7
.4
) 
17
.7
 (1
1.
7)
 
7.
8 
(3
.2
) 
.0
2 
 
8.
1 
(3
.5
) 
.0
2 
rs
13
21
21
61
 
A
/G
 
0.
06
 
13
.7
 (6
.8
) 
12
.8
 (1
0.
1)
 
-1
.2
 (2
.3
) 
.6
1 
 
10
.1
 (7
.3
) 
19
.8
 (1
2.
7)
 
9.
8 
(3
.5
) 
<.
01
 
 
10
.5
 (4
.0
) 
.0
1 
rs
92
06
 
G
/A
 
0.
31
 
14
.1
 (5
.6
) 
13
.0
 (8
.3
) 
-0
.8
 (1
.5
) 
.6
0 
 
8.
9 
(6
.4
) 
13
.0
 (9
.6
) 
4.
3 
(2
.1
) 
.0
5 
 
5.
2 
(2
.1
) 
.0
4 
	 	
	
Processed on: 2-11-2016
506329-L-bw-Poppinga
129
Chapter 6
	 	Ta
bl
e 
2:
 S
N
P
s 
as
so
ci
at
ed
 w
ith
 th
e 
ex
pr
es
si
on
 o
f A
K
A
P
5 
an
d 
A
K
A
P
12
 in
 th
e 
lu
ng
. *
M
aj
or
 a
lle
le
 fi
rs
t. 
 
S
N
P
 
A
lle
le
s*
 
eQ
TL
 m
et
a-
an
al
ys
is
 
be
ta
-e
st
im
at
e 
(S
.D
.) 
FD
R
 e
Q
TL
 
m
et
a-
an
al
ys
is
 p
-v
al
ue
 
A
K
A
P
5 
 
 
 
rs
22
36
22
4 
G
/A
 
1.
70
∙1
0-
2 
(5
.7
1∙
10
-4
) 
2.
80
∙1
0-
2  
A
K
A
P
12
 
 
 
 
 rs
90
06
54
 
C
/T
 
9.
03
∙1
0-
2 
(1
.6
8∙
10
-2
) 
8.
30
∙1
0-
8  
 rs
10
87
26
70
 
G
/A
 
8.
90
∙1
0-
2 
(1
.6
9∙
10
-2
) 
1.
33
∙1
0-
7  
 rs
37
34
79
9 
C
/A
 
7.
59
∙1
0-
2 
(1
.6
4∙
10
-2
) 
3.
82
∙1
0-
6  
 rs
93
22
31
7 
G
/A
 
7.
55
∙1
0-
2 
(1
.6
7∙
10
-2
) 
6.
16
∙1
0-
6  
 rs
18
90
13
5 
G
/T
 
7.
41
∙1
0-
2 
(1
.6
6∙
10
-2
) 
7.
58
∙1
0-
6  
 rs
90
06
53
 
G
/A
 
6.
53
∙1
0-
2 
(1
.6
2∙
10
-2
) 
5.
54
∙1
0-
5  
 rs
94
79
01
1 
T/
C
 
1.
55
∙1
0-
1  (
3.
11
∙1
0-
2 )
 
6.
02
∙1
0-
7  
 rs
22
25
75
 
T/
C
 
8.
42
∙1
0-
2 
(1
.7
2∙
10
-2
) 
1.
00
∙1
0-
6  
 rs
22
97
77
8 
A
/G
 
7.
03
∙1
0-
2 
(1
.6
9∙
10
-2
) 
3.
28
∙1
0-
5  
 rs
77
57
00
2 
G
/A
 
-8
.7
7∙
10
-2
 (2
.2
2∙
10
-2
) 
7.
62
∙1
0-
5  
 rs
93
22
31
7 
G
/A
 
6.
18
∙1
0-
2 
(1
.7
3∙
10
-2
) 
3.
60
∙1
0-
4  
06
Processed on: 2-11-2016
506329-L-bw-Poppinga
130
Chapter 6	
	
SNPs in the β2-adrenoceptor gene that cause a mutation at amino acid 16 of the 
extracellular domain affect β2-agonist-induced bronchoprotection in certain 
populations.(11) We now show that proteins that bind the β2-adrenoceptor, at the 
intracellular domain, carry mutations to affect responsiveness as well. 
In conclusion, SNPs in AKAP5 and in particular AKAP12 associate with β2-
agonist responsiveness and these associations are different between never and current 
smoking asthmatics.  
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Supplementary table 1: Patient characteristics Data presented as mean (S.D.), unless indicated otherwise. 
	
    Never smokers Current 
smokers 
p-value 
N  92 62  
Male gender, n (%) 39 (42.4) 45 (72.6) < 0.001 
age, years 49.8 (8.4) 49.5 (8.2) 0.847 
FEV1 % predicted pre bronchodilator 71.4 (21.4) 72.2 (24.4) 0.829 
FEV1 reversibility % predicted  13.6 (7.2) 11.0 (8.4) 0.054 
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General discussion and conclusions 
Objective and main conclusion 
In the current thesis we aimed to unravel roles of A-kinase anchoring proteins (AKAPs) 
in the lung. AKAPs are scaffolding proteins crucial for locating enzymes to the proper 
location in the cell. In particular, we focused on their potential involvement in the 
regulation of the bronchodilatory action of β2-agonists and in inflammation in relation to 
chronic obstructive pulmonary disease (COPD). One of the main causes of COPD is the 
exposure to cigarette smoke. We found that after cigarette smoke exposure AKAP5 and 
AKAP12, both important in β2-adrenoceptor regulation, are decreased in airway smooth 
muscle (ASM) cells. We also found that AKAP5 and AKAP12 are expressed at a lower 
level in COPD patients compared to non-COPD patients. Inhibiting protein kinase A 
(PKA)-AKAP interactions with the dominant interfering peptide st-Ht31 increased 
cigarette smoke extract (CSE)-induced release of the neutrophil attractant interleukin-8 
(IL-8) from human ASM cells. Deficiency of AKAP5 enhanced cigarette smoke-induced 
neutrophilia in mice, demonstrating the importance of proper AKAP functions in 
regulating airway inflammation. Furthermore, deficiency of AKAP12 in mice leads to 
decreased airway responsiveness to β2-agonists, and also to an increase in pulmonary 
inflammation, most notably neutrophilia. Thus, the lower expression of AKAP12 in COPD 
patients may also have important clinical consequences. Indeed, single nucleotide 
polymorphisms (SNPs) in AKAP12 are associated with altered reversibility of lung 
function by β2-agonists. 
 
Implications of AKAP functions for COPD  
AKAPs are a family of scaffolding proteins that share the ability to bind the cyclic AMP 
(cAMP) effector PKA to different areas of the cell. Importantly certain AKAPs also bind to 
receptors, including the β2-adrenoceptor (Chapter 2). Coordination of cAMP signaling is 
crucial to prevent disorganization of its signaling properties inside the cell and 
disturbance of AKAP-driven coordination of cAMP signaling has been suggested to lead 
to various diseases, including cardiovascular diseases, cancer (1-5) and 
neurodegenerative diseases (Chapter 2). In this thesis we unraveled the role for altered 
AKAP functions in the pathophysiology and pharmacological treatment of chronic 
obstructive pulmonary disease (COPD).  
In order to identify the potential impact of compartmentalized cAMP signaling in 
the ASM, we first assessed the expression profile of AKAPs and its potential alteration 
upon exposure to cigarette smoke. In chapter 3 we showed that ASM expresses 
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patients may also have important clinical consequences. Indeed, single nucleotide 
polymorphisms (SNPs) in AKAP12 are associated with altered reversibility of lung 
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AKAPs are a family of scaffolding proteins that share the ability to bind the cyclic AMP 
(cAMP) effector PKA to different areas of the cell. Importantly certain AKAPs also bind to 
receptors, including the β2-adrenoceptor (Chapter 2). Coordination of cAMP signaling is 
crucial to prevent disorganization of its signaling properties inside the cell and 
disturbance of AKAP-driven coordination of cAMP signaling has been suggested to lead 
to various diseases, including cardiovascular diseases, cancer (1-5) and 
neurodegenerative diseases (Chapter 2). In this thesis we unraveled the role for altered 
AKAP functions in the pathophysiology and pharmacological treatment of chronic 
obstructive pulmonary disease (COPD).  
In order to identify the potential impact of compartmentalized cAMP signaling in 
the ASM, we first assessed the expression profile of AKAPs and its potential alteration 
upon exposure to cigarette smoke. In chapter 3 we showed that ASM expresses 
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AKAP5, AKAP8, AKAP9, AKAP12 and Ezrin. In line, Penn and colleagues have also 
demonstrated the expression of these as well as other AKAPs in ASM cells (6). We 
demonstrated that the AKAP expression profile in ASM cells changed upon exposure to 
CSE, with AKAP5, AKAP12 and AKAP9 being decreased and Ezrin being increased 
(Chapter 3). We also found both AKAP5 and AKAP12 to be lower expressed in lung 
tissue of COPD patients compared to non-COPD patients (Chapter 3). As AKAP5 and 
AKAP12 have been implicated in β2-adrenoceptor responsiveness (Chapter 2) (7-9), our 
findings suggest that AKAP expression might be linked to β2-agonist responsiveness. 
We confirmed the downregulation AKAP5 and AKAP12 in the lung upon cigarette smoke 
exposure using an acute murine model of cigarette smoke-induced pulmonary 
inflammation (Chapter 4). Although AKAP5 and AKAP12 are also highly expressed in 
the airway epithelium, we previously demonstrated that CSE exposure did not affect 
AKAP5 and AKAP12 expression in human bronchial epithelial cells (10). Histological 
staining showed that Ezrin expression, although increased in CSE-treated ASM cells, 
was lower in COPD – compared to non-COPD control lung tissue (Chapter 3). However, 
it must be noted that Ezrin was not detected in the ASM in either non-COPD or COPD 
tissue, whereas Ezrin was highly expressed in the airway epithelium (Chapter 3). In 
contrast, others found Ezrin to be higher expressed in the epithelium of COPD – 
compared to control subjects (11). In the airway epithelium it is required for mucus 
production (11). Recently, genome-wide gene expression profiling in lung tissue samples 
has confirmed that Ezrin is higher expressed in lungs from COPD patients compared to 
control subjects (12). Vitamin D receptor knock out mice were characterized by an 
increased Ezrin expression (13) Together these data may provide an additional 
explanation for a higher Ezrin expression found in COPD, although reduced vitamin D 
signaling in COPD patients is still under debate (14, 15). 
Taken together, findings from our group and others put forward several AKAPs 
as potential candidate drug targets in COPD. We focused on AKAP5 and AKAP12 as 
known interactors with β2-adrenoceptors, and their beneficial effects on the regulation of 
smooth muscle tone and inflammation. We hypothesized that lower AKAP5 and AKAP12 
expression, as observed in COPD, affects the therapeutic efficacy of β2-agonists to 
induce bronchorelaxation as well as the anti-inflammatory properties of cAMP.  
 
β2-agonist treatment in COPD 
Patients suffering from COPD are often treated chronically with β2-adrenergic 
bronchodilator drugs. Chronic β2-adrenergic stimulation can lead to decreased receptor 
	
	
functioning, either due to a decreased expression of the receptor at the cell membrane 
or due to disturbed signaling (16, 17). In addition, β2-adrenoceptor activation has been 
associated with different signaling pathways such as the canonical adenylyl cyclase or 
the non-canonical extracellular signal-regulated kinase (ERK) pathway. The latter can be 
activated either by Gi signaling or after G-protein coupled receptor kinase 
(GRK)/arrestin-mediated desensitization of the β2-adrenoceptor (18, 19) and is 
associated with detrimental effects of β2-agonists for patients, which may also result in 
reduced efficacy (20). Thus far this has been mainly studied in the context of asthma, 
but might hold true also in the treatment of the symptoms in COPD patients. 
Based on findings in the literature (7-9), we postulated that AKAPs play a role in 
β2-agonist responsiveness by modulating the expression of β2-adrenoceptor at the 
membrane (Chapter 2). We demonstrated that treatment of ASM cells with st-Ht31 
increased activation of the ERK pathway in the absence of a β2-agonist (Chapter 3). 
Non-canonical GRK-mediated β2-adrenoceptor signaling does not appear to be 
mediated via AKAP5 or AKAP12 as GRK-mediated (Ser355/356) β2-adrenoceptor 
phosphorylation is rather reduced than increased in AKAP12-/- –, and also reduced to 
some extent in AKAP5-/- mice (Chapter 5). Ser355/356 phosphorylation of the β2-
adrenoceptor only occurs in the presence of a ligand (21), and is shown to mediate non-
canonical ERK signaling (22). Taken together the data suggest that AKAP12 is 
necessary for GRK/arrestin-mediated signaling. However, we only investigated 
Ser355/356 phosphorylation of the β2-adrenoceptor in the absence of a β2-agonist and 
thus far it has been shown in vitro that downregulation of AKAP12 does not change β2-
adrenoceptor-mediated ERK signaling (23). In vivo, AKAP12-mediated ERK signaling 
still remains an option as multiple routes potentially activate ERK signaling downstream 
of the β2-adrenoceptor and biased signaling properties of certain ligands (24, 25). 
Removal of AKAP5 or disturbing its interaction with the β2-adrenoceptor does decrease 
β2-adrenoceptor-mediated ERK signaling (23, 26). However, AKAP5 has been related to 
Gi-mediated ERK activation, not GRK/arrestin-mediated ERK signaling (26, 27). These 
are two independent signaling pathways downstream of the β2-adrenoceptor (28). 
Therefore, if AKAP5 and AKAP12 influence β2-agonist responsiveness through 
activation of non-canonical β2-adrenoceptor signaling the involvement of separate 
signaling pathways is rather likely. We found an increased ERK signaling in ASM cells 
after treatment with st-Ht31, and ERK signaling has been shown to increase IL-8 release 
(29-31). However, whether the increased neutrophilia found in AKAP12-/- mice depends 
on this ERK signaling remains to be studied, as there was no basal increase in KC 
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was lower in COPD – compared to non-COPD control lung tissue (Chapter 3). However, 
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contrast, others found Ezrin to be higher expressed in the epithelium of COPD – 
compared to control subjects (11). In the airway epithelium it is required for mucus 
production (11). Recently, genome-wide gene expression profiling in lung tissue samples 
has confirmed that Ezrin is higher expressed in lungs from COPD patients compared to 
control subjects (12). Vitamin D receptor knock out mice were characterized by an 
increased Ezrin expression (13) Together these data may provide an additional 
explanation for a higher Ezrin expression found in COPD, although reduced vitamin D 
signaling in COPD patients is still under debate (14, 15). 
Taken together, findings from our group and others put forward several AKAPs 
as potential candidate drug targets in COPD. We focused on AKAP5 and AKAP12 as 
known interactors with β2-adrenoceptors, and their beneficial effects on the regulation of 
smooth muscle tone and inflammation. We hypothesized that lower AKAP5 and AKAP12 
expression, as observed in COPD, affects the therapeutic efficacy of β2-agonists to 
induce bronchorelaxation as well as the anti-inflammatory properties of cAMP.  
 
β2-agonist treatment in COPD 
Patients suffering from COPD are often treated chronically with β2-adrenergic 
bronchodilator drugs. Chronic β2-adrenergic stimulation can lead to decreased receptor 
	
	
functioning, either due to a decreased expression of the receptor at the cell membrane 
or due to disturbed signaling (16, 17). In addition, β2-adrenoceptor activation has been 
associated with different signaling pathways such as the canonical adenylyl cyclase or 
the non-canonical extracellular signal-regulated kinase (ERK) pathway. The latter can be 
activated either by Gi signaling or after G-protein coupled receptor kinase 
(GRK)/arrestin-mediated desensitization of the β2-adrenoceptor (18, 19) and is 
associated with detrimental effects of β2-agonists for patients, which may also result in 
reduced efficacy (20). Thus far this has been mainly studied in the context of asthma, 
but might hold true also in the treatment of the symptoms in COPD patients. 
Based on findings in the literature (7-9), we postulated that AKAPs play a role in 
β2-agonist responsiveness by modulating the expression of β2-adrenoceptor at the 
membrane (Chapter 2). We demonstrated that treatment of ASM cells with st-Ht31 
increased activation of the ERK pathway in the absence of a β2-agonist (Chapter 3). 
Non-canonical GRK-mediated β2-adrenoceptor signaling does not appear to be 
mediated via AKAP5 or AKAP12 as GRK-mediated (Ser355/356) β2-adrenoceptor 
phosphorylation is rather reduced than increased in AKAP12-/- –, and also reduced to 
some extent in AKAP5-/- mice (Chapter 5). Ser355/356 phosphorylation of the β2-
adrenoceptor only occurs in the presence of a ligand (21), and is shown to mediate non-
canonical ERK signaling (22). Taken together the data suggest that AKAP12 is 
necessary for GRK/arrestin-mediated signaling. However, we only investigated 
Ser355/356 phosphorylation of the β2-adrenoceptor in the absence of a β2-agonist and 
thus far it has been shown in vitro that downregulation of AKAP12 does not change β2-
adrenoceptor-mediated ERK signaling (23). In vivo, AKAP12-mediated ERK signaling 
still remains an option as multiple routes potentially activate ERK signaling downstream 
of the β2-adrenoceptor and biased signaling properties of certain ligands (24, 25). 
Removal of AKAP5 or disturbing its interaction with the β2-adrenoceptor does decrease 
β2-adrenoceptor-mediated ERK signaling (23, 26). However, AKAP5 has been related to 
Gi-mediated ERK activation, not GRK/arrestin-mediated ERK signaling (26, 27). These 
are two independent signaling pathways downstream of the β2-adrenoceptor (28). 
Therefore, if AKAP5 and AKAP12 influence β2-agonist responsiveness through 
activation of non-canonical β2-adrenoceptor signaling the involvement of separate 
signaling pathways is rather likely. We found an increased ERK signaling in ASM cells 
after treatment with st-Ht31, and ERK signaling has been shown to increase IL-8 release 
(29-31). However, whether the increased neutrophilia found in AKAP12-/- mice depends 
on this ERK signaling remains to be studied, as there was no basal increase in KC 
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release (Chapter 4). Similarly, for the AKAP5-/- mice an enhanced KC release was only 
seen after cigarette smoke treatment (Chapter 4). A potential explanation might be that 
we measured cytokine release in the bronchoalveolar lavage fluid, which contains 
mediators released from more cell types than just ASM cells. Similarly, we studied the 
β2-adrenoceptor phosphorylation in whole lung lysates. Therefore, we cannot exclude an 
increased ERK signaling at the level of ASM cells. However, our data suggest that the 
contribution of increased ERK signaling in the ASM might have only minor implications 
on IL-8/KC release in vivo.  
β2-Adrenoceptor activation leading to ASM relaxation is perhaps the most 
important bronchodilatory pathway in the lung. Here we found that treatment with st-Ht31 
reduced β2-agonist-induced relaxation of guinea pig ASM (Chapter 5). As discussed in 
chapter 2, we expected AKAP12 and AKAP5 to be involved in β2-agonist-induced ASM 
relaxation. AKAP5 was found in vitro to be involved in processes preceding 
internalization of the β2-adrenoceptor (7, 23), whereas AKAP12 bound to the β2-
adrenoceptor was found to be necessary for β2-adrenoceptor recycling (8, 9, 23). 
Therefore, lower expression of either AKAP5 or AKAP12, as we found in COPD patients 
compared to non-COPD patients (Chapter 3), was expected to have an effect on β2-
agonist effectiveness. Indeed, AKAP12-/- mice showed decreased ASM relaxation 
induced by the β2-agonist isoprenaline, however, AKAP5-/- showed no difference 
compared to wildtype mice (Chapter 5; Figure 2).  
Surprisingly AKAP12-/- mice showed a decrease in the phosphorylation of 
Ser355/Ser356 of the β2-adrenoceptor, known to be targeted by GRK (Chapter 5). GRK-
mediated phosphorylation of the β2-adrenoceptor is known to precede desensitization 
and internalization, and until now AKAP12 was primarily implicated in resensitization 
(Chapter 2). Our results suggest that AKAP12 is more important in β2-adrenoceptor 
regulation than thought previously, although to what extent remains to be explored 
(Figure 2).  
We reported here on a link between AKAP12 and β2-agonist responsiveness 
and a decreased AKAP12 expression after cigarette smoke exposure, the question 
remains if β2-agonist responsiveness, smoking and AKAP12 are interconnected. Using 
existing databases from smoking asthmatics we showed that SNPs in the AKAP12 gene 
are associated with β2-agonist responsiveness in smokers, but not in non-smokers 
(Chapter 6). Although the exact mechanism is unclear, rs13212161 and rs12201388, 
which cause a change in amino acid sequence, are interesting (Chapter 6). Changes in 
the amino acid composition of AKAP12 may lead to altered protein structure and 
	
	
compromise protein-protein interactions that are important for its functions, including the 
regulation of β2-adrenoceptor function. Our observations at least suggest that the above 
mentioned SNPs may affect the function of AKAP12. For the AKAP5 gene we found the 
SNP rs745686 to affect β2-agonist responsiveness. However, this SNP only had an 
effect in the never-smoking population (Chapter 6). With cigarette smoke being a 
leading cause of COPD, it would be of more interest to look at SNPs affected in smoking 
subjects, as for the AKAP12 SNPs, instead of never-smoking subjects, as for the AKAP5 
SNPs.  
 
Pulmonary inflammation 
COPD has a strong inflammatory component, particularly neutrophilia which are 
attracted to the lungs by the release of particularly IL-8. Previously, we and others have 
shown that CSE exposure of ASM cells caused the production of IL-8 (30, 31). CSE-
induced IL-8 release was reduced by a β2-agonist, via parallel stimulation of PKA and 
exchange protein directly activated by cAMP (Epac), and subsequent reduced activation 
of ERK1/2 and NFκ-B, respectively (29). CSE exposure decreased Epac expression in 
ASM cells (29), a process involving the induction of miRNA-7 (32). Since AKAPs are 
known to interact with both PKA and Epac proteins, the role of AKAPs in regulating 
these processes was subsequently studied.  
In chapter 3 we confirmed that CSE-induced IL-8 release by ASM is reduced 
by the β2-agonist fenoterol as well as direct PKA activation. Interestingly, we also 
showed that disruption of AKAP-PKA complexes using the dominant interfering peptide 
st-Ht31 caused a small increase in basal IL-8 release from ASM cells and augmented 
CSE-induced IL-8 release. Disrupting AKAP-PKA complexes using st-Ht31 prevented 
both the β2-agonist-induced inhibition of CSE-induced ERK1/2 activation and the 
subsequent reduction of IL-8 release (Chapter 3). These findings demonstrate that anti-
inflammatory effects mediated by the β2-adrenoceptor depend on proper AKAP-PKA 
interactions (Figure 1). The anti-inflammatory effect of direct activation of PKA by the 
cAMP analogue 6-Bnz-cAMP - thereby bypassing the β2-adrenoceptor - was insensitive 
to treatment with st-Ht31, providing further support for the importance of AKAPs in 
coordinating the signal from the β2-adrenoceptor to PKA (Chapter 3). In vivo, β2-
agonists exert anti-inflammatory effects in the presence of PDE4 inhibitors (33). 
However, β2-agonists are not used for anti-inflammatory purposes due to the rapid 
desensitization of the β2-adrenoceptor combined with the relatively low expression on 
inflammatory cells (34). To investigate a role for AKAPs in the inflammatory response in 
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(Chapter 2). Our results suggest that AKAP12 is more important in β2-adrenoceptor 
regulation than thought previously, although to what extent remains to be explored 
(Figure 2).  
We reported here on a link between AKAP12 and β2-agonist responsiveness 
and a decreased AKAP12 expression after cigarette smoke exposure, the question 
remains if β2-agonist responsiveness, smoking and AKAP12 are interconnected. Using 
existing databases from smoking asthmatics we showed that SNPs in the AKAP12 gene 
are associated with β2-agonist responsiveness in smokers, but not in non-smokers 
(Chapter 6). Although the exact mechanism is unclear, rs13212161 and rs12201388, 
which cause a change in amino acid sequence, are interesting (Chapter 6). Changes in 
the amino acid composition of AKAP12 may lead to altered protein structure and 
	
	
compromise protein-protein interactions that are important for its functions, including the 
regulation of β2-adrenoceptor function. Our observations at least suggest that the above 
mentioned SNPs may affect the function of AKAP12. For the AKAP5 gene we found the 
SNP rs745686 to affect β2-agonist responsiveness. However, this SNP only had an 
effect in the never-smoking population (Chapter 6). With cigarette smoke being a 
leading cause of COPD, it would be of more interest to look at SNPs affected in smoking 
subjects, as for the AKAP12 SNPs, instead of never-smoking subjects, as for the AKAP5 
SNPs.  
 
Pulmonary inflammation 
COPD has a strong inflammatory component, particularly neutrophilia which are 
attracted to the lungs by the release of particularly IL-8. Previously, we and others have 
shown that CSE exposure of ASM cells caused the production of IL-8 (30, 31). CSE-
induced IL-8 release was reduced by a β2-agonist, via parallel stimulation of PKA and 
exchange protein directly activated by cAMP (Epac), and subsequent reduced activation 
of ERK1/2 and NFκ-B, respectively (29). CSE exposure decreased Epac expression in 
ASM cells (29), a process involving the induction of miRNA-7 (32). Since AKAPs are 
known to interact with both PKA and Epac proteins, the role of AKAPs in regulating 
these processes was subsequently studied.  
In chapter 3 we confirmed that CSE-induced IL-8 release by ASM is reduced 
by the β2-agonist fenoterol as well as direct PKA activation. Interestingly, we also 
showed that disruption of AKAP-PKA complexes using the dominant interfering peptide 
st-Ht31 caused a small increase in basal IL-8 release from ASM cells and augmented 
CSE-induced IL-8 release. Disrupting AKAP-PKA complexes using st-Ht31 prevented 
both the β2-agonist-induced inhibition of CSE-induced ERK1/2 activation and the 
subsequent reduction of IL-8 release (Chapter 3). These findings demonstrate that anti-
inflammatory effects mediated by the β2-adrenoceptor depend on proper AKAP-PKA 
interactions (Figure 1). The anti-inflammatory effect of direct activation of PKA by the 
cAMP analogue 6-Bnz-cAMP - thereby bypassing the β2-adrenoceptor - was insensitive 
to treatment with st-Ht31, providing further support for the importance of AKAPs in 
coordinating the signal from the β2-adrenoceptor to PKA (Chapter 3). In vivo, β2-
agonists exert anti-inflammatory effects in the presence of PDE4 inhibitors (33). 
However, β2-agonists are not used for anti-inflammatory purposes due to the rapid 
desensitization of the β2-adrenoceptor combined with the relatively low expression on 
inflammatory cells (34). To investigate a role for AKAPs in the inflammatory response in 
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vivo studies we did not need β2-agonists however, as st-Ht31 already increased basal 
IL-8 release from ASM cells (Chapter 3). Our results from chapter 3 suggest a role for 
AKAPs in the regulation of inflammation independent of β2-adrenoceptor signaling. 
Therefore, we focused on the basal roles of AKAP5 and AKAP12 in cigarette smoke-
induced inflammation. In chapter 4, we confirmed that KC, the murine equivalent of IL-8, 
was induced in the lung by cigarette smoke as shown previously (35) (Figure 1). 
Cigarette smoke-induced KC release was increased in AKAP5-/- mice compared to 
wildtype mice and accordingly the number of neutrophils was higher in the lung of 
AKAP5-/- mice compared to wildtype mice. Our findings indicate that AKAP5 is able to 
dampen cigarette smoke-induced inflammation in the lung (Figure 1). AKAP12-/- mice 
already showed an increased pulmonary neutrophilia without exposure to cigarette 
smoke and without an increased KC release (Figure 1). The AKAP12-/- mice also had an 
increase in macrophages and a trend for increased lymphocytes in the lung. Together 
these findings indicate that AKAP12 has an anti-inflammatory role, in the absence of an 
inflammatory signal. However, the increased infiltration of inflammatory cells seen in the 
AKAP12-/- mice is independent of an increase in KC release. It might be that in the lung, 
AKAP12 positive cells are important for resolving ongoing inflammation as was found in 
the brain (36). Therefore, AKAP12 deficient mice may be unable to remove inflammatory 
cells once present. In addition, inflammatory cells may proliferate more due to the loss of 
AKAP12, as AKAP12 is known as an inhibitor of proliferation (2, 37). However, the 
processes being involved in the recruitment of these inflammatory cells to the lung still 
remains to be characterized. In conclusion, both AKAP5 and AKAP12 possess anti-
inflammatory capabilities, particularly with respect to neutrophilia. Therefore, the lower 
expression of AKAP5 and AKAP12 found in lung tissue of COPD patients compared to 
non-COPD patients as described in chapter 3 could contribute to increased pulmonary 
inflammation (Figure 1). 
 
	
	
	
Figure 1: Cigarette smoke-induced reduction of AKAP5 and AKAP12 expression results in exaggerated 
neutrophilia. Exposure to cigarette smoke increases the release of the neutrophil attractant IL-8/KC, a process 
involving activation of ERK1/2. This process can be reduced by activating the cAMP/PKA pathway either by 
activating the β2-adrenoceptor (β2-AR) or inhibiting phosphodiesterases (PDE). AKAP5
-/- mice exhibit an increase 
in cigarette smoke-induced KC release, suggesting that this process is inhibited in the presence of functional 
AKAP5. AKAP12-/- mice exhibit an increase in neutrophils independent of KC release, suggesting an effect 
downstream of KC. Our findings indicate that cigarette smoke-induced reduction in AKAP5 and AKAP12 
expression may further amplify cigarette smoke-induced neutrophilia. Activation of ERK1/2 is inhibited by β2-
agonist-induced PKA in an AKAP-dependent manner, a process potentially hampered in vivo by receptor 
desensitization and PDE4-dependent degradation of cAMP.  
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Figure 1: Cigarette smoke-induced reduction of AKAP5 and AKAP12 expression results in exaggerated 
neutrophilia. Exposure to cigarette smoke increases the release of the neutrophil attractant IL-8/KC, a process 
involving activation of ERK1/2. This process can be reduced by activating the cAMP/PKA pathway either by 
activating the β2-adrenoceptor (β2-AR) or inhibiting phosphodiesterases (PDE). AKAP5
-/- mice exhibit an increase 
in cigarette smoke-induced KC release, suggesting that this process is inhibited in the presence of functional 
AKAP5. AKAP12-/- mice exhibit an increase in neutrophils independent of KC release, suggesting an effect 
downstream of KC. Our findings indicate that cigarette smoke-induced reduction in AKAP5 and AKAP12 
expression may further amplify cigarette smoke-induced neutrophilia. Activation of ERK1/2 is inhibited by β2-
agonist-induced PKA in an AKAP-dependent manner, a process potentially hampered in vivo by receptor 
desensitization and PDE4-dependent degradation of cAMP.  
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Taken together, ASM expresses several AKAPs and the β2-adrenoceptor 
associated AKAP5 and AKAP12 are decreased by cigarette smoke (Chapters 3 & 4) 
and are lower expressed in COPD patients compared to non-COPD patients (Chapter 
3). Reduction in AKAP12 increases pulmonary inflammation and reduces β2-agonist 
responsiveness, at least in the ASM. It remains to be studied whether this pulmonary 
inflammation and β2-agonist responsiveness is linked and can be influenced by AKAP12. 
It is known that β2-adrenoceptor-mediated anti-inflammatory effects in vivo are limited 
when PDE4 is not simultaneously inhibited. AKAP12 has no direct protein-protein 
interaction with PDE4; however there are PDE4 isoforms that are recruited to the β2-
adrenoceptor following GRK-mediated phosphorylation (27), which is reduced in 
AKAP12-/- mice (Chapter 5). We speculate that in the absence of AKAP12, there is 
potentially less PDE4 in the proximity of the receptor to degrade cAMP, and also less 
PKA activation due to the lack of AKAP12-PKA interactions, causing reduced anti-
inflammatory signaling and potentially reducing the additive effect of PDE4 inhibitors. 
However, what the actual functional outcomes are needs further investigation.  
Reduction in AKAP5 increases the sensitivity to cigarette smoke-induced 
neutrophilia suggesting that the lower expression of AKAP5 observed in COPD patients 
compared to non-COPD patients (Chapter 3) may lead to an increase in cigarette 
smoke-induced inflammation in the lung (Figure 2). The role of AKAP5 in inflammation 
is thus far unstudied, so no clear mechanism can be put forward at this point, but a role 
for Epac, suggested to bind AKAP5 in neurons (38), can be excluded because Epac 
knock out mice did not show the same increased sensitivity to cigarette smoke-induced 
neutrophilia (39).  
For COPD patients, cAMP signaling in AKAP5 and AKAP12 compartments may 
be crucial to maintain a healthy lung and the cigarette smoke-induced loss of these 
proteins will exaggerate pulmonary inflammation and reduce therapeutic efficacy of β2-
agonist. Therefore, an approach to ameliorate symptoms and perhaps even progression 
of disease, improving AKAP5– and AKAP12-mediated signaling could provide a novel 
therapeutic potential.  
	
	
	 	
Figure 2: AKAP12 mediated β2-agonist-induced ASM relaxation. Activation of β2-adrenoceptors (β2-AR) 
induces airway smooth muscle relaxation in an AKAP12-dependent manner. After agonist binding, the receptor 
undergoes recycling a process involving AKAP12 and GRK-mediated phosphorylation of the β2-adrenoceptor. 
Receptor recycling is required to maintain long term functioning for β2-agonist-induced airway smooth muscle 
relaxation. As cigarette smoke induced reduction of AKAP12 expression our findings also imply that the loss of 
AKAP12 may impair β2-agonist responsiveness. 
 
Translational aspects of AKAPs  
Based on the novel findings presented in this thesis, AKAP research potentially opens 
an entire new field of drug discovery. Current drugs mainly target receptors or enzymes 
irrespective of their location in the cell. The potential benefit of specific targeting of 
scaffolding proteins is that one would be able to target only a specific subset of receptors 
and/or enzymes, thereby limiting side effects due to inhibition of potential beneficial 
effects of these effectors. In combination with existing drugs (e.g. PDE4 inhibitors) such 
compounds could even provide improved efficacy, as AKAPs can also shield enzymes 
from selective drugs, as shown for PKC (48). 
Although therapeutic outlooks for the use of AKAPs have been reviewed before 
in detail elsewhere (5, 49-51), here the potential in the context of this thesis will be 
discussed. The most widely used dominant interfering peptide used in AKAP research, 
(st-)Ht31, was discovered to inhibit sperm mobility (52) and subsequently a patent was 
applied for male contraception (US 6011013 A). Although far from therapeutic 
Processed on: 2-11-2016
506329-L-bw-Poppinga
147
Chapter 7	
	
Taken together, ASM expresses several AKAPs and the β2-adrenoceptor 
associated AKAP5 and AKAP12 are decreased by cigarette smoke (Chapters 3 & 4) 
and are lower expressed in COPD patients compared to non-COPD patients (Chapter 
3). Reduction in AKAP12 increases pulmonary inflammation and reduces β2-agonist 
responsiveness, at least in the ASM. It remains to be studied whether this pulmonary 
inflammation and β2-agonist responsiveness is linked and can be influenced by AKAP12. 
It is known that β2-adrenoceptor-mediated anti-inflammatory effects in vivo are limited 
when PDE4 is not simultaneously inhibited. AKAP12 has no direct protein-protein 
interaction with PDE4; however there are PDE4 isoforms that are recruited to the β2-
adrenoceptor following GRK-mediated phosphorylation (27), which is reduced in 
AKAP12-/- mice (Chapter 5). We speculate that in the absence of AKAP12, there is 
potentially less PDE4 in the proximity of the receptor to degrade cAMP, and also less 
PKA activation due to the lack of AKAP12-PKA interactions, causing reduced anti-
inflammatory signaling and potentially reducing the additive effect of PDE4 inhibitors. 
However, what the actual functional outcomes are needs further investigation.  
Reduction in AKAP5 increases the sensitivity to cigarette smoke-induced 
neutrophilia suggesting that the lower expression of AKAP5 observed in COPD patients 
compared to non-COPD patients (Chapter 3) may lead to an increase in cigarette 
smoke-induced inflammation in the lung (Figure 2). The role of AKAP5 in inflammation 
is thus far unstudied, so no clear mechanism can be put forward at this point, but a role 
for Epac, suggested to bind AKAP5 in neurons (38), can be excluded because Epac 
knock out mice did not show the same increased sensitivity to cigarette smoke-induced 
neutrophilia (39).  
For COPD patients, cAMP signaling in AKAP5 and AKAP12 compartments may 
be crucial to maintain a healthy lung and the cigarette smoke-induced loss of these 
proteins will exaggerate pulmonary inflammation and reduce therapeutic efficacy of β2-
agonist. Therefore, an approach to ameliorate symptoms and perhaps even progression 
of disease, improving AKAP5– and AKAP12-mediated signaling could provide a novel 
therapeutic potential.  
	
	
	 	
Figure 2: AKAP12 mediated β2-agonist-induced ASM relaxation. Activation of β2-adrenoceptors (β2-AR) 
induces airway smooth muscle relaxation in an AKAP12-dependent manner. After agonist binding, the receptor 
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relaxation. As cigarette smoke induced reduction of AKAP12 expression our findings also imply that the loss of 
AKAP12 may impair β2-agonist responsiveness. 
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Based on the novel findings presented in this thesis, AKAP research potentially opens 
an entire new field of drug discovery. Current drugs mainly target receptors or enzymes 
irrespective of their location in the cell. The potential benefit of specific targeting of 
scaffolding proteins is that one would be able to target only a specific subset of receptors 
and/or enzymes, thereby limiting side effects due to inhibition of potential beneficial 
effects of these effectors. In combination with existing drugs (e.g. PDE4 inhibitors) such 
compounds could even provide improved efficacy, as AKAPs can also shield enzymes 
from selective drugs, as shown for PKC (48). 
Although therapeutic outlooks for the use of AKAPs have been reviewed before 
in detail elsewhere (5, 49-51), here the potential in the context of this thesis will be 
discussed. The most widely used dominant interfering peptide used in AKAP research, 
(st-)Ht31, was discovered to inhibit sperm mobility (52) and subsequently a patent was 
applied for male contraception (US 6011013 A). Although far from therapeutic 
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application, quinones demonstrated to cause alkylation of AKAP3 and AKAP4 selectively 
in spermatozoa, thereby reducing their motility. In addition, these compounds act against 
Chlamydia by alkylating a major chlamydial membrane protein, providing these drugs 
with a dual function against pregnancy and the transmission of sexually transmitted 
diseases (53). No male contraception has thus far come to market; however, a 
precedent has been made for AKAPs to be used as drug target, but also for drug design 
as described at the end of this section (Chapter 2). 
Effects of non-selective PKA-AKAP interaction inhibitors such as st-Ht31 have 
been as diverse as the described functions of PKA itself. In sensory neurons for 
example, st-Ht31 could prevent forskolin-induced potentiation of heat-activated ion 
channels through the VR1 channel and could therefore potentially inhibit inflammatory 
hyperalgesia (54). The data suggest that st-Ht31 may be beneficial to use in the context 
of disease. However, in chapter 3 we show that st-Ht31 increases cytokine release and 
in chapters 3 and 5 we show that st-Ht31 decreases β-agonist responsiveness. The 
data indicate that in the ASM st-Ht31 or other non-selective AKAP-PKA disruptors would 
not be viable drug candidates, perhaps even harmful. By contrast, in airway epithelium 
we could find beneficial effects of st-Ht31 by promoting epithelial barrier function (10). To 
prevent side effects, there is a need for more selective compounds, targeting only one 
compartment. A step towards this aim has been done with the development of the Rselect 
compounds (55). These peptides, created using a phage display technique are dominant 
interfering peptides that can remove PKA from selective AKAPs, although thus far only 
available for AKAP2 and AKAP7 complexes (55). 
Besides affecting protein-protein interactions, there is an option to reverse 
pathological changes in AKAP expression. Although for AKAP5 there is little known 
about its transcriptional cues, for AKAP12 there are known transcriptional inducers. Most 
relevant may be glucocorticoids (56). AKAP12 expression can also be pharmacologically 
induced by COX-2 inhibition (57), lysophosphatidylcholine (58) and angiotensin II (59). 
Furthermore, AKAP12 mRNA can be induced pharmacologically by the phorbol ester	
phorbol-12-myristate-13-acetate and by retinoids. The induction by phorbol-12-myristate-
13-acetate and retinoids is enhanced by the addition of the protein synthesis inhibitor 
cycloheximide, suggesting that both mRNA transcription and stability contribute to the 
steady-state control of mRNA expression (60-64).  
In addition to classical pharmacological induction, AKAP12 expression is 
strongly regulated at an epigenetic level by both DNA methyltransferases and histone 
deacetylases, although there appears to be an isoform specific regulation at this level. 
	
	
The AKAP12 gene produces three proteins derived from 2 transcription variants, 305 
kDa AKAP12α representing Gravin/SSeCKS and present in human, rat and mouse, 287 
kDa AKAP12β, only found in humans, and 250 kDa AKAP12γ, found in human, rat and 
mouse (65, 66). The lung expresses AKAP12α, AKAP12β but not AKAP12γ (66). 
AKAP12 is reduced in many cancers (37) and treatment with the DNA methyltransferase 
inhibitor 5-aza-2’-deoxycytidine (5-Aza-dC) can restore AKAP12 expression in most 
cancer cell lines (67, 68), demonstrating the reversible nature of this epigenetic 
regulation in these cells. In cell lines unable to restore AKAP12 expression after 5-Aza-
dC treatment, AKAP12β expression can be restored after treatment with the histone 
deacetylase inhibitor trichostatin A, whereas restoration of AKAP12α expression 
required a combination of both 5-Aza-dC and trichostatin A (67). Similar results were 
found for lung cancers where only 50% of the lung cancer cell lines could restore 
AKAP12α expression with 5-Aza-dC alone (69, 70). Therefore, it is possible to restore 
AKAP12 expression, even isoform specifically, although it is currently unclear what the 
role of the different isoforms is in the lung and how they are regulated. 
Although the use of AKAP complex disruptors might still seem far in the future, 
the knowledge obtained about the protein-protein interactions has been used in drug 
design. A method of drug design, named the Dock-and-Lock method, uses the 
dimerization and docking domain found in the regulatory subunit of PKA and the 
anchoring domain of an interactive AKAP, each attached to a biological entity (Chapter 
2) (71). The Dock-and-Lock method created an unlimited amount of combinations to be 
made by mixing and matching dimerization and docking domains with anchoring 
domains with different biological entities. The Dock-and-Lock method has subsequently 
led to several patents in cancer (US 7901680 Β2), HIV (US 8481041 Β2), siRNA delivery 
(US 8491914 Β2) and several other applications.  
 
From this thesis, the following conclusions can be drawn: 
- ASM cells express several members of the scaffolding protein AKAP family, 
including AKAP5, AKAP12 and Ezrin (Chapter 3). These AKAP family 
members are known to regulate the recycling of the β2-adrenoceptor, and may 
therefore be important for airway β2-adrenoceptor functioning (Chapter 2).  
- Cigarette smoke reduces AKAP5 and AKAP12 expression in cultured ASM 
cells, this could contribute to the lower AKAP5 and AKAP12 expression found 
in lung tissue from COPD patients compared to non-COPD patients (Chapter 
3).  
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strongly regulated at an epigenetic level by both DNA methyltransferases and histone 
deacetylases, although there appears to be an isoform specific regulation at this level. 
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required a combination of both 5-Aza-dC and trichostatin A (67). Similar results were 
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AKAP12α expression with 5-Aza-dC alone (69, 70). Therefore, it is possible to restore 
AKAP12 expression, even isoform specifically, although it is currently unclear what the 
role of the different isoforms is in the lung and how they are regulated. 
Although the use of AKAP complex disruptors might still seem far in the future, 
the knowledge obtained about the protein-protein interactions has been used in drug 
design. A method of drug design, named the Dock-and-Lock method, uses the 
dimerization and docking domain found in the regulatory subunit of PKA and the 
anchoring domain of an interactive AKAP, each attached to a biological entity (Chapter 
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From this thesis, the following conclusions can be drawn: 
- ASM cells express several members of the scaffolding protein AKAP family, 
including AKAP5, AKAP12 and Ezrin (Chapter 3). These AKAP family 
members are known to regulate the recycling of the β2-adrenoceptor, and may 
therefore be important for airway β2-adrenoceptor functioning (Chapter 2).  
- Cigarette smoke reduces AKAP5 and AKAP12 expression in cultured ASM 
cells, this could contribute to the lower AKAP5 and AKAP12 expression found 
in lung tissue from COPD patients compared to non-COPD patients (Chapter 
3).  
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- AKAP-PKA interactions are important to reduce basal and cigarette smoke-
induced IL-8 release from ASM cells as well as to mediate the anti-
inflammatory effect of β2-agonists hereon (Chapter 3).  
- In vivo, AKAP12 and AKAP5 control basal and cigarette smoke-induced 
pulmonary inflammation, respectively, in particular neutrophilia (Chapter 4).  
- AKAPs, and specifically AKAP12, mediates a normal β2-agonist-induced ASM 
relaxation (Chapter 5). 
- AKAP12 regulates GRK-mediated phosphorylation of the β2-adrenoceptor in 
ASM (Chapter 5).  
- The AKAP12 gene carries SNPs that associate with β2-agonist-induced 
improvement of lung function and that affect the amino acid sequence - but not 
the gene expression - of AKAP12, suggesting that there is a need to study 
protein-protein interaction domains of AKAP12, such as the β2-adrenoceptor 
binding domain, more closely in COPD (Chapter 6).  
 
Given the anti-inflammatory roles of AKAP5 and AKAP12, the observed decrease in the 
expression of AKAP5 and AKAP12 in patients with COPD could contribute to the 
pulmonary inflammation, particularly neutrophilia, observed in these patients. In addition, 
since AKAP12 mediates β2-agonist-induced ASM relaxation, loss of AKAP12 in COPD 
may hamper bronchodilation in response to treatment with β2-agonists. Therefore, 
therapeutic options that can restore functional AKAP5 and/or AKAP12 complexes could 
possibly enhance existing pharmacological approaches and decrease disease 
progression in COPD. 
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- AKAP-PKA interactions are important to reduce basal and cigarette smoke-
induced IL-8 release from ASM cells as well as to mediate the anti-
inflammatory effect of β2-agonists hereon (Chapter 3).  
- In vivo, AKAP12 and AKAP5 control basal and cigarette smoke-induced 
pulmonary inflammation, respectively, in particular neutrophilia (Chapter 4).  
- AKAPs, and specifically AKAP12, mediates a normal β2-agonist-induced ASM 
relaxation (Chapter 5). 
- AKAP12 regulates GRK-mediated phosphorylation of the β2-adrenoceptor in 
ASM (Chapter 5).  
- The AKAP12 gene carries SNPs that associate with β2-agonist-induced 
improvement of lung function and that affect the amino acid sequence - but not 
the gene expression - of AKAP12, suggesting that there is a need to study 
protein-protein interaction domains of AKAP12, such as the β2-adrenoceptor 
binding domain, more closely in COPD (Chapter 6).  
 
Given the anti-inflammatory roles of AKAP5 and AKAP12, the observed decrease in the 
expression of AKAP5 and AKAP12 in patients with COPD could contribute to the 
pulmonary inflammation, particularly neutrophilia, observed in these patients. In addition, 
since AKAP12 mediates β2-agonist-induced ASM relaxation, loss of AKAP12 in COPD 
may hamper bronchodilation in response to treatment with β2-agonists. Therefore, 
therapeutic options that can restore functional AKAP5 and/or AKAP12 complexes could 
possibly enhance existing pharmacological approaches and decrease disease 
progression in COPD. 
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Nederlandse samenvatting 
De ziekte chronic obstructive pulmonary disease (chronische obstructieve longziekte) 
ofwel COPD wordt gekenmerkt door een progressieve afname van de longfunctie door 
blootstelling aan onder andere sigarettenrook, waarbij ontstekingsprocessen in de long 
een belangrijke rol spelen. Belangrijke ontstekingscellen in de ontwikkeling van COPD 
zijn neutrofielen, macrofagen én lymfocyten die schade aanrichten in het longweefsel. 
Eén van de standaardbehandelingen voor benauwdheid bij COPD patiënten betreft het 
gebruik van luchtwegverwijdende bèta-agonisten, welke aangrijpen op de bètareceptor. 
Receptoren zijn eiwitten die na binding het signaal van boodschapperstoffen van buiten 
de cel kunnen doorgeven, zoals de bètareceptor die het signaal doorgeeft van bèta-
agonisten. Bij deze signaaloverdracht wordt onder andere het enzym protein kinase A, 
ofwel PKA geactiveerd, dat vervolgens in staat is om verschillende processen in de cel 
te stimuleren, bijvoorbeeld de ontspanning van gladde spiercellen (hoofdstuk 2). COPD 
patiënten worden vaak langdurig behandeld met deze bèta-agonisten, wat nadelige 
bijwerkingen kan opleveren, daarom zijn er alternatieve behandelingsstrategieën nodig. 
A-kinase anchoring proteins, ofwel AKAPs vormen een familie van eiwitten die 
allemaal de mogelijkheid hebben het enzym PKA te binden en zijn te vinden in 
verschillende gedeelten van de cel. Belangrijk is dat bepaalde AKAPs ook aan 
receptoren op de cel kunnen binden. Een goede organisatie van PKA door AKAPs is 
noodzakelijk om tal van cellulaire processen op een goede wijze te laten verlopen en 
verstoring van deze organisatie leidt mogelijk tot verschillende ziekten, zoals 
cardiovasculaire ziekten, kanker of neurodegeneratieve ziekten (hoofdstuk 2). In het 
bijzonder van de AKAP familieleden AKAP5 en AKAP12 wordt aangenomen dat ze 
belangrijk zijn voor het behouden van de werking van bèta-agonisten, die gebruikt 
worden bij de behandeling van benauwdheid bij COPD patiënten. Daarom verwachten 
wij dat AKAPs mogelijk een doelwit vormen voor alternatieve behandelingsstrategieën. 
Dit proefschrift heeft zich gericht op de rol van AKAPs, in de long, in het 
bijzonder op de rol van AKAPs in de luchtwegverwijdende effecten van bèta-agonisten 
en in luchtwegontsteking in relatie tot COPD.  
 
AKAP aanwezigheid in de luchtweg gladde spier 
Om een rol voor AKAPs in de ontspanning van de luchtweg gladde spiercel te kunnen 
identificeren hebben we eerst onderzocht welke AKAPs in deze cel aanwezig zijn. 
Vervolgens hebben we het effect van blootstelling aan sigarettenrook op de 
aanwezigheid van AKAPs in deze cellen bestudeerd, om na te gaan of sigarettenrook de 
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aanwezigheid van AKAPs kan beïnvloeden. In hoofdstuk 3 lieten we zien dat luchtweg 
gladde spiercellen de AKAPs AKAP5, AKAP8, AKAP9, AKAP12 en AKAP78, beter 
bekend als Ezrin, tot expressie brengen. We lieten zien dat sigarettenrookextract de 
aanwezigheid van AKAP5, AKAP12 en AKAP9 kan verlagen en die van Ezrin juist kan 
verhogen (hoofdstuk 3). Het was al eerder bekend dat AKAP5 en AKAP12 mogelijk een 
rol spelen in de werking van bèta-agonisten (hoofdstuk 2), daarom hebben wij ons 
verder op deze twee AKAPs gericht. Ook in muizen, blootgesteld aan sigarettenrook, 
werd een verlaging van AKAP5 en AKAP12 in de long waargenomen (hoofdstuk 4). We 
vonden ook dat AKAP5 en AKAP12 zijn verlaagd in longweefsel van COPD patiënten in 
vergelijking met gezond longweefsel (hoofdstuk 3). Dit betekent dat AKAP5 en AKAP12 
inderdaad van belang kunnen zijn voor COPD patiënten. Wij hebben geprobeerd te 
achterhalen wat dit belang zou kunnen zijn en hebben ons gericht op 
luchtwegontstekingen en de werking van bèta-agonisten.  
 
AKAPs en luchtwegontstekingen 
Omdat sigarettenrook een oorzaak is van luchtwegontsteking bij COPD gingen we 
verder met onderzoek naar wat het effect zou zijn als we de werking van AKAPs zouden 
remmen door middel van de stof st-Ht31, die voorkomt dat PKA aan AKAPs bindent. We 
richtten ons op daarbij de ontstekingsstof interleukine-8 (IL-8) die neutrofielen aantrekt 
en onder andere wordt geproduceerd door luchtweg gladde spiercellen. De door de 
sigarettenrook veroorzaakte vrijmaking van IL-8 door deze cellen werd sterk verhoogd 
wanneer de werking van AKAPs door st-Ht31 werd geremd (hoofdstuk 3). De 
vrijmaking van IL-8 door luchtweg gladde spiercellen kon onder normale 
omstandigheden worden tegengegaan met bèta-agonisten, maar dit effect werd 
eveneens sterk verminderd wanneer de werking van AKAPs werd geremd (hoofdstuk 
3), wat aangeeft dat AKAPs een rol spelen in het onderdrukken van 
ontstekingsprocessen door bèta-receptoractivatie. 
Bevindingen in een muizenmodel voor sigarettenrook-geïnduceerde ontsteking 
waren in overeenstemming met deze ontsteking regulerende rol van AKAPs. We 
maakten hierbij gebruik van muizen waar het DNA van AKAP5 of AKAP12 was 
verwijderd, waardoor ze deze eiwitten niet kunnen maken. In normale muizen vonden 
we dat sigarettenrook een luchtwegontsteking veroorzaakte. We vonden dat muizen 
zonder AKAP5 een versterkte luchtwegontsteking na blootstelling aan sigarettenrook 
hadden, voornamelijk gekenmerkt door infiltratie van neutrofiele cellen die vooral door 
IL-8 (KC genaamd in muizen) worden aangetrokken (hoofdstuk 4). Muizen zonder 
	
	
AKAP12 hadden echter al een verhoogde hoeveelheid ontstekingscellen, zoals 
neutrofielen, macrofagen én lymfocyten in de luchtwegen zonder blootstelling aan 
sigarettenrook, wat betekent dat AKAP12 onder gezonde omstandigheden een rem is op 
de ontwikkeling van ontstekingen in de long (hoofdstuk 4). 
 
AKAPs en bèta-agonisten 
Door ander onderzoek werd eerder gesuggereerd dat AKAP5 en AKAP12 een 
belangrijke rol kunnen spelen in de werking van bèta-agonisten door de hoeveelheid 
receptoren op de cel constant te houden (hoofdstuk 2). Wij verwachtten daarom dat het 
feit dat COPD patiënten een verlaagde hoeveelheid AKAP5 en AKAP12 hebben, 
mogelijk veroorzaakt door het roken, van klinisch belang kon zijn bij gebruik van bèta-
agonisten. Daarom gebruikten we muizen zonder AKAP5 of AKAP12 om de bronchus 
verwijdende werking van bèta-agonisten te bestuderen. We zagen in geisoleerde 
luchtwegpreparaten van deze muizen dat voornamelijk AKAP12 van belang is voor de 
bronchusverwijdende werking van bèta-agonisten (hoofdstuk 5). Dit werd ondersteund 
door waarnemingen in rokende astma patiënten, waarbij genvarianten van AKAP12 
geassocieerd konden worden met de mate van bronchusverwijding door bèta-agonisten 
(hoofdstuk 6). Dit impliceert dat AKAP5 en AKAP12 belangrijk zijn voor de werking van 
bèta-agonisten .  
 
Algemene conclusie 
COPD patiënten hebben een lagere hoeveelheid AKAP5 en AKAP12 in de luchtweg 
gladde spier wat kan leiden tot een versterkte luchtwegontsteking na blootstelling aan 
sigaretten. Bovendien leidt het verlies van AKAP12 tot een verminderde werking van 
bèta-agonisten, waardoor benauwdheid minder goed kan worden bestreden. Nieuwe 
therapeutische opties zouden zich dan ook moeten richten op het herstel van functionele 
AKAP5 en/of AKAP12 complexen om zo het verergeren van de ziekte tegen te gaan en 
bestaande therapieën te verbeteren. 
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crossed my path in this long period, so let me begin to say that I acknowledge every 
person for their contribution to becoming the person that I am today and hope to be 
forgiven if your name is not mentioned individually.  
Let me start at the beginning with the lab in Berlin, Enno Klußmann, you were 
a patient person allowing me to explore all that I wished to study. Thank you for 
providing me an opportunity to start something that I could not have done in the 
Netherlands. Philipp Skroblin, you helped me practically with starting up and would 
remain a source of information even after leaving back to Groningen, together with Antje 
you also showed me the Berlin nightlife. Antje Schmidt, also thank you for helping me 
to go to a dentist when I really needed some German assistance, it was a life saver. 
Kerstin Zühlke and Jens Furkert thank you for helping me with the more radioactive 
experiments and also for assisting my student Laura when she joined your lab. Andrea 
Geelhaar and Beate Eisermann, two wonderful technicians, we would communicate 
using both my limited German and your English and everything in between, but we could 
always manage and you were always prepared to help. Danke Schön! 
Dörte Faust and definitely also Matthias Pfeifer (Horst), you remained my 
best connection after leaving Berlin, always allowing me to stay at your house to visit 
thesis defenses and later when you moved to London to stay and visit during my 
meetings and courses there. I am sure we will stay in touch and find out way in or 
outside the scientific world. Berlin has given me good friends and hopefully longtime 
collaborators.  
In Groningen I would like to thank Martina Schmidt and Harm Maarsingh for 
providing me the opportunity to turn my work from Berlin into a grant proposal, allowing 
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outside the scientific world. Berlin has given me good friends and hopefully longtime 
collaborators.  
In Groningen I would like to thank Martina Schmidt and Harm Maarsingh for 
providing me the opportunity to turn my work from Berlin into a grant proposal, allowing 
me to follow my own ideas. Having received several offers for projects already funded at 
other departments, I should thank Herman Meurs for convincing me to stay when there 
was no money, stating it was a unique opportunity to create a new research line. 
Something that would eventually prove to be true and lead to many other PhD’s joining 
my quest for compartmentalization in the lung. Nothing more thrilling in science than to 
see your ideas grow and blossom.  
Irene Heijink thank you for support during my PhD, but also for believing in my 
ideas for a grant to start with my post-doctoral career. But also to provide support when I 
would feel that my own department would fail to provide this.  
This is perhaps also a good moment to acknowledge my reading committee, 
thank you all for reading and approving my thesis. Uli Eisel, together with Ingrid Nijholt 
you brought AKAPs into the context of Epac compartmentalization and my Master 
project was originally aimed to copy this into the lung, without you this thesis would not 
have even existed. Sven van IJzendoorn, we mainly interacted when I would use your 
microscope in the early years of my PhD, you published on AKAPs one year before Uli 
making you the original Groningen AKAP expert. However Groningen has not been able 
to keep its interest in AKAPs, I hope this will now change. Ray Penn, we have met each 
other on several occasions, either when you would visit our lab for a thesis defense or at 
the ATS or YIM. I am happy you agreed to be on the reading committee. As most people 
that I met that worked on AKAPs before, you also did not seem to enjoy it very much. 
However being the only one besides me that worked on AKAPs in airway smooth 
muscle you would have to deal with my excitement about this topic. Thank you for 
bringing in sometimes heavily required advice, talking to you has shaped several 
chapters in this thesis.  
With an increasing amount of people working on compartmentalization, I should 
thank those people in particular for a great collaboration, sharing our growing pains in 
science. Anouk Oldenburger, thank you for teaching me my first human cell culturing 
techniques after working only mainly with bacteria and fungi. You have been able to start 
with AKAPs in the epithelial barrier, which was eventually published quite nicely, 
providing a lot of work for people in the future. Sepp Jansen looking from the cancer 
perspective also trusted in my suggestion to look for a role of Ezrin in epithelial-to-
	
	
mesenchymal transition which was also appreciated by the reviewers, and this was 
published quickly. Thank you our interesting talks. 
Pablo Muñoz-Llancao, always critical on AKAPs, as I was on Epac, you and I 
were able to write a nice review summarizing quite nicely what I would expect to be the 
role of AKAPs in β2-adrenoceptor cycling. Knowing now more, one might wonder how 
much is true, but it was a great start for a hypothesis. Of course Pablo, you were more 
than just a co-author, I had the “pleasure” and honor of being your paranymph, standing 
by to support you during your defense and everything leading up to that moment. You 
and I had drinks, too many to mention, leading to the best discussions on scientific 
topics. I am sure when you come to your senses and focus again on some AKAPs we 
can have many nice topics together to study in the brain. Now we both have become 
lone wolves again, but we shan’t forget the wolf pack.  
Bing Han, you were my asthmatic counterpart; starting on the original 
‘good’/’bad’ AKAP hypothesis in asthma. Although this did not go as expected and you 
were diverted more to company projects, leading to a nice publication on Sul-121, we 
also finished a project together to be published in your thesis and hopefully a paper or 
two. Now you will continue as department head for animal studies at Mucosis B.V., I 
wish you luck but I am sure you will do fine! Thank you for your teachings on China and 
being a support when both had to struggle to get our thesis to the reading committee.  
Haoxiao Zuo, coming to the department as Bing’s girlfriend, later fiancée and 
eventually wife, you became my student upon my request as I saw that you could do 
much more than was provided to you at the time. You set a foundation for AKAPs in 
EMT and on my recommendation you later became a PhD focusing on cAMP/cGMP 
compartmentalization using FRET reporter mice. Thank you for still including me in the 
discussions, I still believe in the idea and I hope you can achieve our goals in this 
project. I will stay in touch to help you, as I know you and I both appreciate the 
discussion.  
Not only PhD students provided support, also Carolina Elzinga was a major 
support for me inside the lab, but also inside my mind when things got though. Always 
available even when not in the department, you tried to always help me understand why 
people act in certain ways or explained to me to just accept things as some people will 
never change. To you perhaps the quote at the beginning of my thesis should make the 
most sense. Reminding me that happiness should be a priority and that a PhD is not a 
necessity for that happiness, gave me inspiration to keep on struggling, as you told me 
many others had done before me. Only the faces change, not the problems. 
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Also the other technicians gave support and sometimes much needed comic 
relief, especially Mark Menzen who was one of the few that made me feel welcome from 
the start. You found a better future before I left, leaving too soon, however I wish you 
much happiness with your newborn family. Sophie Bos and Annet Zuidhof, I 
appreciated your company and especially that you helped me with killing the animals 
and/or counting endless slides with cells, I would not have been able to do it alone, 
thank you. 
I would also like to thank the many students that I have supervised over the last 
years, especially the students that have stayed for several months. It was always sad to 
see you leave. 
Adinda Mieras, you helped me to set-up AKAPs in the brain, although this 
never really continued, I enjoyed learning together about this, you were very eager to 
learn and went above and beyond to prove your worth. Years later you have started your 
own PhD studies and I wish you good luck with that.  
Laura Holtzer, you went to Berlin for me, back to where I began. You 
continued characterizing the AKAPs expressed in the airway smooth muscle cells and 
helped me tremendously with your western blotting skills. I think you were a very smart 
student and I feel you would have made a great scientist. You preferred to continue as a 
pharmacist; however not without leaving with a co-authorship also found in this thesis as 
chapter 3.  
Sjoerd de Haan, you always talked too much and you have made it into your 
career, as an account manager. I think you have found your calling. A lot of your time 
was spent talking in the coffee room or in someone’s office, but you worked hard and I 
enjoyed having you around and I hope you can still use some of my teachings in your 
future career.  
Saskia Driessen, you were a very hard worker. Not really used to socializing 
with your supervisor, you preferred to refill pipette tips and clean the lab. I think every 
student can learn from you. Luckily you loosened up and I think we had a great time. I 
hope you enjoyed, even when everybody was focusing on your face turning very bright 
red, you still could stay professional. Another student lost to the pharmacy, but I hope 
you enjoy it.  
Ksenia Myacheva, the red threat from Russia. I had the weirdest 
conversations with you I have to say. I really enjoyed having you in the lab, bribing me 
with Russian money which was quite worthless to you, but precious to me. You did great 
work and together with the work of Haoxiao, I think we made a very nice EMT story, 
	
	
although we will have to wait whether this will still be picked up for publication during 
Haoxiao’s PhD studies. As a TOP master student, of course you continued to do a PhD 
at a top institute. I hope to hear more about your science soon.  
Sybrig de Vries! Very quiet girl, but secretly having a great sense of humor 
and really talkative if someone could finally pull it out of you. You were amazing with 
your pipetting patience, dozens and dozens of 48-wells plates you pipetted for genetic 
characterization of the AKAP12 mice. Dozens more pictures you took and quantified for 
histological characterization of the AKAP12 mice. I am happy to say that not all went to 
waste and you came to be co-author of chapter 4. Sadly we never got the time to do the 
same for the AKAP5 mice. Although you were promised a job at our department, money 
never came, but now you luckily have a job as a technician in the best province the 
Netherlands has to offer.  
Of course there have been plenty more students staying for only a few weeks 
and many more students supervised by others that I have shared great moments with, 
thank you all for your company and fun moments.  
 To close on my direct collaborators, I want to acknowledge all of my co-authors 
not already mentioned. Christian Gonzalez-Billault, we have worked together on our 
review, which I feel is a good start of my book. I hope in the future we can collaborate 
more on studying compartmentalization in neuronal systems, I think there is still more to 
explore. Andrew Halayko, you always had good comments on my papers when we 
used the hTERT ASM cell lines. You have a great sense of humor, pleasure to meet you 
around ATS, YIM and other meetings. If I ever have the urge to work with hTERTs 
again, I will know where to find you. Irwin Gelman, we have only had contact via the e-
mail and yet I am thrilled to have an expert on AKAP12 be a co-author on my papers, 
thank you for letting me use your AKAP12 knock out mice, it allowed us to test our in 
vitro work in a system more closely resembling the real situation. Wim Timens as a 
pathologist you taught me to recognize the airway smooth muscle bundles in histological 
stainings and you always had great suggestions to improve the paper and the statistics. 
Thank you. Laura Hesse, without hesitation you helped me to get data on KC release in 
my mouse samples. This to me shows the real power of GRIAC, especially as you 
expected nothing in return. Of course, I was very happy to acknowledge you with a co-
authorship. Thank you very much! Alen Faiz, thank you for your help with the eQTL 
analysis and your large amount of patience, trying to explain to me what you actually did. 
I am really happy to have a paper that can put this thesis closer to the patient situation. 
Maarten van den Berge, also you helped to arrange a lot of things with the eQTL 
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analysis and to arrange things with the eQTL lung consortium, thank you also for looking 
to the manuscript in detail and trying to teach me how to write this properly. Judith 
Vonk, you performed all the SNP analyses regarding the association with the 
improvement of lung function and the link with smoking. I could not have understood 
how to write this paper without you and you have taught me some of the different 
languages epidemiologists speak compared to my molecular biologist language. Thank 
you. Corry-Anke Brandsma, although our interaction was limited for this thesis, we 
have interacted on other occasions, especially as you brought some more AKAPs in the 
lung field. To you they might just be genes, but I will be curious to see what happens 
with Ezrin and MAP2, as Ezrin is next to AKAP12 one of my favorites. Similar for you 
Gerard Koppelman, you brought me to AKAP1 and perhaps I can study more on the 
role of this AKAP in lung diseases in the future. Time will tell. Thank you all. 
Of course, there are many more people within GRIAC to thank and I would 
especially thank Dirkje Postma to be willing to give me some guidance for my future 
and tell me to talk to Gerard about AKAP1, it helped me to move forward in my career. 
Seeing your farewell symposium also inspired me to find a great mentor and hope to be 
a great mentor to others in the future.  
Working in a department, one interacts with a lot of people not directly involved 
in your work or even in similar topics. I would like to thank all those that have assisted 
me in the year whenever I had questions or trouble or just to have a drink with.  
Allereerst een belangrijk persoon die niet echt onderdeel is van de afdeling, 
speciaal voor jou in het Nederlands, want Engels is niet je favoriete taal. Sylvia van der 
Heide, je bent meestal de eerste person die mij begroet in de ochtend en je hebt (bijna) 
nooit geklaagd over de rommel in mijn kantoor of de blikjes bier in mijn vuilnisbak van de 
avond daar voor. Je bent de enige geweest die mij ooit heeft kunnen dwingen mijn 
bureau soms op te ruimen, zodat jij je werk kon doen. Dank je wel voor de leuke tijd en 
ik hoop je nog eens tegen te komen! 
An important drinking buddy was David Wright, the first “real” post-doc I could 
experience in the lab, leaving so very quickly again to start a new career in scientific 
communication. We will keep in touch through the wonders of the internet and I hope 
you will find a good career outside of academic research. Tim Koopmans, of course 
you belong to this same category, eventually only lone wolves will remain, but we will 
keep in touch. We shared the burden of being Pablo’s paranymph, thank you for letting 
me annoy you in your office when I needed to. Also a thank you to Hana Černecká for 
your friendship and giving me the honor to be your paranymph, it was nice that you 
	
	
joined me to study for the diploma in advanced pharmacology. As a lab head you are 
already becoming an important person at Bayer and I am sure that your career will 
proceed very rapidly. Tjitske Oenema together we were Hana’s paranymphs and you 
were always the source of information for me within the department, staying up to date 
with all the social developments. Now you are study director at ABL, another former 
colleague with a fancy sounding job, you deserve it and I hope you enjoy it. Kuldeep 
Kumawat, the hardworking Indian, perhaps my favorite office mate during my PhD, you 
always showed to be the most informed on the scientific developments in our field; one 
of the smartest people I met in the department. Although you went for the US, you came 
back to the Netherlands again now Post-doc in Utrecht and hopefully soon able to start 
your own lab somewhere. Pavan Prabhala, our time together was short, your sense of 
humor is weird but you were fun company we shall have a beer in the future. Good luck 
with all your research aspirations, curing the problem of air pollution. Boy van Basten, 
also our time together in the office was short-lived, although you are one of the people in 
the department I knew the longest, starting already at the student dancing society SSV 
The Blue toes and you did your Bachelor and Master projects with Anouk. I enjoyed our 
conversations; we were very different, although somewhat similar in other aspects, 
besides the dancing and watching dr. Who, we also had a unique way of looking at the 
world and its inhabitants. You continued to work more in the education part with Martina, 
but now you have managed to start a PhD in Scotland, I wish you the best of luck and 
hope to see your papers soon.  
Now remains some seniors of the department. Reinoud Gosens, we had great 
conversations during drinks, meals and conferences. Having experienced you for more 
than six years, now an associate professor, I think you will continue to progress through 
your career rapidly and I am sure that I will contact you in the future for advice on career 
progression in (pulmonary) science or to take a glance at my grant proposals. Thank you 
also for suggesting me to discuss with Gerard on AKAP1, although the direction 
changed, it was the hint that would lead to my next job.  
Hans Zaagsma, always willing to talk about science, to provide guidance and 
curious about the progress of the “Akappen”, you are an example of the truly passionate 
scientist and I wish to be able to keep the same passion for as long as you have. Thank 
you for allowing me access to your knowledge and advise me on my career even more 
than 10 years after your retirement from our department.  
Jacques Hille, we shared an office in the final months of my stay at the 
department. However, we were already in touch from the start when you allowed my 
Processed on: 2-11-2016
506329-L-bw-Poppinga
171
Chapter 9	
	
analysis and to arrange things with the eQTL lung consortium, thank you also for looking 
to the manuscript in detail and trying to teach me how to write this properly. Judith 
Vonk, you performed all the SNP analyses regarding the association with the 
improvement of lung function and the link with smoking. I could not have understood 
how to write this paper without you and you have taught me some of the different 
languages epidemiologists speak compared to my molecular biologist language. Thank 
you. Corry-Anke Brandsma, although our interaction was limited for this thesis, we 
have interacted on other occasions, especially as you brought some more AKAPs in the 
lung field. To you they might just be genes, but I will be curious to see what happens 
with Ezrin and MAP2, as Ezrin is next to AKAP12 one of my favorites. Similar for you 
Gerard Koppelman, you brought me to AKAP1 and perhaps I can study more on the 
role of this AKAP in lung diseases in the future. Time will tell. Thank you all. 
Of course, there are many more people within GRIAC to thank and I would 
especially thank Dirkje Postma to be willing to give me some guidance for my future 
and tell me to talk to Gerard about AKAP1, it helped me to move forward in my career. 
Seeing your farewell symposium also inspired me to find a great mentor and hope to be 
a great mentor to others in the future.  
Working in a department, one interacts with a lot of people not directly involved 
in your work or even in similar topics. I would like to thank all those that have assisted 
me in the year whenever I had questions or trouble or just to have a drink with.  
Allereerst een belangrijk persoon die niet echt onderdeel is van de afdeling, 
speciaal voor jou in het Nederlands, want Engels is niet je favoriete taal. Sylvia van der 
Heide, je bent meestal de eerste person die mij begroet in de ochtend en je hebt (bijna) 
nooit geklaagd over de rommel in mijn kantoor of de blikjes bier in mijn vuilnisbak van de 
avond daar voor. Je bent de enige geweest die mij ooit heeft kunnen dwingen mijn 
bureau soms op te ruimen, zodat jij je werk kon doen. Dank je wel voor de leuke tijd en 
ik hoop je nog eens tegen te komen! 
An important drinking buddy was David Wright, the first “real” post-doc I could 
experience in the lab, leaving so very quickly again to start a new career in scientific 
communication. We will keep in touch through the wonders of the internet and I hope 
you will find a good career outside of academic research. Tim Koopmans, of course 
you belong to this same category, eventually only lone wolves will remain, but we will 
keep in touch. We shared the burden of being Pablo’s paranymph, thank you for letting 
me annoy you in your office when I needed to. Also a thank you to Hana Černecká for 
your friendship and giving me the honor to be your paranymph, it was nice that you 
	
	
joined me to study for the diploma in advanced pharmacology. As a lab head you are 
already becoming an important person at Bayer and I am sure that your career will 
proceed very rapidly. Tjitske Oenema together we were Hana’s paranymphs and you 
were always the source of information for me within the department, staying up to date 
with all the social developments. Now you are study director at ABL, another former 
colleague with a fancy sounding job, you deserve it and I hope you enjoy it. Kuldeep 
Kumawat, the hardworking Indian, perhaps my favorite office mate during my PhD, you 
always showed to be the most informed on the scientific developments in our field; one 
of the smartest people I met in the department. Although you went for the US, you came 
back to the Netherlands again now Post-doc in Utrecht and hopefully soon able to start 
your own lab somewhere. Pavan Prabhala, our time together was short, your sense of 
humor is weird but you were fun company we shall have a beer in the future. Good luck 
with all your research aspirations, curing the problem of air pollution. Boy van Basten, 
also our time together in the office was short-lived, although you are one of the people in 
the department I knew the longest, starting already at the student dancing society SSV 
The Blue toes and you did your Bachelor and Master projects with Anouk. I enjoyed our 
conversations; we were very different, although somewhat similar in other aspects, 
besides the dancing and watching dr. Who, we also had a unique way of looking at the 
world and its inhabitants. You continued to work more in the education part with Martina, 
but now you have managed to start a PhD in Scotland, I wish you the best of luck and 
hope to see your papers soon.  
Now remains some seniors of the department. Reinoud Gosens, we had great 
conversations during drinks, meals and conferences. Having experienced you for more 
than six years, now an associate professor, I think you will continue to progress through 
your career rapidly and I am sure that I will contact you in the future for advice on career 
progression in (pulmonary) science or to take a glance at my grant proposals. Thank you 
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students to use your office space to write their report and process data. We had nice 
conversations and you could provide me insights from a different perspective. I valued 
our conversations and I hope you enjoyed them as well.  
 Spending months at a department I had done several times before. However, 
years were a new experience and it was one that I was not really looking forward to, as I 
worried to get bored. However, it became clear quite quickly that the only way I could 
continue studying AKAPs was to get a PhD. Since then many, many people not yet 
mentioned have passed through the department or are still there that have influenced 
this long time spent at the department. I hate listing names, therefore I thank all the 
other (former) members of Molecular Pharmacology that have not been mentioned 
yet for the lessons they had to offer me.  
 The final groups of people that I got in touch with during my PhD are those that 
provided advice and/or service to allow proper experiments to be performed. I would like 
to thank Ben Giepmans and Klaas Sjollema for all their help with my cloning of the 
EosFP linked β2-adrenoceptor and also for all the guidance at the microscope. I really 
hope that someone will continue with this work someday. Marjan Luinge, my go-to 
person in the Pathology lab, thank you for aiding me in my staining protocols which 
could not be done in our lab. Roelof Jan van der Lei, you were essential for my FACS 
experiments to purify my EosFP-expressing cells. I am happy we got to work together at 
least briefly so many years after our time studying in Leeuwarden. Finally, for all my 
animal chapters I depended a lot on the CDP to assist me with the breeding. Thank you 
Yvonne Heddema and Pieter Steijvers, for keeping my mice alive and Juul Baller to 
help me set up the breeding lines.  
An important part of the thesis occurs outside of the lab, where ideas can hit 
you unexpectedly. For me this was especially true while deep under water during my 
SCUBA diving with GBD Calamari and Duikvereniging Hydrofiel; for which I would like 
to thank all the member together as there are too many to mention separately.  
Of course, my number one diving buddy should be mentioned separately as a 
friend from high school, colleague at IMENz, diving buddy since 2011 and my 
paranymph, Robert Woudstra. Together we learned how to dive during our stay on 
Gran Canaria and we have been able to log many dives together in the Netherlands and 
in the Mediterranean Sea. We have followed similar pathways coming together again as 
technicians in the same company and sharing our networks in Groningen. I hope to log 
dives together again in the future! 
	
	
I am happy that I have been able to stay in touch with good friends since high 
school, David de Groot, it was a different millennium when we first met and yet, 
Pokémon have returned again while writing this acknowledgement. Many things have 
changed, and yet so many things have remained the same. We were the only ones 
going to the same applied university after high school and we have had a nice time also 
partying in Groningen. Peter van de Lageweg, starting also in Leeuwarden after high 
school, you and I were not satisfied and both continued for a Master’s degree. However, 
you went very far away from Frisia, all the way to Eindhoven, but you always wanted 
something better than Frisia. Now you are a graduated architect working in Amsterdam 
on apps for construction sites. Another interesting addition to birthday parties is Ynze 
Goinga, now studying in the UK and I think I should call you a civil engineer, although 
the civil part… Together with Peter you are the real engineers in the group and I expect 
great things when you will graduate. Lars van Dorenmalen, the international 
businessman, I have missed you at too many birthdays and I don´t really understand 
what you do, but you are for sure one of the people interested in the world and its 
wellbeing, volunteering at the moment of writing in Bangladesh to increase sustainability. 
I am happy to count someone this responsible for our future as one of my friends. 
Marleen Lamberts, the only girl from our little high school group. The first to have a 
child, Ayden Lamberts, a wonderful young man that has a great group of guys to look 
up to. You have always been a great friend, someone to talk to and have deep thoughts 
with. I am sure it has sometimes been hard to be the only girl, but growing up with 
brothers allowed you to handle us appropriately. We have all come a long way since our 
times at the Drachtster Lyceum, relationships have come and gone but I am happy that 
have been able to stay connected. I am sure that our friendship of so many years will 
continue no matter the distance.  
Valerie Wiersma, you were there in high school, during my Bachelor, Master 
and you are the only one that continued with me into a PhD. Our paths have been so 
similar for the last 15 years or so and you eventually even married into GRIAC with 
Daan Pouwels. Your passion lies in your family, which should be expanding around the 
time of my defense(!), but I am sure that your intellect and talents will not be lost to 
science and you can continue your career as a power couple with Daan as the future of 
the lung field and you the future of the cancer field. Both of us suck at keeping close 
when focusing on our research, hopefully we can now start again after getting rid of 
these PhD studies. Perhaps we can have future collaborations, AKAPs are of course 
important in cancer as well (also in DAMP signaling).  
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Speaking of being bad at keeping in touch, other friends from my Bachelor 
studies must have felt neglected for the last years also and I hope to make up for this 
one day. The brothers Meihuizen, Gerard Meihuizen you have become a farmer and a 
father, big changes since our time in biotechnology. Rolf Meihuizen, the best of us, 
always keeping in touch and showing your social skills, now finishing your second study 
at the University of Utrecht. Hope you can find a fitting career after this. It is fitting that 
perhaps my only true Groninger friends were studying in Frisia and you prepared me 
well for my time in Groningen. Brandt Meylis, actually one of the few people from 
Leeuwarden that I know that actually ended up doing what we were trained to do. You 
had to go all the way to Leiden to do this, creating difficulties to meet each other too 
often, but I enjoyed Leiden the few times I was there and you convince me that it might 
be a nice city to work. Years have passed since our times in Brandt´s hokje, complaining 
about certain teachers whose names shall never be mentioned again. It is perhaps true 
that the best friends are shaped in shared misery. There were of course others that 
shaped my time in Leeuwarden and during the 1.5 years spend on internships in 
Groningen thank you all for the memories and lessons that formed the mind and the 
person capable of doing this research. Thank you all.  
My oldest friend, Sijtze Henk Wiegersma, it has been since the early ‘90s that 
we have been friends spending our holidays playing games, learning all about Grand 
Theft Auto without the help of the internet. You stayed with the cars, as you have always 
wanted to be a car mechanic. We have always been able to talk about anything and find 
support. You have shown more wisdom to me than some people carrying a PhD, never 
be limited by the opinion of others. I am sure you can do whatever you put your mind to, 
every education was a battle that you have won. I am proud to call you my paranymph.  
Staying in Boornbergum we get to family, without the mental support of family I 
would never have been able to become the first member of the family to go the 
university and even get a PhD. Avelien and Marijke Huitema, always mentioned 
together in my memories, twin ladies with such different personalities. We grew up 
together in the same street, eventhough you were my cousins you have always felt like 
sisters to me and I was honored that you could be my witnesses at my wedding. Avelien, 
you have shown that struggle will be rewarded and I hope you can start soon as a 
teacher or as anything you can really enjoy doing, you deserve it. Marijke, together with 
your now husband, Nicola, you have left Frisia far behind to go to Belgium to be able to 
stay together. Nicola Williams, you left everything behind in Africa for a better future. 
Together you have tought me to leave the comfort zone to improve your situation. 
	
	
Alexander Poppinga and Anje Geerligs, you have provided me the honor of being an 
uncle to Jurryt and Thymen who will continue our family name to the next generation. 
Thank you for being part of the family. Heit and Mem, you provided a crucial ingredient 
to this thesis, the name on the cover and the person behind it. Growing up in a family of 
entrepeneurs I learned that work does not stop on Friday or after five o’clock, if you want 
your company to succeed it needs to be a part of you and you need to be a part of it. A 
company, a career, can only be as succesfull as the amount of energy you put into it and 
expecting things to be arranged for you and handed to you will lead you to fail when the 
people supporting you leave your life. Thank you for many life lessons that have shaped 
me.  
Moving far away to Indonesia to save perhaps the best for last. Putri 
Wulandari, without a doubt a creative brain to support me with obtaining the final form of 
my thesis. Many thanks for your creative input and hard work on that and also for taking 
care of Vessa for me while you are staying in the Netherlands. To us, you are part of our 
Indonesian family.  
Herren Tania, being my brother (in law) now officially, you have entertained me 
with a good supply of games while in Indonesia and you have enjoyed our house in the 
Netherlands, perhaps inspiring you to move your newly founded banana business to 
Europe? Being the youngest is never easy, I know, but you have the opportunity to learn 
from your older siblings that have graduated before you. I hope we can continue to 
support your growth and you can perhaps make the whole family rich soon. Hanel 
Tania, together with Herren you are the younger siblings I never had, the benefits of 
marriage. You have started your own marriage recently with Sylvia Gunawan and will 
explore all that comes with marrying a woman with a PhD. I wish you both a lot of 
happiness in this new adventure. You are the business power couple of the family, 
together with Herren you are sure to hear from me, when academia will leave me poor in 
the streets!  
Gotok Hianwijaya and Aprillia Linggaraja, thank you for being such caring 
parents for Vessa and supporting our relationship with such enthusiasm. I am sure many 
can only wish to have such a close family connection spreading over the world.  
Navessa Tania, Vessa, the love of my life and my beautiful bride. Many 
overlapping life-events, including the both of us switching from microbiology to 
pharmaceutical sciences and even the both of us joining iGEM Groningen gave us 
opportunities to meet but not until	we ended up together in pharmacology did we finally 
succeed. I am happy we finally got to meet each other and lucky that you travelled all the 
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finally finished for me and for you it is ending soon, finally we can start anew elsewhere. 
Onwards to the unknown!	 
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